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A = Anxiolytic 
ACTRN = Australian New Zealand Clinical Trials Registry 
AD = Alzheimer’s Disease 
ADL = Activities of Daily Living  
ALF = Assisted Living Facility 
AT = Atypical Antipsychotic 
ATC = Anatomic Therapeutic Chemical classification 
CDR = Clinical Dementia Rating 
CI = Confidence Interval 
CN = Conventional Neuroleptic 
CNS = Central Nervous System 
DAP = Drug with Anticholinergic Properties 
DBI = Drug Burden Index 
DDI = Drug-Drug Interaction 
EP = Extrapyramidal 
GEE = Generalized Estimating Equation  
H = Hypnotic 
HR = Hazard Ratio 
HRQoL = Health Related Quality of Life 
IRR = Incidence Rate Ratio 
LTCF = Long-Term Care Facility 
LTCW = Long-Term Care Ward 
MAI  = Medication Appropriateness Index  
MMSE = Mini-Mental State Examination 
MNA = Mini-Nutritional Assessment 
NH = Nursing Home 
NHD = Nursing Home for people with Dementia 
NNH = Number Needed to Harm 
NSAID = Non-Steroidal Anti-Inflammatory Drug  
OR = Odds Ratio 
PHM = Potentially Harmful Medication 
PID = Potentially Inappropriate Drug  
PIM = Potentially Inappropriate Medication   
PPI = Proton Pump Inhibitor 
PWB = Psychological Well-Being 
QoL = Quality of life 
RAI = Resident Assessment Instrument 
RCT = Randomized Controlled Trial 
RR = Relative Risk 
S = Sedative 
SAA = Serum Anticholinergic Activity  
SD =Standard Deviation 
SSRI = Selective Serotonin Reuptake Inhibitor 
TCA = Tricyclic Antidepressant 
WHO = World Health Organization 
15D = 15-Dimensional 








PHMs in this study: 1. Beers’ 2003 Potentially inappropriate drugs 
(PIDs), 2. Drugs with anticholinergic properties (DAPS) according to 
Rudolph’s anticholinergic risk scale (ARS), Beers’ 2003 
anticholinergic drugs, and the Svenska Socialstyrelsen 2010 list, 3. Use 
of >2 psychotropics concomitantly according to Svenska 
Socialstyrelsen, 4. Proton Pump Inhibitors (PPIs), 5. Non-Steroidal 




PID is a term first used in Beers’ 1997 updated criteria. PIDs are drugs 




PIM refers to inappropriate drugs according to various international 
criteria. 
Older people People aged ≥65 years. 
Educational 
intervention 
An educational intervention seeks to reform an older practice through 
training. In this study, education is based on constructive learning 
theory. This means learning with an active process in which learners 
construct new concepts based upon their previous knowledge to solve 
problems. 
Nursing home Institutional settings providing 24-hour care for older people with 
multimorbidity and need for assistance in activities of daily living 
(ADL) and instrumental activities of daily living (IADL).  
Assisted living facility Home-like environment that provides room and board for older people. 
Level of assistance and costs depend on each resident’s needs 
according to medical conditions and ADL and IADL skills. Care 
available around the clock. Nowadays in Finland, an assisted living 
facility resident’s need for assistance and the level of care are quite 
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Background: Institutionalized older people are frail and they suffer from a high number of 
comorbidities. Polypharmacy is also common. In older age, changes in pharmacokinetics often lead 
to slower metabolism and higher drug concentrations. Thus, older people are prone to adverse 
effects of drugs and their drug treatment is challenging.  
Over the last few decades, several criteria have been developed to define potentially inappropriate 
medication for older people. Beers’ list of inappropriate drugs in 1991 in USA was the first explicit 
criteria for inappropriate drugs, and it has been updated in 1997, 2003, 2012, and 2015. Many 
countries have developed their own criteria. There are also some implicit criteria for beneficial 
medication such as STOPP and START criteria.  
Drugs with anticholinergic properties (DAPs) are known to be potentially harmful. Their use may 
lead to many adverse effects such as cognitive decline, delirium, falls, dry mouth, urinary retention, 
and constipation. Several criteria measure anticholinergic burden. However, no consensus exists 
regarding the best criteria for the adverse events related to the use of DAPs.  
The use of psychotropic drugs among institutionalized older people has been excessive for many 
decades. US legislation has given instructions to reduce the use of psychotropic drugs in nursing 
homes since 1987. Psychotropic drugs may lead to a number of adverse effects such as cognitive 
decline, extrapyramidal symptoms, falls, and disabilities. The use of antipsychotics among older 
people with dementia is associated with strokes and increased risk for mortality. Although the 
adverse effects of antipsychotics are known, antipsychotic use in Finland remains high.  
Nowadays there is also evidence that some commonly used medications, such as proton pump 
inhibitors (PPIs) and non-steroidal anti-inflammatory drugs (NSAIDs), may not be safe in older 
people. The use of PPIs is associated with, for instance, Clostridium difficile infections and 
pneumonia and the use of NSAIDs with gastric and duodenal ulcer bleeding and heart failure. 
There is a paucity of studies exploring how potentially harmful medications (PHMs) according to 
various criteria accumulate among institutionalized older people and how they affect their welfare 
and survival. Several randomized controlled trials (RCTs) have been performed to reduce the use of 
harmful drugs. Most of these trials have focused on psychotropics. Interventions have diminished 
the use of psychotropics. However, the effects on rate of falls, quality of life, and mortality remain 
unclear.  
Aims: This study explored the use of PHMs among older people living in assisted living facilities in 
Helsinki and in nursing homes in Kouvola. PHMs were defined according to the literature. In a 
cluster RCT, the aim was to investigate the effect of staff training on the use of PHMs among 
residents in assisted living facilities in Helsinki and its outcomes. Specific aims were to clarify the 
use of PHMs (Studies 1 and 2), the burden and overlapping of PHMs, and their associations with 
residents’ health-related quality of life (HRQoL), psychological well-being (PWB), and 3-year 
mortality (Study 1). Other aims were to evaluate the feasibility of educational intervention (Study 2) 
and the effect of the intervention on the use of PHMs and HRQoL, use of hospital days, and 
mortality among older people in assisted living facilities during a 12-month follow-up (Study 3), as 
well to evaluate the effect of educational intervention on residents’ falls and cognition during a 12-
month follow-up (Study 4). 
Methods: Participants were recruited from assisted living facilities in Helsinki (Studies 1-4) and 
from nursing homes in Kouvola (Study 1). Participants or their closest proxy (in case of 
participants’ MMSE <20) gave written consent to participate. Inclusion criteria were age ≥65 years 
and living permanently in assisted living facility in Helsinki or in nursing home in Kouvola, native 
Finnish speaking, using at least one drug, having estimated lifetime ≥ 6 months, and voluntary 
participation. Study 1 was a cross-sectional study with a 3-year follow-up for mortality. Studies 2-4 
were based on a cluster RCT. Units had to be randomized instead of participants to avoid 
contamination of the intervention. Units were chosen with the aid of Resident Assessment 
Instrument (RAI) assessment, which was used to select wards with as similar as possible patient 
profiles, or case-mix. Altogether, 227 residents were included and randomized into either the 
intervention group (n=118) or the control group (n=109). The intervention was an educational 
intervention to staff, based on constructive learning theory. Nursing staff of the intervention wards 
received two afternoon training sessions about medication for older persons, both potentially 
inappropriate and beneficial. Physicians were also welcome to training. The learning process was 
activating and used patient cases. Nursing staff of the control wards received the same training after 
a one-year follow-up. The primary outcome measures were the proportion of persons using PHMs 
(Beers’ drugs, DAPs, or >2 psychotropics) and the change in the number of PHMs. Secondary 
outcome measures were change in HRQoL according to the 15D HRQoL and in cognition during 
the 12-month follow-up. In addition, the number of falls and fallers and the use of health care 
services during the follow-up were retrieved from medical records. Mortality up to 12 months was 
compared between intervention and control arms.  
Results: The characteristics of participants were quite similar in the intervention, control, and 
Kouvola group. Participants’ mean age ranged from 83 to 84 years and the majority (65-77%) of 
participants were woman.  The mean number of regular drugs was over 7. Charlson comorbidity 
index (a method calculating the risk of comorbidity on death) was highest in the intervention group, 
3.2, and lowest in the Kouvola group, 2.2. The proportion of all participants using any harmful drug 
was 78%. In Study 1, there was a stepwise association between the use of PHMs according to three 
definitions (Beers’ drugs 2003, DAPs, and use of >2 psychotropics concomitantly) and HRQoL, 
PWB, and self-rated health; the more criteria fulfilled, the lower the HRQoL, PWB, and self-rated 
health. Burden of PHMs was not associated with mortality in the 3-year follow-up. 
 
In RCT, as an effect of intervention, the prevalence of PHMs, especially psychotropics, decreased 
significantly in the intervention group (-11.7%, 95% confidence interval (CI) -20.5 to -2.9; 
p=0.009), whereas there was no significant change in the control group (+3.4%, 95% CI -3.7 to 
10.6; p=0.34). HRQoL decreased significantly less in the intervention group (-0.038, 95% CI -0.054 
to -0.022) than in the control group (-0.072, 95% CI -0.089 to -0.055; p=0.005). Residents in the 
intervention group used significantly less hospital days than those in the control group, 
1.4/person/year (95% CI 1.2 to 1.6) versus 2.3/person/year (95% CI 2.1 to 2.7), incidence rate ratio 
(IRR) for intervention group was 0.60, 95% CI 0.49 to 0.75; p <0.001 (adjusted for age, sex and 
comorbidities). There was no difference in the use of ambulatory services. Residents in the 
intervention wards fell significantly less than in the control wards. The age-, sex-, and comorbidity-
adjusted IRR for falls in the intervention wards was 0.72 (95% CI 0.59 to 0.88; p <0.001). When 
exploring falls according to subgroups, residents with MMSE scores >10 had the greatest benefit 
from the intervention. No difference emerged between the groups in changes of cognition according 
to verbal fluency or clock drawing test or in one-year mortality.  
Conclusions: A high burden of PHMs according to different criteria was associated with a lower 
quality of life. Nursing staff education on medication for older persons was beneficial. The use of 
PHMs, especially psychotropic medications, the rate of falls, and the use of hospital days all 
decreased more in the intervention group than in the control group. The quality of life decreased 
less in the intervention group than in the control group. However, no effect was observed on 
cognition or mortality, nor was there a difference in 3-year mortality according to burden of PHMs. 
The intervention was quite light and can easily be applied to other similar units.  
 
Tiivistelmä (Finnish Abstract) 
 
Tausta: Laitoksissa asuvat ikääntyneet ovat hauraita ja monisairaita. Heillä on myös usein 
monilääkitystä. Ikääntyneillä tapahtuvat muutokset farmakokinetiikassa johtavat usein metabolian 
hidastumiseen ja lääkeainepitoisuuksien nousuun. Näin ollen iäkkäät ovat herkkiä lääkeaineiden 
haittavaikutuksille ja heidän lääkehoitonsa on haastavaa. 
Vanhuksille potentiaalisesti haitallisten lääkeaineiden tunnistamiseksi on viime vuosikymmenien 
aikana kehitetty useita eri kriteeristöjä. Vuonna 1991 USA:ssa julkaistu Beersin lista 
sopimattomista lääkeaineista oli ensimmäinen poissulkeva kriteeristö iäkkäille sopimattomista 
lääkkeistä ja sitä on päivitetty vuosina 1997, 2003, 2012 ja 2015. Monet maat ovat luoneet omat 
kriteeristönsä. STOPP ja START kriteeristöön sisältyy myös implisiittinen osio hyödyllisistä 
lääkeaineista. 
Myös antikolinergisesti vaikuttavien lääkkeiden tiedetään olevan potentiaalisesti haitallisia. Niiden 
käyttö voi aiheuttaa monia haittavaikutuksia kuten kognition alenemista, sekavuutta, kaatumisia, 
suun kuivumista, virtsaamisvaikeuksia ja ummetusta. Antikolinergista taakkaa voidaan mitata 
monilla eri kriteereillä. Kuitenkaan ei ole päästy yhteisymmärrykseen siitä, mikä menetelmistä on 
parhaiten yhteydessä antikolinergisten lääkeaineiden käyttöön liittyviin haittatapahtumiin. 
Psyykenlääkkeitä on käytetty laitoksissa asuvilla vanhuksilla liikaa vuosikymmenien ajan. USA:ssa 
lainsäädännöllä ohjeistettiin vähentämään psyykenlääkkeiden käyttöä vanhainkodeissa jo vuonna 
1987. Psyykenlääkkeiden käyttöön voi liittyä haittavaikutuksia kuten kognition laskua, 
ektrapyramidaalioireita, kaatumisia ja toiminnanvajauksia. Antipsykoottien käyttöön muistisairailla 
vanhuksilla liittyy aivohalvauksien ja lisääntyneen kuolleisuuden riski. Huolimatta siitä, että 
psyykenlääkkeiden aiheuttamat haittatapahtumat tunnetaan, niiden käyttö myös Suomessa on 
pysynyt runsaana. 
Nyttemmin on myös näyttöä siitä, että jotkin varsin yleisesti käytetyt lääkkeet kuten protonipumpun 
estäjät ja tulehduskipulääkkeet eivät mahdollisesti ole vanhuksille turvallisia. Happosalpaajien 
käyttö on yhteydessä esimerkiksi Clostridium difficile-infektioihin ja keuhkokuumeseen, 
tulehduskipulääkkeiden käyttö maha- ja pohjukkaissuoliverenvuotoihin ja sydämen 
vajaatoimintaan. 
On varsin niukasti tutkimuksia, joissa on selvitetty eri perusteiden mukaisesti haitallisiksi 
katsottujen lääkkeiden kertymistä laitoksissa asuville vanhuksille ja miten se vaikuttaa heidän 
hyvinvointiinsa ja eloonjäämiseensä. Monia satunnaistettuja, kontrolloituja tutkimuksia on tehty 
haitallisten lääkkeiden käytön vähentämiseksi. Monet näistä tutkimuksista ovat keskittyneet 
psyykenlääkkeisiin. Interventioilla psyykenlääkkeiden käyttöä on saatu vähennettyä. Vaikutukset 
kaatumisten määrään, elämänlaatuun ja kuolleisuuteen ovat kuitenkin jääneet epäselviksi. 
Tutkimuksen tavoitteet: Tällä tutkimuksella selvitettiin iäkkäiden helsinkiläisten palvelutalojen ja 
kouvolalaisten vanhainkotien asukkaiden potentiaalisesti haitallisten lääkkeiden käyttöä. 
Haitallisiksi katsotut lääkeaineet määriteltiin kirjallisuuden perusteella. Tutkimuksen tavoitteena oli 
ryhmäsatunnaistetussa, kontrolloidussa tutkimuksessa selvittää, oliko henkilökunnan koulutuksella 
vaikutusta helsinkiläisten palvelutalojen asukkaiden haitallisten lääkkeiden käyttöön ja sen 
seurauksiin. Erityistavoitteena oli selvittää potentiaalisesti haitallisten lääkkeiden käyttöä (osatyöt 1 
ja 2), niiden taakkaa ja päällekkäisyyttä sekä yhteyttä asukkaiden terveyteen liittyvään 
elämänlaatuun, psyykkiseen hyvinvointiin ja kolmen vuoden kuolleisuuteen (osatyö 1). Muina 
tavoitteina oli myös selvittää koulutusintervention toteutettavuus (osatyö 2) ja intervention vaikutus 
palvelutalojen asukkaiden potentiaalisesti haitallisten lääkkeiden käyttöön, terveyteen liittyvään 
elämänlaatuun, sairaalapäivien käyttöön sekä kuolleisuuteen 12 kuukautta kestävänä seuranta-
aikana (osatyö 3), sekä intervention vaikutus asukkaiden kaatumisiin ja kognitioon 12 kuukautta 
kestävänä seuranta-aikana (osatyö 4).  
Menetelmät: Osallistujat rekrytoitiin helsinkiläisistä tehostetun palveluasumisen yksiköistä (osatyöt 
1-4) ja kouvolalaisista vanhainkodeista (osatyö 1). Osallistujat tai lähimmät omaiset (mikäli 
osallistujan MMSE oli <20) antoivat osallistumisesta kirjallisen suostumuksen. 
Sisäänottokriteereinä olivat ≥65 vuoden ikä, pysyvä asuminen helsinkiläisessä tehostetun 
palveluasumisen yksikössä tai kouvolalaisessa vanhainkodissa, suomi äidinkielenä, vähintään 
yhden lääkkeen käyttö ja odotettu elinikä vähintään 6 kuukautta sekä vapaaehtoinen osallistuminen. 
Osatyö 1 oli poikkileikkaustutkimus, jossa oli kolmen vuoden kuolleisuuden seuranta. Osatyöt 2-4 
perustuivat satunnaistettuun, kontrolloituun tutkimukseen, missä ryhmät satunnaistettiin. Yksiköt 
satunnaistettiin yksittäisten asukkaiden sijasta, jotta voitiin välttää intervention kontaminoituminen. 
Resident Assessment Instrument (RAI)-selvityksen perusteella valittiin osastot, joissa oli 
mahdollisimman samankaltaiset potilasprofiilit (case-mix). Kokonaismäärä oli yhteensä 227 
asukasta, heidät satunnaistettiin interventioryhmään (n=118) tai kontrolliryhmään (n=109). 
Interventiona oli hoitohenkilökunnan koulutusinterventio, joka perustui konstruktiiviseen 
oppimisteoriaan. Interventioyksiköiden sairaanhoitajat saivat kahden iltapäivän kestävän 
koulutuksen ikääntyneiden lääkityksestä, sekä potentiaalisesti haitallisesta että hyödyllisestä. Myös 
lääkärit olivat tervetulleita koulutukseen. Oppimisprosessi oli aktivoivaa ja siinä hyödynnettiin 
potilastapauksia. Kontrolliyksiköiden sairaanhoitajat saivat saman koulutuksen 12 kuukauden 
seuranta-ajan jälkeen. Ensisijainen päätetapahtuma oli tutkittavien osuus, jotka käyttivät haitallisia 
lääkkeitä sekä muutos haitallisten lääkkeiden käytön lukumäärissä (Beersin lääkkeet, 
antikolinergiset lääkkeet tai yli 2 psyykelääkettä) Toissijaiset päätetapahtumat olivat muutos 
terveyteen liittyvässä elämänlaadussa (15D), ja kognitiossa12 kuukauden seurannassa. Lisäksi 
kaatujien ja kaatumisten lukumäärä sekä terveyspalveluiden käyttö selvitettiin sairaskertomuksista. 
Kuolleisuutta interventio- ja kontrolliryhmien välillä verrattiin 12 kuukauden ajalta.  
Tulokset: Osallistujien ominaisuudet olivat jokseenkin samanlaisia interventio-, kontrolli- ja 
Kouvola-ryhmissä. Keski-ikä oli 83-84 vuotta, enemmistö, 65-77%, osallistujista oli naisia. 
Säännöllisiä lääkkeitä oli käytössä keskimäärin yli 7. Charlsonin sairastavuusindeksi (menetelmä, 
joka laskee sairastavuuden huomioiden kuolemanriskin) oli korkein interventioryhmässä, 3.2, ja 
matalin Kouvolan ryhmässä, 2.2. Osallistujista 78% käytti jotakin haitalliseksi katsottua lääkettä. 
Osatyössä 1 oli portaittainen yhteys kolmella eri kriteeristöllä määritettyjen potentiaalisesti 
haitallisten lääkkeiden (Beersin 2003 lääkkeet, antikolinergisesti vaikuttavat lääkkeet ja >2 
psyykenlääkettä) käytön ja terveyteen liittyvän elämänlaadun, henkisen hyvinvoinnin ja 
itsearvioidun terveydentilan välillä. Mitä useampaan kriteeristöön sisältyviä lääkkeitä oli käytössä, 
sitä huonompia nämä olivat. Haitallisten lääkkeiden taakka ei ollut yhteydessä kuolleisuuteen 3 
vuoden seuranta-aikana. 
Kontrolloidussa satunnaistetussa interventiotutkimuksessa intervention ansiosta potentiaalisesti 
haitallisten lääkkeiden, erityisesti psyykenlääkkeiden, prevalenssi laski merkitsevästi 
interventioryhmässä (-11.7%, 95% CI -20.5 - -2.9; p=0.009), mutta kontrolliryhmässä muutosta ei 
tapahtunut (+3.4%, 95% CI -3.7 - 10.6; p=0.34). Elämänlaatu heikkeni merkitsevästi vähemmän 
interventioryhmässä (-0.038, 95% CI -0.054 - -0.022) kuin kontrolliryhmässä (-0.072, 95% CI -
0.089 - -0.055; p=0.005). Interventioryhmän asukkailla sairaalapäivien käyttö oli merkitsevästi 
vähäisempää verrattuna kontrolliryhmän asukkaisiin, 1.4/henkilö/vuosi (95% CI 1.2 -1.6) versus 
2.3/henkilö/vuosi (95% CI 2.1 - 2.7, incidence rate ratio (IRR) interventioryhmälle 0.60, 95% CI 
0.49 - 0.75; p <0.001, vakioitu iällä, sukupuolella ja sairastavuudella). Polikliinisten palvelujen 
käytössä ei ollut eroa. Interventioyksiköiden asukkaat kaatuivat merkitsevästi harvemmin verrattuna 
kontrolliyksiköiden asukkaisiin. Iällä, sukupuolella ja sairastavuudella vakioitu kaatumisen riski 
interventioryhmässä verrattuna kontrolliryhmään oli 0.72 (95% CI 0.59 - 0.88; p<0.001). Kun 
kaatumisia tutkittiin alaryhmissä, asukkaat, joiden MMSE oli yli 10, hyötyivät eniten interventiosta. 
Ryhmien välillä ei ollut eroa kielellisellä sujuvuudella tai kellotaululla tutkituissa kognition 
muutoksissa eikä yhden vuoden kuolleisuudessa. 
Johtopäätökset: Eri kriteereiden mukaisten potentiaalisesti haitallisten lääkkeiden taakka liittyi 
huonompaan elämänlaatuun. Hoitohenkilökunnan koulutus iäkkäiden lääkityksestä onnistui hyvin. 
Potentiaalisesti haitallisten lääkkeiden, erityisesti psyykenlääkkeiden, käyttöä pystyttiin 
vähentämään ja kaatumisten määrä ja sairaalahoitopäivien käyttö olivat vähäisempiä 
interventioryhmässä kuin kontrolliryhmässä. Elämänlaatu heikkeni vähemmän interventioryhmässä 
kuin kontrolliryhmässä. Kognitioon tai kuolleisuuteen ei kuitenkaan ollut vaikutusta. Myöskään 
haitallisten lääkkeiden kertymisellä ei ollut vaikutusta kolmen vuoden kuolleisuuteen. Interventio 




1 Introduction    
 
Older institutionalized residents are often frail. Moreover, they frequently have high numbers of 
comorbidities, ADL disabilities, and cognitive decline (Onder et al. 2012a). They are thus prone to 
polypharmacy and adverse effects of drugs (Onder et al. 2012a, 2012b). Furthermore, drug 
metabolism changes with age, predisposing older people to adverse drug reactions (Mangoni and 
Jackson 2004). Therefore, medication prescribing to older people has become an important focus in 
geriatric research as well as a public health issue worldwide (Spinewine et al. 2007).  
Several drugs or drug classes have been defined as harmful to older people. Beers’ list of 
inappropriate drugs was the first explicit criteria defining inappropriate medication among nursing 
home residents (Beers et al. 1991). The list was created by consensus of an expert panel. The Beers’ 
list considered drugs as inappropriate if their adverse effects exceeded the benefits, if they did not 
have evidence of the desired effects, or if there was a safer alternative available (Beers et al. 1991). 
Beers’ criteria have been updated four times and they cover also home-dwelling older people (Beers 
1997, Fick et al. 2003, AGS 2012, AGS 2015). Beers’ inappropriate lists are best suited for use in 
USA, as they include a number of drugs not available in other countries. Many countries have 
subsequently developed their own prescribing recommendations for older people (Spinewine et al. 
2007, Dimitrow et al. 2011, Dimitrow et al. 2013). 
Use of drugs with anticholinergic properties (DAPs) is associated with pronounced central and 
peripheral side effects, such as cognitive decline, delirium, falls, dry mouth, constipation, and 
urinary retention, among older people (Rudolph et al. 2008, Panula et al. 2009, Gerretsen and 
Pollock 2011, Viipuri 2016). Due to their marked side effects in older people, the prescribing of 
anticholinergic drugs requires careful consideration of their benefits and harms (Cardwell et al. 
2015). Anticholinergic drugs are included in many lists of inappropriate drugs, but experts have 
also created their own lists of anticholinergic drugs harmful to older people (Viipuri 2016).  
The Omnibus Budget Reconciliation Act of 1987 (OBRA 87) in the USA paid attention to nursing 
home residents’ overuse of psychoactive drugs (Hughes et al. 2005). Older people are especially 
prone to sedative and other central nervous system adverse effects of psychotropic drugs (Mangoni 
and Jackson 2004). Psychotropic drugs expose older people to cognitive decline, falls, disabilities, 
and various other adverse effects (Rosenberg et al. 2012, Pratt et al. 2014). OBRA 87 recommended 
reducing the use of psychotropic drugs. Antipsychotic drug use in US nursing homes declined after 
implementation of this regulation (Garrard et al. 1995). However, atypical antipsychotics and other 
psychotropic drugs are still widely used in long-term care, especially for neuropsychiatric 
symptoms associated with dementia, even though there is limited evidence to support their use 
(Seitz et al. 2013). The Swedish National Board of Health and Welfare (Svenska Socialstyrelsen) 
has stated that the use of three or more psychotropic drugs simultaneously is harmful to older 
people (Socialstyrelsen 2010, Socialstyrelsen 2017).  
Various harmful drugs for older people have been associated with increased risk of adverse drug 
events, increased health care usage, and even increased mortality (Gurwitz et al. 2000, Lau et al. 
2005, Spinewine et al. 2007). Less is known about how the use of these drugs or drug classes has 
accumulated among older frail people in institutional settings, and whether reducing the use of these 
drugs would improve outcomes. Intervention trials have aimed to diminish the use of inappropriate 
medication in older people (Alldred et al. 2016, Johansson et al. 2016). In many interventions, the 
use of harmful drugs has decreased (Alldred et al. 2016). However, the effects on other outcomes, 
such as hospitalizations, falls, quality of life (QOL), and mortality, have been less clear (Alldred et 
al. 2016, Johansson et al. 2016). 
This study examines the accumulation of harmful drugs in institutionalized older people, and the 
effect of nursing staff education in assisted living facilities on residents’ use of potentially harmful 
drugs and secondary outcomes such as falls, cognition, health-related quality of life (HRQoL), use 














2 Review of the literature 
 
2.1 Ageing and medication 
  
2.1.1 Pharmacokinetics and pharmacodynamics 
 
The human body undergoes many age-related changes, which may have effects on 
pharmacokinetics and pharmacodynamics (Mangoni and Jackson 2004, Boparai and Korc-
Grodzicki 2011).  Pharmacokinetics refers to the process of absorption, distribution, metabolism, 
and elimination of a drug in the body, whereas pharmacodynamics comprises the biochemical and 
physiological effects of drugs (Boparai and Korc-Grodzicki 2011, Rang et al. 2016). Ageing is 
associated with certain changes in pharmacokinetics (McLean and Le Couteur 2004, Mangoni and 
Jackson 2004). Also, variability between individuals in physiological responses increases with age 
(Mangoni and Jackson 2004). Drug metabolism is markedly slower in frail older people than in 
healthy older people with normal weight (Turnheim 2004, Hubbard et al. 2012). 
In the elderly, the secretion of hydrochloric acid and pepsin decreases, but gastric emptying and 
digestion and motility of the small intestine remain relatively unchanged (Turnheim 2004, Mangoni 
and Jackson 2004). Thus, the absorption of vitamin B12, iron, and calcium through active transport 
is reduced, but in general ageing does not notably change drug absorption (Boparai and Korc-
Grodzicki 2011). The total body mass and proportion of body water decrease, while the proportion 
of body fat increases (Mangoni and Jackson 2004, Turnheim 2004, Boparai and Korc-Grodzicki 
2011, Hubbard et al. 2012). Thus, distribution volume of hydrophilic drugs decreases (e.g. 
gentamycin, digoxin, lithium, and theophylline), increasing their concentration. Respectively, the 
distribution volume of lipid-soluble drugs (e.g. lipophilic benzodiazepines, morphine, lidocaine, 
thiopental, phenytoin, and verapamil) increases (Boparai and Korc-Grodzicki 2011, Hubbard et al. 
2012, Mukhtar and Jackson 2015). Slow release of these drugs from fat storage prolongs the drugs’ 
effect (Hubbard et al. 2012). Diazepam’s half-life in adults is about 30 hours, while in older people 
it is about 90 hours (Boparai and Korc-Grodzicki 2011). Binding of drugs to albumin is not affected 
during normal ageing, however, frail older people often have lower levels of serum albumin. They 
are prone to toxicity of acidic drugs, such as warfarin, digoxin, naproxen, ceftriaxone, lorazepam, 
and valproic acid, which are usually bound extensively to albumin (Boparai and Korc-Grodzicki 
2011, Hubbard et al. 2012).  
During ageing liver mass and its blood flow decrease, and, as a consequence, the first-pass 
metabolism slows down (Mangoni and Jackson 2004, Boparai and Korc-Grodzicki 2011). This may 
increase the bioavailability of many drugs (e.g. propranolol and labetalol). On the other hand, if 
drugs are pro-drugs and have to be activated in the liver (e.g. enalapril and perindopril), their first-
pass metabolism may be slowed down and drug effects reduced (Mangoni and Jackson 2004, 
Boparai and Korc-Grodzicki 2011).  
Many drugs are eliminated through the kidneys (Boparai and Korc-Grodzicki 2011). Glomerular 
filtration rate (GFR) often decreases in older age, especially if a person has a disease such as 
hypertension or diabetes that affects renal function (McLean and Le Couteur 2004, Hubbard et al. 
2012). As a consequence, this may lead to accumulation of renally cleared drugs (e.g. allopurinol, 
atenolol, diuretics, digoxin, lithium, water-soluble antibiotics, and NSAIDs) (Mangoni and Jackson 
2004, Boparai and Korc-Grodzicki 2011, Mukhtar and Jackson 2015). Use of diuretics may reduce 
the extracellular space even more, increasing toxic drug effects (Turnheim 2004).   
Furthermore, there are pharmacodynamic changes that can increase an older person’s sensitivity to 
medication, especially to drugs that affect the central nervous system (Mangoni and Jackson 2004, 
Mukhtar and Jackson 2015).  The brain weight decreases and the number of synapses decreases 
(Turnheim 2004). There is an age-related functional decline in the dopaminergic system, which may 
partly explain why older people are more sensitive to antipsychotic drugs and lower doses are 
recommended (Turnheim 2004, Uchida et al. 2009). The reduction in acetylcholine may explain 
older people’s sensitivity to anticholinergic side effects (Turnheim 2004). Older people have 
reduced beta-adrenoceptor function (Mangoni and Jackson 2004, Turnheim 2004), and thus, are less 
sensitive to the chronotropic effects of isoprenaline (Mangoni and Jackson 2004). Progressive 
reduction in homeostatic mechanisms is also related to the ageing process. A typical example of this 
is older people’s sensitivity to postural hypotension achieved by blood pressure-lowering drugs 
(Turnheim 2004, Boparai and Korc-Grodzicki 2011). 
 
2.1.2 Problems related to drug use among older people in institutional settings 
 
Polypharmacy is common in institutional settings (Onder et al. 2012b). While no consensus exists 
on the definition of polypharmacy, in institutional care it is generally defined as the use of five or 
more drugs and excessive polypharmacy is defined as 10 or more regular drugs (Onder et al. 
2012b). Mean number of drugs among nursing home residents was 7.0-7.1 in Europe, including 
Finland, according to the Services and Health for Elderly in long TERm care (SHELTER) study 
(Onder et al. 2012b). The corresponding figure in Finnish studies was 7.9 in 2003 (Hosia-Randell et 
al. 2008) and 7.3 in 2011 (Pitkälä et al. 2015).  
People living in institutional settings suffer from comorbidities, disabilities, and cognitive decline 
(Onder et al. 2012a). According to the SHELTER study, the mean age of residents in institutional 
settings of seven EU countries, including Finland, was above 80 years. More than 80% needed 
assistance in Activities of Daily Living (ADL), and about 70% suffered from cognitive impairment 
(Onder et al. 2012a). They also had a high prevalence of urinary incontinence, pain, depression, 
behavioural symptoms, falls, and pressure ulcers (Onder et al. 2012a). Thus, pharmacological 
treatment is challenging and often leads to polypharmacy (Onder et al. 2012b). Polypharmacy (use 
of 5-9 drugs) was observed in 50% and excessive polypharmacy (use of ≥10 drugs) in almost one-
quarter of nursing home residents in Europe (Onder et al. 2012b). The use of multiple drugs 
increases the risk of drug-drug interactions and drug-disease interactions (Onder et al. 2012b).  
Excessive polypharmacy has been reported to be associated with malnutrition and a decline in 
functional and cognitive capacity (Jyrkkä et al. 2011). Excessive polypharmacy was also shown to 
be associated with depression, falls, pain, dyspnoea, and gastrointestinal symptoms and inversely 
associated with cognitive impairment and ADL disability (Onder et al. 2012b). In a systematic 
review, polypharmacy was associated with comorbidity and number of prescribers, while older age, 
cognitive impairment, ADL disability, and length of stay in long-term care facilities (LTCF) were 
inversely associated with polypharmacy (Jokanovic et al. 2015).  
Polypharmacy was not associated with mortality in a prospective cohort study with a 2-year follow-
up (Schlesinger et al. 2016). However, excessive polypharmacy was associated with one-year 
mortality among cognitively impaired nursing home residents (Onder et al. 2013), and, according to 
a cohort study, with 10-year mortality in older people aged ≥75 years (Jyrkkä et al. 2009). 
 
2.2 Potentially harmful medications (PHMs) for older people 
 
Appropriate prescribing for older people is challenging.  Adverse drug effects may lead to excess 
health care use and hospitalizations (Hanlon et al. 1997, Lau et al. 2005, Perri et al. 2005, Price et 
al. 2014). The quality of prescribing drugs has been defined in several ways. Often older people 
may not receive all the drugs that their disease or condition requires (underprescribing). 
Alternatively, older people may get more drugs than are clinically indicated (overprescribing), or 
they may even receive incorrectly prescribed drugs (misprescribing) (Spinewine et al. 2007). Poor 
quality of prescribing raises health care costs significantly (Fick et al. 2003).  
Experts in many countries have developed their own criteria for potentially inappropriate drugs to 
improve older people’s drug treatment (Dimitrow et al. 2011). These criteria can be defined as 
implicit or explicit (Spinewine et al. 2007). Explicit criteria are drug- or disease-oriented, and they 
give instructions to avoid certain drugs that can be potentially harmful for older people (Beers et al. 
1991). Implicit criteria are more patient-oriented and based on tailored clinical judgements about 
appropriateness (Spinewine et al. 2007).  
 
2.2.1 Various criteria for inappropriate prescribing 
 
Various criteria for inappropriate medications are summarized in Table 1. 
Overuse of psychotropics in nursing homes received much attention already in 1987 in the USA 
(OBRA 87). Four years later, geriatrician Mark Beers and colleagues were the first to develop 
explicit criteria with the aid of an expert panel for drugs that are inappropriate for nursing home 
residents (Beers et al. 1991).  In Beers’ criteria, drugs are considered inappropriate if their 
unwanted effects exceed their benefits, if they lack efficacy, or if there is safer alternative available 
(Beers et al. 1991). Beers’ criteria were based on American practices. Beers’ list has been extended 
to community-dwelling older people and updated four times since the first panel’s work (Beers 
1997, Fick et al. 2003, AGS 2012, AGS 2015). Beers’ lists are the most commonly used criteria for 
inappropriate drugs. However, Beers’ criteria have been criticized for including a large proportion 
of medications that are not available in other countries (O’Mahony et al. 2010). Beers’ criteria have 
also been criticized for not taking into account drug-drug interactions and duplicate drug classes. 
Furthermore, both the Beers’ lists of drugs independent of diagnoses and drugs related to certain 
conditions were criticized for being in a random order (O’Mahony and Gallagher 2008). They also 
lacked recommendations for often under-prescribed evidence-based medications for older people. 
In Canada, McLeod and colleagues created their own national recommendations for older people’s 
medication. The consensus panel of 32 specialists in clinical pharmacology, geriatrics, family 
medicine, and pharmacy used a modified Delphi method and identified 38 inappropriate practices in 
prescribing to older people. Inappropriate prescribing had to meet three criteria: increase in the 
potential risk of serious adverse effect, more effective or less risky alternative therapy was 
available, and change of practice could decrease morbidity of older people. These practices were 
divided into four groups: prescribing to treat cardiovascular diseases, psychotropic drugs, non-
steroidal anti-inflammatory drugs (NSAIDs) and other analgesics, and others. Of these practices, 18 
were generally contraindicated in older people, 16 involved drug-disease-interaction, and four 
involved drug-drug-interactions. Three of these four drug-drug interactions were related to oral 
warfarin use (McLeod et al. 1997).  
Zhan with colleagues gathered an expert panel in the USA consisting of seven experts in geriatrics, 
pharmaco-epidemiology, and pharmacy. They categorized potentially inappropriate medication for 
community-dwelling older people (Zhan et al. 2001).  Their list was based on 1997 Beers’ criteria. 
A modified Delphi method with two rounds was used. The panel classified 33 drugs into three 
categories: 11 drugs that should always be avoided, 8 drugs that are rarely appropriate, and 14 drugs 
that have some indications but are often misused among community-dwelling older people. For 
example, diazepam was included in the “rarely appropriate list”. The panel believed that long-acting 
benzodiazepines were mostly inappropriate. However, diazepam and chlordiazepoxide could be 
used for a short treatment course for alcohol withdrawal. Amitriptyline was in the “some 
indications” category; the panel’s consensus was that it could be used in low doses for the treatment 
of neuropathic pain, but it should not usually be used for treatment of depression (Zhan et al. 2001).   
A French consensus panel created their own list of inappropriate medications for older people 
(Laroche et al. 2007). It included 34 criteria applicable to people ≥75 years, comprising 29 
medications or medication classes for all patients and 5 for specific medical conditions. According 
to this list, NSAIDs, for instance, were allowed, except for indomethacin and phenylbutazone or 
simultaneous use of two or more NSAIDs. Many anticholinergic psychotropics were not allowed, 
but meprobamate was allowed as an alternative drug, but not for gastrointestinal dysfunction. The 
list of inappropriate drugs consisted of anticholinergic antihistamines, muscle relaxants, and 
antispasmodics, and simultaneous use of drugs with anticholinergic properties was discouraged. 
Long-acting benzodiazepines, centrally acting antihypertensives, and short-acting calcium-channel 
blockers were included in the list, as was digoxin > 0.125 mg/d. However, contrary to Beers’ list 
(Fick et al. 2003), amiodarone was allowed. There were also medication recommendations for 
certain clinical conditions and two warnings for drug-drug interactions as follows: simultaneous use 
of two or more psychotropic drug from the same therapeutic class and simultaneous use of 
cholinesterase inhibitor drugs and drugs with anticholinergic properties (Laroche et al. 2007). 
In Ireland, an 18-member expert panel using a Delphi consensus method developed the STOPP 
(Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to 
Right Treatment) criteria (Gallagher et al. 2008, O’Mahony et al. 2010).  
Experts from geriatric medicine, clinical pharmacology, clinical pharmacy, old age psychiatry, and 
primary care created 65 STOPP criteria (drugs to avoid) and 22 START criteria (drugs indicated in 
certain conditions). STOPP criteria were arranged according to physiological systems, e.g. 
cardiovascular system, central nervous system and psychotropic drugs, gastrointestinal system, 
respiratory system, musculoskeletal system, urogenital system, and endocrine system. In addition, 
drugs causing adverse effects such as falls, analgesic drugs having high risk of adverse effects, and 
medications from duplicate drug classes were advised to be avoided. Contrary to Beers’ criteria, 
there were also START criteria for drugs considered indicated for older people in certain 
conditions, such as warfarin in the presence of atrial fibrillation. Recommendations were also made 
for respiratory, central nervous, gastrointestinal, musculoskeletal, and endocrine system 
medications (Gallagher et al. 2008, O’Mahony et al. 2010).  The STOPP criteria covered many 
drugs not mentioned in Beers’ criteria. For example, there was a recommendation to avoid NSAIDs 
with moderate-severe hypertension, with heart failure, and with chronic renal failure. In addition, 
the criteria advised not using PPIs at full therapeutic dose for more than 8 weeks when treating 
peptic ulcer. It has been suggested that the STOPP criteria might be more helpful than Beers’ 
criteria to identify potentially inappropriate medications that may lead to acute hospitalizations 
(Gallagher and O’Mahony 2008). STOPP and START criteria have been updated in 2015 
(O’Mahony et al. 2015). This new version contains 80 STOPP criteria and 34 START criteria. The 
new STOPP criteria were antiplatelet/anticoagulant drugs, drugs affecting renal function, and drugs 
that may increase anticholinergic burden. The new START criteria included new categories of 
drugs such as medications for the urogenital system, analgesics, and vaccines. Fifteen of the criteria 
from STOPP/START version 1 (Gallagher et al. 2008, O’Mahony and Gallagher 2008) are not 
included in STOPP/START version 2 (O’Mahony et al. 2015). 
Because of the severity of medication-related problems, there was a need for local 
recommendations based on Australian data (Basger et al. 2008). Beers’ list was not appropriate for 
the Australian health care environment. Prescribing indicator tools were developed after examining 
the most common reasons for older Australians seeking or receiving health care (Basger et al. 2008) 
and cross-referencing these with the 50 highest-volume Pharmaceutical Benefits Scheme 
medications prescribed. They identified a total of 48 indicators. Eighteen indicators concerned 
avoidance of medications in certain conditions or diseases and 19 concerned recommended 
treatment in certain conditions or diseases. There were also indicators for medication monitoring, 
specific drug interactions, questions about any changes in medication in the previous 90 days, 
smoking, and vaccination status (Basger et al. 2008).  
Furthermore, Norwegian researchers created their own criteria to suit their practices for older 
people (Rognstad et al. 2009). The Norwegian General Practice (NORGEP) criteria for potentially 
inappropriate medication were developed as explicit criteria to be used in general practice for 
home-dwelling older people (>70 years). It included 36 drugs, drug dosages, and drug combinations 
to be avoided for safety reasons. There were such drugs as tricyclic antidepressants, conventional 
antipsychotics, long-acting benzodiazepines, theophylline, sotalol, and first-generation 
antihistamines. Combinations to be avoided among older people included warfarin with NSAIDs, or 
selective serotonin reuptake inhibitors (SSRIs) with certain quinolones or macrolides. According to 
these criteria, NSAIDs or coxibs should not be used with angiotensin converting enzyme (ACE) 
inhibitors, diuretics, glucocorticoids, or SSRIs. There was also a recommendation not to 
simultaneously use three or more drugs belonging to the groups of centrally acting analgesics, 
antipsychotics, antidepressants, and benzodiazepines (Rognstad et al. 2009). 
Norwegians also developed their own explicit criteria for inappropriate medication for nursing 
home residents aged >70 years (Nyborg et al. 2015). These Norwegian General Practice Nursing 
Home (NORGEP-NH) criteria for potentially inappropriate medication were created by a three-
round consensus process using the Delphi technique. The panel consisted of geriatricians, general 
practitioners, and clinical pharmacologists. NORGEP-NH included many of the same medications 
as NORGEP, but, for example, zopiclone was recommended to have a maximum dose of 5 mg 
instead of 7.5 mg. There were also recommendations for critical assessment of continuing 
antipsychotics, antidepressants, urologic spasmolytics, anticholinesterase inhibitors, 
antihypertensives, bisphosphonates, statins, and any preventive medications. 
The Swedish National Board of Health and Wellfare developed its own indicators for older people’s 
medication. These were published for the first time in 2004 and updated in 2010 and 2017 
(Socialstyrelsen 2010, Socialstyrelsen 2017). The recommendations were targeted to older people 
(≥75 years) and based on the international literature. There were 9 drug-specific and 11 disease-
specific indicators. Drug-specific indicators were defined and categorized as follows: 1. Drugs to be 
avoided among people ≥75 years unless there is a specific indication for their use. The expected 
benefit of the drug should exceed the risks. These drugs include long-acting benzodiazepines such 
as diazepam or nitrazepam, drugs with anticholinergic properties, and tramadol. 2. Preparations for 
which a correct and current indication is of particular importance. These include drugs that are quite 
commonly prescribed and often without a clear indication. There is a risk for adverse effects. These 
include medications such as NSAIDs, paracetamol (acetaminophen), opioids, antipsychotics, proton 
pump inhibitors (PPIs) and SSRIs. 3. Drugs that often are used regularly, although they should be 
used only for a short period of time like hypnotics, bowel-stimulating laxatives, NSAIDs, oral 
glucocorticoids, and antipsychotics. 4. Avoiding overdosing of some drugs. For example, 
risperidone should not be used >1.5 mg/day among people ≥75 years, oxazepam not >30 mg/day, 
and zopiclone not >7.5 mg/day. 5. Warning for polypharmacy: older people should not use ≥10 
drugs at the same time, regularly or pro re nata (as needed). There is a risk for side effects, drug-
drug interactions, and difficulties in complying with the instructions. Also simultaneous use of two 
or more drugs of the same drug class, like two or more opioids or two benzodiazepines, may be 
inappropriate. Sometimes this is necessary and justified, e.g. two or more antiparkinson drugs or 
combinations of antidepressants. Simultaneous use of three or more psychotropics is also 
considered to be inappropriate because there is risk for drug-drug interactions and side effects. 6. 
Combinations of drugs that may lead to clinically significant drug-drug interactions (D-class 
interactions), e.g. the combination of warfarin and NSAID. 7. Drugs for which use or dosing must 
be adjusted according to renal function, e.g. digoxin and potassium-sparing diuretics. 8. Drugs 
leading to side effects like orthostatic hypotension or increasing the risk for falls or impaired 
cognition. 9. There were also recommendations on the hypnotics and sedatives to be avoided and 
others specified that are safer to use. There were also 11 different recommendations according to 
diagnoses, e.g. hypertension, ischaemic heart disease, heart failure, diabetes, sleeping problems, and 
chronic obstructive pulmonary disease (COPD) (Socialstyrelsen 2010).  
In Finland, there is the Meds75+ database that describes inappropriate and appropriate medications 
for older people (Fimea 2016). Fimea (Finnish Medicines Agency) operates under the Ministry of 
Social Affairs and Health of Finland. Its aim is to maintain and improve the health of the population 
by supervising and developing the pharmaceutical sector. The database, available since 2010, is 
primarily intended for physicians and other health care professionals, and its purpose is to support 
the clinical decision-making on the pharmacotherapy of people ≥75 years and to improve 
medication safety in primary health care. A team of pharmacotherapy experts developed the 
database, which is currently being updated; the first part of the update was published in 2013 and 
the update is ongoing. Medicinal substances are classified into the categories A (green), B (grey), C 
(yellow), and D (red). The category indicates how suitable the medicinal substance is for people 
≥75 years. The categories are based on a multidisciplinary clinical consensus (Fimea 2016). 
Category A medicinal substances are appropriate for older people and can be used similarly as in 
younger patients. Category B includes medicinal substances for which there is little scientific 
evidence, practical experience, or efficacy in persons over 75 years of age. Category C medicinal 
substances can be used for older people, but the dose might either have to be reduced or the 
frequency of administration decreased due to mild or moderate renal insufficiency or a significant 
risk of interactions or adverse reactions. Category D medicinal substances should be avoided in 
older people. They can be used only in exceptional cases or on a one-off basis. Changes due to 
ageing predispose older people to adverse or dangerous reactions to these substances. The risk of 
adverse reactions typically exceeds potential benefits. In individual cases, the use of category D 
medicinal products can be considered. The drug information on each pharmaceutical substance 
contains information on the effects and dosing of the substance and the most typical adverse 
reactions and interactions, e.g. whether the drug has anticholinergic, serotonergic, or sedative side 
effects. Indications and contraindications are not mentioned. 
Leikola and colleagues in Finland developed a Comprehensive Medication Review (CMR) 
procedure to improve pharmacotherapy among community-dwelling older people (Leikola 2012). 
The CMR includes a review of the literature and medication review procedures and pilot testing by 
experienced pharmacists. Inappropriate drugs are based on Beers’ criteria. Pharmacists receive 
special training in order to qualify for CMR. The procedure includes clinical patient information, a 
home visit with patient interview, discussion with the collaborating physician, and documentation. 
The focus is on inappropriate drugs, undertreatment, and adequate treatment of pain. 
In Finland, a tool for practical nurses working in home care has also been developed to recognize 
drug-related problems (Dimitrow 2016). A three-round Delphi survey with a panel of 18 experts 
validated the draft tool. The final Drug-Related Problem-Risk Assessment Tool (DRP-RAT) 
contains 18 items, focusing on both DRPs related to pharmacology and the medicine use process. 
Recommendations to solve problems are also included (Dimitrow 2016).  
In addition to many explicit criteria (Beers et al. 1991, Beers 1997, Laroche et al. 2007) and 
explicit-implicit criteria (Gallagher et al. 2008), also implicit criteria have been created to evaluate 
the appropriateness of medication prescribed to older people (Hanlon et al. 1992). This Medication 
Appropriateness Index (MAI) consists of 10 criteria in question form to consider when evaluating a 
prescribed drug. The questions are the following: 1. Is there an indication for the drug? 2. Is the 
medication effective for this condition? 3. Is the dosage correct?  4. Are the directions correct? 5. 
Are the directions practical? 6. Are there clinically significant drug-drug interactions? 7. Are there 
clinically significant drug-disease/condition interactions? 8. Is there unnecessary duplication with 
other drugs? 9. Is the duration of therapy acceptable? 10. Is this drug the least expensive alternative 
compared to others of equal utility?  The MAI is calculated according to the answers to these 
questions (Hanlon et al. 1992). The MAI may be useful for research studies, quality improvement, 
and patient care (Samsa et al. 1994).  
 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2.2 Beers’ inappropriate drugs 
 
Polypharmacy was common already in the 1990s among institutionalized older people in the USA. 
According to a well-known study, nursing home residents were prescribed on average eight 
medications and more than half of the residents were on psychotropics and one in four on 
antipsychotics (Beers et al. 1988). There was a need for criteria to define appropriateness of 
medication for older persons. To help overcome differences in published opinions, a panel of 
experts defined the first Beers’ inappropriate drugs for older people (Beers et al. 1991). The best 
criteria were considered to result from the consensus of experts in the fields of geriatric medicine, 
geropsychiatry, and geriatric pharmacology, guided by published statements (Beers et al. 1991). 
The criteria were based on a comprehensive literature review (Beers et al. 1991).  
 
2.2.2.1 Development of Beers’ list over decades 
 
Differences in medications between Beers’ lists 2003, 2012, and 2015 are presented in Appendix 1.  
There were 30 drugs/drug categories to be avoided in the first Beers’ criteria such as sedative-
hypnotics, antidepressants, antipsychotics, antihypertensives, non-steroidal anti-inflammatory 
agents, oral hypoglycaemics, analgesics, dementia treatments, platelet inhibitors, histamine 2 
blockers, antibiotics, decongestants, iron supplements, muscle relaxants, gastrointestinal 
antispasmodics, and antiemetics. Of these, 19 should always be avoided and 11 received 
recommendations for dose, frequency, or duration of treatment (Beers et al. 1991).  
The first Beers’ criteria were updated in 1997. The new recommendations concerned all older 
people (≥65 years) regardless of where they lived (Beers 1997). Beers’ criteria 1991 identified 
inappropriate medication use in nursing homes in the absence of clinical information on diagnoses. 
When Beers’ criteria were updated, there was a database available with more information on older 
people’s diagnoses and conditions. The revised criteria consisted of 28 criteria describing the 
potentially inappropriate use of older people’s medication. There were also 35 criteria defining 
potentially inappropriate medication use in older persons related to 15 common medical conditions. 
In Beers’ 1997 criteria, a new term “potentially inappropriate medication” (PID) instead of 
“inappropriate medication” appeared for the first time. In the original article (Beers 1997), Beers 
presented criteria for potentially inappropriate drugs related to 19 conditions, e.g. patients with 
heart failure should not receive disopyramide or drugs with high sodium content, patients with 
ulcers should not receive NSAIDs, Aspirin >325 mg, or potassium supplements, and patients with 
peripheral vascular disease should avoid β-blockers. 
The next Beers’ criteria update was published in 2003 (Fick et al. 2003). Recognition of 
medication-related problems was considered important because these problems were thought to 
increase hospital admissions, costs, and even deaths (Hanlon et al. 1997, Lazarou et al. 1998). New 
drugs had been released, knowledge about older drugs had increased, and drugs had been removed 
from the market, so it was time to update the criteria for potentially inappropriate drugs among 
older people. Beers’ criteria 2003 consisted of 48 medications or classes of medications that should 
be avoided or limited in their doses or duration of treatment in older persons. In the Beers’ update 
2003, there was also a list of 20 diseases or conditions and medications to be avoided when treating 
older adults with these conditions. New conditions comprised depression, cognitive impairment, 
Parkinson’s disease, anorexia, malnutrition, syndrome of inappropriate antidiuretic hormone 
secretion (SIADH), and obesity.  
Fifteen medications or medication classes were dropped from the list compared with Beers’ 1997 
criteria. Most of the dropped medications were related to certain conditions. These included 
recently started corticosteroid therapy with diabetes, β-blockers with diabetes, asthma, peripheral 
vascular disease, and syncope and falls. Furthermore, sedative-hypnotics with COPD, potassium 
supplements with gastric or duodenal ulcers, metoclopramide with seizures or epilepsy, narcotics 
with bladder outflow obstruction or constipation, desipramine, SSRIs and β–agonists with 
insomnia, and bethanechol chloride with bladder outflow obstruction were excludedfrom the list. 
Guidelines changed as follows: reserpine should be avoided only at doses >0.25 mg, oxybutynin 
was considered safe in its extended-release form, and dipyridamole should be avoided only in its 
short-acting form.  
Compared with the previous update, 25 drugs or drug classes independent of diagnoses were added 
like ketorolac, orphenadrine, nitrofurantoin, clonidine, cimetidine, ferrous sulphate, amphetamines, 
short-acting nifedipine, daily fluoxetine was included again in PIDs, stimulant laxatives except 
when using opioids simultaneously, amiodarone, NSAIDS such as naproxen, oxaprozin, and 
piroxicam, oestrogens in older women, methyltestosterone, and mesoridazine (Fick et al. 2003).  In 
addition, the criteria included 19 medications or medication classes to be avoided related to certain 
conditions such as benzodiazepines and tricyclic antidepressants with falls, barbiturates, 
antispasmodics, and muscle relaxants with cognitive impairment, and metoclopramide, 
conventional antipsychotics, and tacrine with Parkinson disease (Fick et al. 2003). Appendix 2 
presents a list of Beers’ drugs 2003 available in Finland in 2011 as well as their drawbacks. 
The Beers’ criteria have been criticized for including a high number of medications not available in 
European countries (O’Mahony et al. 2010). The earliest lists also failed to include many 
psychotropics that can cause adverse effects. 
Potentially inappropriate medications (PIMs) were still commonly used among vulnerable older 
adults, and it was again necessary to update recommendations for medication for older people.  
Updating was realized with the support of the American Geriatrics Society.  Consensus was reached 
after a systematic literature review by a panel of 11 specialists in geriatric care and 
pharmacotherapy (AGS 2012). In the AGS 2012 criteria, medications were divided into three 
categories: PIMs and classes to avoid among older adults; PIMs and classes to avoid among older 
adults related to certain conditions; and medications to be used with caution among older adults. 
The 2012 AGS Beers’ criteria were, like the two previous criteria, intended to be used among all 
people aged 65 years or older regardless of where they live. In this updating, the quality of evidence 
was estimated to be as high-moderate-low and the strength of the recommendation as strong-weak-
insufficient. Most of the estimations for quality of evidence were moderate or high, and most of the 
recommendations were strong (AGS 2012). 
There were 34 potentially inappropriate medications or medication classes to be avoided among all 
older people aged 65 years or more. Differences between Beers’ list 2003 and Beers 2012 in 
medications independent of diagnoses or conditions are presented in Appendix 1.  A notable 
difference was that there were altogether 16 NSAIDs in oral use to be avoided in the new list. 
Benzodiazepines should always be avoided; there were no more maximum doses. There were also 
12 conventional antipsychotics and 10 atypical antipsychotics that should be avoided. This 
recommendation was based on studies suggesting risk of antipsychotic use, which may cause 
strokes and even deaths in persons with dementia (AGS 2012). New potentially inappropriate drugs 
were, for example, spironolactone >25 mg/d, testosterone, oestrogens also with progestins, oral 
aspirin >325 mg/d, megestrol, glyburide, and sliding scale insulin therapy.  
New drugs added to the list related to certain conditions were, for example, glitazones with heart 
failure, acetylcholinesterase inhibitors with a history of syncope, and SSRIs with falls and fractures 
(AGS 2012). There was also a list of medications that should be used with caution among older 
people. For example, aspirin for primary prevention of cardiac events among people ≥80 years was 
not evidence-based, vasodilators should be used with caution because they may cause syncope, and 
when using SSRIs, sodium level should be monitored. 
The latest Beers’ criteria update was published in 2015 (AGS 2015). The criteria were applicable to 
all individuals aged 65 years or more, except those in hospice and palliative care. Compared with 
the 2012 criteria, there were only a few changes in these lists.  Antiarrhythmic drugs, except 
disopyramide and dronedarone, were removed, and amiodarone and digoxin were advised to be 
avoided as first-line treatment for atrial fibrillation. Constipation was removed from the “according 
to certain conditions list”. Proton pump inhibitors (PPIs) should not be used for more than 8 weeks 
unless for high-risk patients because of an association between the use of PPIs and Clostridium 
difficile infection, bone loss, and fractures.  Desmopressin was added to an independent list of 
conditions (incontinence) for risk of hyponatremia and first-generation antihistamine meclizine to 
the anticholinergic list. The hypnotics eszopiclone and zaleplon should be avoided in patients with 
dementia or cognitive impairment.  Antipsychotics should be avoided as first-line treatment in 
delirium. Some medications, such as nitrofurantoin, were moved to another category or modified. 
Nitrofurantoin can be used with caution also in individuals with creatinine clearance ≥30 ml/min 
(vs. the earlier ≥60 ml/min), but only in the short term.  
A new list in the 2015 Beers’ criteria included drug-drug interactions (excluding anti- 
infectives). This list was selective and not comprehensive. An example from this list is a 
recommendation for not using more than two central nervous system drugs concomitantly. 
Concomitant use of warfarin with NSAIDs was also forbidden (AGS 2015).  Potentially 
inappropriate medications based on renal function were also on the new list. There were 
medications that should be avoided or for which the dose should be adjusted according to decreased 
renal function such as amiloride, triamterene, some non-vitamin K antagonist oral anticoagulants, 
duloxetine, and famotidine (AGS 2015). 
See Appendix 1. 
2.2.2.2 Prevalence of Beers’ drugs in institutional settings 
The prevalence of PID use in institutional settings is presented in Table 2. 
Of home care patients (≥65 years) in eight European countries, 20% used inappropriate medication 
according to three different criteria (Beers’ lists 1997 and 2003, and McLeod’s list 1997) (Fialová 
et al. 2005). The highest prevalence was in the Czech Republic, 41%, and the lowest in Denmark, 
6% (Fialová et al. 2005). According to a cross-sectional study (data from 1 November 1998 to 31 
March 1999 in Finland), 13% of 3219 home-dwellers used inappropriate medication from Beers’ 
list 1997 (Pitkälä et al. 2002a). According to register-based data from 2007, the use of Beers’ 
criteria 2003 PIDs among all home-dwelling older people was still quite low in Finland, 15% 
(Leikola et al. 2011). In Italy, the prevalence of the use of Beers’ 2003 PIDs among the community-
living 80+ years population was 26% (Landi et al. 2007).  
Use of Beers’ inappropriate drugs was common also among community-dwelling older people in 
USA. According to a retrospective cohort study, 40% used one and 13% two or more Beers’ drugs 
(Fick et al. 2008). According to a recent American study, 43% of community-dwelling adults aged 
≥65 years used Beers’ 2012 inappropriate drugs, NSAIDs being the most common (11%) (Davidoff 
et al. 2015). Based on a systematic review, the use of PIMs varied markedly in studies in 1997-
2009, from 12% to 63% (Guaraldo et al. 2011).  PIMs were defined using Beers’ criteria/other 
criteria derived from Beers (Guaraldo et al. 2011). 
According to a retrospective cohort study, 40% of US nursing home residents used Beers’ 1991 
inappropriate medication, 10% used two or more, and 7% of all prescriptions were inappropriate 
(Beers et al. 1992). From almost 20 000 nursing home residents, 49% used inappropriate 
medication in USA during a one-year follow-up (Gupta et al. 1996). Of nursing home residents 
(N=20 573), 33% were on inappropriate medication, whereas among community-dwelling persons 
(N=44 259) the respective figure was 24% (Piecoro et al. 2000). Dhall and colleagues (2002) 
investigated in USA how the use of PIDs changed during the 90 days after admission to a nursing 
home. At admission, 33% of residents received at least one PID; during the following 90 days the 
drug was discontinued in 16% of these residents. Among those not receiving any PID initially, 
medication commenced in 18% (Dhall et al. 2002). Later, the prevalence of inappropriate 
medication has varied between 26% and 50% in USA (Briesacher et al. 2005, Lau et al. 2004, 
Rigler et al. 2005). The highest prevalence of 50% was found in a study in which also PIDs 
according to conditions were considered (Lau et al. 2004). Comparing the prevalence in 1997 
versus 2000 among nursing home residents, the use of PIDs had decreased from 29% to 26% and in 
assisted living facilities from 22% to 19% (Briesacher et al. 2005). A study investigated the effect 
of implementing the modified updated Beers’ criteria in nursing homes on the use of inappropriate 
medication among nursing home residents in USA. The use of any PIM decreased from 43% in 
1997 to 40% in 2000, resident characteristics adjusted Odds ratio (OR) = 0.85, 95% CI  0.84 to 
0.87) (Lapane et al. 2007).  
The use of potentially inappropriate medication among older people is also common in institutional 
settings in other countries. In Finland, approximately one-third of the residents in nursing homes 
were on PIDs (Raivio et al. 2006, Hosia-Randell et al. 2008). In Italy, almost half of the residents in 
nursing homes were exposed to PIDs according to the Beers’ 2003 list (Ruggiero et al. 2010). Of 
residents in long-term care facilities in Japan, 21% used PIDs according to a diagnosis-independent 
list and 18% according to a certain conditions list (Niwata et al. 2006).  
In Tasmania, Australia, 35% of residential care home residents used at least one Beers’ criteria 
2003 medication and females more often received inappropriate psychotropic medication (Stafford 
et al. 2011). Compared with potentially inappropriate medication according to McLeod’s criteria 
(19%), Beers’ criteria identified more inappropriate drugs (Stafford et al. 2011). Some years later, 
the use of PIDs was still high in Australia (55%) (Bosboom et al. 2012). In Malaysia, 33% of 211 
nursing home residents used PIDs according to Beers’ 2003 criteria, whereas the proportion of PIDs 
was 24% according to STOPP criteria (Chen et al. 2012). The highest prevalence of PIDs among 
nursing home residents was found in Brazil, 83% (Vieira de Lima et al. 2013). 
 








Table 2. Prevalence of Beers’ potentially inappropriate drugs (PID) in institutional settings. 
 




Beers et al. 1992 USA NH 1106/80% 84 1991 40 
Gupta et al. 1996 USA NH 19932/74% 60% >80 1991  49 
Piecoro et al. 2000  USA NH 20573 ≥65 1997 33 
Dhall et al. 2002 USA NH 29062/69% 82% ≥75 1997 33 
Lau et al. 2004  USA NH 3372/74% ≥65 1991, 1997  50 
Perri et al. 2005 USA NH 1117/82% 85  1997 47 
Rigler et al. 2005 USA NH 1164/77% 82% >75   1997 38 
Niwata et al. 2006  Japan LTCF 1669/75% 85   2003 21 
Raivio et al. 2006 Finland NH+AH 425/82% 86  2003 36 








Hosia-Randell et al. 
2008 
Finland NH 1987/81% 84  2003 35 
Ruggiero et al. 2009 Italy NH 496/75% 82 2003 17  
Ruggiero et al. 2010 Italy NH 1716/72% 84 2003 48 
Stafford et al. 2011  Australia RCH 2345/76% 63% ≥85 2003 35 
Bosboom et al. 2012  Australia RAFC 226/75% 86 2003  55 
Chen et al. 2012 Malaysia NH 211/61% 78 2003 33 
Vieira de Lima et al. 
2013 
Brazil LTCF 261/58% >60, 22% ≥85 2012 83 
AH= Acute Hospitals; CMS = Centers for Medicare and medicaid Services; LTCF= Long-Term Care Facilities; NH= 




2.2.2.3 Factors associated with use of Beers’ drugs 
 
The use of Beers’ inappropriate drugs has been associated with polypharmacy (Dhall et al. 2002, 
Pitkälä et al. 2002a, Lau et al. 2004, Fialová et al. 2005, Perri et al. 2005, Niwata et al. 2006, Raivio 
et al. 2006, Landi et al. 2007, Hosia-Randell et al. 2008, Ruggiero et al. 2010, Guaraldo et al. 2011, 
Stafford et al. 2011, Chen et al. 2012, Vieira de Lima et al. 2013). Residents who were administered 
psychotropics more often received PIDs (Fialová et al. 2005, Niwata et al. 2006, Hosia-Randell et 
al. 2008, Stafford et al. 2011). 
Some studies showed that the use of PIDs was associated with younger age (Piecoro et al. 2000, 
Ruggiero et al. 2010), whereas others reported an association with older age (Landi et al. 2007, Lin 
et al. 2008, Cahir et al. 2014).  White race (Piecoro et al. 2000), female sex (Beers et al. 1992, 
Piecoro et al. 2000, Dhall et al. 2002, Guaraldo et al. 2011, Cahir et al. 2014), poor economic 
situation, and living alone (Fialová et al. 2005) were associated with the probability of receiving 
inappropriate medication.   
Multivariate analysis showed that residents living in larger nursing homes received more 
inappropriate medications than those living in smaller nursing homes (Beers et al. 1992). The risk 
of receiving inappropriate drugs decreased when living in a smaller nursing home (number of beds 
<100) and in nursing homes with a higher ratio (≥1/20) of registered nurses/residents (Lau et al. 
2004).  Use of Beers’ drugs was associated with longer nursing home stays (Chen et al. 2012).  
One prospective cohort study showed an association of PID use with cognitive impairment (Landi 
et al. 2007), whereas most studies have found no association with dementia (Dhall et al. 2002, Lau 
et al. 2004, Perri et al. 2005, Hosia-Randell et al. 2008, Ruggiero et al. 2009). PID use was 
associated with impaired physical condition (Dhall et al. 2002), cerebrovascular diseases and 
dependency (Vieira de Lima et. al. 2013), not having communication problems (Lau et al. 2004), 
and higher number of comorbidities (Landi et al. 2007, Lin et al. 2008, Ruggiero et al. 2010, 
Stafford et al. 2011, Cahir et al. 2014).  Also mental health problems (Lau et al. 2004, Vieira de 
Lima et al. 2013), feeling depressed, and poor subjective health were associated with risk of 
receiving inappropriate medication (Pitkälä et al. 2002a).  
According to a review article, female sex, lower age, being less educated, having more than one 
prescriber, polypharmacy, and comorbidities were predictors for receiving PIDs in institutionalized 
settings (Ruggiero et al. 2009).  
2.2.2.4 Adverse events related to Beers’ drugs  
 
Hospitalizations and mortality 
Adverse events related to Beers’ drugs are summarized in Table 3. 
A systematic review from all health care settings explored outcomes associated with the use of 
Beers’ criteria PIDs (Jano and Aparasu 2007). Use of PIDs among community-living older people 
was associated with hospitalizations, but there was no evidence of an association with other health 
care use, costs, or mortality. In nursing home settings, there was no association with mortality, and 
the association with hospitalizations was inconclusive (Jano and Aparasu 2007). In a retrospective 
cohort study, the use of Beers’ drugs was associated with the risk of nursing home transition 
(Zuckerman et al. 2006).  
A few studies have suggested an association between the use of PIDs and adverse events. 
According to a cross-sectional study among NH residents, PID users were exposed to potential 
drug-drug interactions (Hosia-Randell et al. 2008). A retrospective observational cross-sectional 
study showed that the number of PIDs among nursing home residents was associated with 
pharmaceutical costs, but there was no association with mortality (Gupta et al. 1996). Conversely, 
by minimizing the number of potentially inappropriate medications that prescribers and pharmacies 
used, the total pharmaceutical costs may be decreased (Gupta et al. 1996). According to a US study, 
nursing home residents receiving any Beers’ drug had a greater risk of being hospitalized or to be 
deceased than those not receiving any Beers’ drug, also after multivariate analysis of longitudinal 
cohort data (Lau et al. 2005). In a Swedish population-based, longitudinal cohort study, community-
dwelling older people (≥75 years) using PIDs according to several criteria had an increased risk of 
hospitalization, but not mortality. However, people living in sheltered housing or nursing homes did 
not show an association between the use of PIDs and hospitalization or mortality (Klarin et al. 
2005). Nevertheless, this Swedish study used Beers’ criteria only as part of their definition for 
PIDs. According to a longitudinal cohort study using Beers’ 1997 criteria among NH residents, only 
propoxyphene was significantly associated with adverse health outcomes like hospitalizations (Perri 
et al. 2005). In a retrospective cohort study, the use of PIDs among home-dwelling older people was 
associated with drug-related problems, e.g. falling and confusion, increased costs, and increased use 
of health care services (Fick et al. 2008). In the US study, patients aged 65 years and over admitted 
to hospital had a significantly longer stay in hospital if they received at least three PIDs according 
to Beers’ 2012 criteria (Hagstrom et al. 2015).   
 
However, there are several other studies suggesting no association between the use of PIDs and 
adverse events. Potentially inappropriate drugs among Finnish older people had no effect on 
mortality, hospital admissions, or acute hospital stays (Raivio et al. 2006). According to a 
retrospective cohort study, there was no association between the use of Beers’ 2003 criteria PIDs 
and negative health outcomes (in-hospital mortality, adverse drug reactions, or length of stay) 
among hospitalized older Italian people (Onder et al. 2005). Nine years later, a cross-sectional study 
in Italian internal medicine and geriatric ward patients aged ≥65 years was performed. Of patients, 
20% and 24% were receiving Beers’ criteria 2003 or 2012 drugs, respectively. After a 3-month 
follow-up, the use of Beers’ drugs was not associated with a higher risk of adverse clinical events, 
rehospitalization, or all-cause mortality in univariate or multivariate analyses (Pasina et al. 2014). 
According to the ULISSE project in Italy, use of Beers’ criteria 2003 PIDs among NH residents at 
baseline was associated with an increased risk of hospitalization during the following 12 months 
compared with residents not receiving PIDs (Ruggiero et al. 2010).  The use of ≥2 Beers’ 2012 
PIDs among Irish community-dwelling older people (N=931) was not associated with 
hospitalizations, whereas the use of ≥2 STOPP criteria was (Cahir et al. 2014).  
Australian nursing home residents and other people ≥65 years receiving PIDs were investigated for 
an association with unplanned hospital admissions (Price et al. 2014). An association was present in 
both groups. After adjusting for health and medication profiles, there was 20% greater risk of 
unplanned hospitalization in older people receiving PIDS than in their peers not receiving PIDs 
(Price et al. 2014). When the number of daily doses of PIDs increased in this group, the risk of 
unplanned hospitalization also increased. In addition, when the number of doses per day increased, 
the risk of hospitalization of nursing home residents increased (Price et al. 2014). This may be 
explained by frail older people’s susceptibility to adverse effects of PIMs (Table 3). 
The prevalence of emergency department (ED) visits for adverse drug events in USA has increased 
in 10 years from 2.4 to 4.0 per 1000 ED visits annually. Beers’ criteria medications were found to 
be responsible for only 1.8% of ED visits for adverse drug events (Shehab et al. 2016). In a 
European study, Beers’ 2003 criteria PIDs were considered to be responsible for 6% and STOPP 
criteria PIMs for 11% of hospital admissions (Gallagher and O’Mahony 2008). 
According to a recent systematic review including 39 studies, most (n=33) of which used Beers’ 
criteria, 22 articles reported an association between the use of PIDs and hospitalizations, and seven 
articles reported an association of PIDs with higher costs among older adults (Hyttinen et al. 2016). 
PID users had also more hospitalizations than non-users, both home-dwelling older people and 
nursing home residents. The use of PIDs also increased the number of health care and emergency 
department visits (Hyttinen et al. 2016).  
Quality of life  
 
According to a population-based data with a 2-year follow-up, use of Beers’ 1997 PIDs among 
people aged 65 years and over predicted lower self-perceived health status (Fu et al. 2004).  A 
systematic review exploring Beers’ PIDs found that the use of PIDs was associated with adverse 
drug reactions, but not with health-related quality of life (HRQoL) (Jano and Aparasu 2007).  
Among non-institutionalized people, the use of Beers’ inappropriate drugs was not associated with 
quality of life (QoL) (Franic and Jiang 2006). In a cross-sectional Australian study, there was no 
association between the use of PIDs based on Beers’ 2003 criteria and QoL (Bosboom et al. 2012); 
the same is true of a Malaysian prospective follow-up study with STOPP criteria among nursing 
home residents (Al Aqqad et al. 2014).  However, polypharmacy and Drug Burden Index (DBI) 
(exposure to anticholinergic and sedative medications) were negatively associated with QoL 
(Bosboom et al. 2012).  
 
Use of PIDs may also have an effect on physical performance and function (Landi et al. 2007). 
Italian home-dwelling people aged 80+ years using PIDs had a lower physical battery score, 
walking speed, balance and chair stand test, and hand grip strength, also after adjusting for age and 
other potential confounders. Subjects using two inappropriate drugs had lower results in walking 
speed, physical performance battery score, and ADL score than those using one or none (Landi et 
al. 2007). 
  




Study design, follow-up, 
Beers’ criteria considered 
Findings 
Hospitalizations, use of services, QoL, costs 
 




Number of PIDs associated with costs of 
pharmaceutical services 
Lau et al. 2005, USA (NH) 3372/74%,  
50% ≥85 
Retrospective cohort, 1 year, 
1991, 1997 
Risk of hospitalization increased 
Onder et al. 2005, Italy (H) 5152/52%, 79 Register study, 2003 No association with length of stay 
Perri et al. 2005, USA (NH) 1117/82%, 85 Cohort, 5 months, 1997 PIDs associated with hospitalizations and 
ED visits 
Klarin et al. 2005, Sweden 
(CD, SH, NH) 
785/58%, 82 Longitudinal cohort study, 3 
years, 1997  
Increased risk with ≥1 hospitalization 
among community-dwelling persons aged 
≥75 years 
Raivio et al. 2006, Finland 
(NH+AH) 
425/82%, 86 Retrospective cohort, 2 years, 
2003 
No association with hospital admissions, 
or acute hospital stays 
Zuckerman et al. 2006, USA  487383, 56%, 
74 
Retrospective cohort, 2 years, 
2003 
Association with risk of nursing home 
transition 
Lin et al. 2008 Taiwan (H) 5741/ 56%, 75 Cohort, 6 months, 2003 Risk of hospitalization increased  
Fick et al. 2008, USA (HD) 16877/ 71%, 
73 
Retrospective cohort, 6 
months, 2003 
Health care utilization and costs increased 
among users of PIDs 
Ruggiero et al. 2010, Italy 
(NH) 
1716/72%, 84 Prospective, 1 year, 2003 Association with hospitalizations 
Stockl et al. 2010, USA (CD) 37358, 75%, 
≥65 
Retrospective cohort, 1 year, 
2003 and Zhan criteria 
PID use associated with higher medical 
and health care costs 
Bosboom et al. 2012, 
Australia (RAFC) 
226/75%, 86 Cross-sectional, 2003 Exposure to PIDs not associated with 
lower QoL  




Cross-sectional, 2012, all 
categories 
No association with hospitalizations 
Cahir et al. 2014, Ireland (CD) 931/54%, 78 Retrospective cohort, 6 
months, 2012 
No association with hospitalizations 
Pasina et al. 2014, Italy (H) 844, 51%, 79 Cross-sectional, 3 months, 
2003, 2012 
No association with re-hospitalizations 






Use of PIDs associated with unplanned 
hospitalizations in both groups 














No association with mortality 
Lau et al. 2005, USA (NH) 3372/74%, 
50% ≥85 
Retrospective cohort, 1 year, 
1991, 1997 
Risk of death increased 
Onder et al. 2005, Italy (H) 5152/52%, 79 Register study, 2003 No association with mortality  
Perri et al. 2005, USA (NH)  1117/82%, 85 Cohort, 5 months, 1997 Use of PIDs associated with mortality 
Klarin et al. 2005, Sweden 
(CD, SH, NH) 
785/58%, 82 Longitudinal cohort study, 3 
years, 1997 
No association with mortality 
Raivio et al. 2006, Finland 
(NH, AH) 
425/82%, 86 Retrospective cohort, 2 years, 
2003 
No association with mortality  
Pasina et al. 2014, Italy (H) 844/ 51%, 79 Cross-sectional, 3 months, 
2003, 2012 
No association with mortality  
AH=acute hospitals; CD = community dwelling; DBI= Drug burden index; ED =emergency department; 
H=hospitalized; HD=home dwelling; ICF=intermediate care facilities; LTCF= Long-term care facilities; N.A. = not 
applicable; NH= nursing homes; QoL= Quality of life; RAFC= Residential aged care facilities; SH =Sheltered housing
2.2.3 Drugs with anticholinergic properties (DAPs) 
2.2.3.1 Cholinergic transmission 
Acetylcholine is a neurotransmitter that acts on both the peripheral autonomic nervous system and 
the central nervous system (CNS) (Rang et al. 2016). Acetylcholine acts via muscarinic (M1-5) 
(Kay et al. 2005, Rang et al. 2016) and nicotinic receptors (Rang et al. 2016). Activating muscarinic 
receptors in the peripheral parasympathetic nervous system causes effects such as heart rate 
decrease, urinary bladder contraction, urinary sphincter relaxation, salivary gland blood vessel 
dilatation, salivary gland secretion, eye pupil constriction, and ciliary muscle contraction (Karimi et 
al. 2012, Rang et al. 2016). The location and effect of blockage of different five receptors are 
presented in Table 4. The brain also has nicotinic receptors, which act via other mediators like 
glutamate and dopamine (Rang et al. 2016). However, the term ‘anticholinergic’ traditionally refers 
to muscarinic receptor antagonism (Gerretsen and Pollock 2011).  
Table 4. Muscarinic receptors (M 1-5) in the central nervous system (CNS) and other tissues (Kay 
et al. 2005, Karimi et al. 2012). 
Subtype General distribution in the CNS Non-CNS locations Effect of blockage of receptor 
M1 In cerebral cortex, hippocampus, and 
neostriatum (constitute about half of total 
acetylcholine receptors in CNS) 
Salivary glands, 
sympathetic ganglia 
Impairment of cognitive 
function, delirium, dry mouth 
M2 Located throughout CNS Smooth and cardiac 
muscle, detrusor muscle of 
the bladder 
Cognitive decline, delirium, 
constipation, urinary retention 
M3 Low levels throughout CNS Smooth muscle, salivary 
glands, eyes, detrusor 
muscle of the bladder 
Dry mouth, constipation, 
urinary retention, blurred vision 
M4 In neostriatum, cortex, and hippocampus Salivary glands Impairment of cognitive 
function, delirium, dry mouth 
M5 Projection neurons of substantia nigra 
pars compacta and ventral tegmental 
area, and hippocampus 
Eyes (ciliary muscle) Blurred vision 
 
Drugs with anticholinergic properties (DAPs) are able to block cholinergic muscarinic receptors. 
Some DAPs are used specifically for this effect like drugs to treat an overactive bladder, muscle 
spasms, chronic obstructive pulmonary disease (COPD), and Parkinson’s disease. However, DAPs 
also have a number of unwanted effects (Kay et al. 2005, Lechevallier-Michel et al. 2005, Uusvaara 
et al. 2011, Salahudeen et al. 2014, Nishtala et al. 2016). Because of the increased permeability of 
the blood-brain barrier and age-related pharmacodynamic changes, the ageing brain is particularly 
sensitive to adverse effects of DAPs (Ehrt et al. 2010). Many commonly used drugs are prescribed 
for older people without recognition of the anticholinergic properties of these medications (Nishtala 
et al. 2016). 
2.2.3.2 Definitions of DAPs 
Cumulative exposure to multiple medicines with anticholinergic properties is known as 
anticholinergic burden (Tune 2001). A number of scales have been developed to define drugs with 
anticholinergic properties and to measure the anticholinergic burden (Han et al. 2001, Ancelin et al. 
2006, Carnahan et al. 2006, Hilmer et al. 2007, Boustani et al. 2008, Chew et al. 2008, Han et al. 
2008, Rudolph et al. 2008, Ehrt et al. 2010, Sittironnarit et al. 2011) (see Table 5). Some authors 
have graded the levels of anticholinergic effect for various drugs, and anticholinergic burden can be 
measured by summing up the number of drugs and/or their level of effect on the person using them 
(e.g. Carnahan et al. 2006, Rudolph et al. 2008). Drug burden index (DBI) takes into account both 
DAPs, sedative drugs, and total number of medications (Hilmer et al. 2007). DBI is calculated using 
 Anticholinergic burden has also been measured using 
serum anticholinergic activity (SAA) (Chew et al. 2008). However, there is no consensus which 
definition or which standardized method should be used. Only a few studies have compared how 
various criteria identify the burden of DAPs and how these DAPs according to the different criteria 
overlap. Researchers have found low concordance between Anticholinergic Drug Scale (ADS) 
(Carnahan et al. 2006), Anticholinergic Risk Scale (ARS) (Rudolph et al. 2008), and 
Anticholinergic Cognitive Burden (ACB) (Boustani et al. 2008, Lertxundi et al. 2013, Naples et al. 
2015).  
Table 5 provides examples of various criteria to define DAPs.  In most of the criteria, the 
anticholinergic effect has been graded with a scale in which low points indicate lower levels of 
anticholinergic activity and higher points higher activity. Most lists are based on expert opinion 
and/or literature review, previous anticholinergic lists, or SAA measures. The number of 
anticholinergic drugs varies between 27 to 195 according to different definitions and scales.  
Various lists of DAPs and DAP scales have shown associations of DAPs with adverse effects, thus, 
prognostic validity. For example, the use of drugs according to Carnahan’s Anticholinergic Drug 
Scale (ADS), Rudolph’s Anticholinergic Risk Scale (ARS), or Chew’s list showed associations 
with poor vision, cognitive decline, and depression (Lampela et al. 2013). Many anticholinergic 
lists have been associated with poorer cognitive function (Ancelin et al. 2006, Hilmer et al. 2007, 
Boustani et al. 2008, Han et al. 2008, Uusvaara et al. 2009, Ehrt et al. 2010, Sittironnarit et al. 
2011). However, none of these methods have been widely accepted to assess anticholinergic burden 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Serum anticholinergic activity (SAA) has been considered important in quantifying anticholinergic 
burden; it measures anticholinergic medications, metabolites, and possibly endogenous substances 
(Chew et al. 2008). Evidence suggests an association between higher SAA and lower cognition in a 
small sample (Chew et al. 2005). However, if SAA is determined to be elevated, this does not 
provide any guidance as to which medications should be discontinued (Carnahan et al. 2006). When 
SAA from 107 most frequently used medications by older long-term care (LTC) residents was 
measured, 39 showed detectable SAA (Chew et al. 2008). Measurement of SAA is not widely 
available clinically (Gerretsen and Pollock 2011). In addition, it is a measure of anticholinergic 
activity in serum, not in CNS (Gerretsen and Pollock 2011). Besides, it has been argued that this 
value is no better than lists of drugs with known anticholinergic properties (Lampela et al. 2013). A 
cross-sectional Finnish study found no association between SAA levels and cognition or other 
anticholinergic adverse drug events (Lampela et al. 2013). According to a recent systematic review 
and meta-analysis, four studies showed no association between SAA and cognitive decline, whereas 
four studies supported this association. In conclusion, SAA has limitations and its use is still under 
development (Salahudeen et al. 2016).  
 
2.2.3.3 Prevalence of DAPs in institutional settings 
The prevalence of the use of DAPs has varied according to the definition used, population 
characteristics, and time when study performed (Uusvaara et al. 2011, Salahudeen et al. 2015). 
Many definitions include older drugs, which are no longer used, affecting prevalence rates. In 
addition, different countries have various DAPs available.  When anticholinergic medication was 
calculated by using nine different scales, prevalence of DAPs varied widely, from 23% to 56%, 
among the same participants (Salahudeen et al. 2015). 
In institutional settings, the prevalence rates for DAPs have varied between 12% and 82% (Table 
6). Some studies include only drugs with high anticholinergic burden, thus providing fairly low 
prevalence rates (Kersten et al. 2013b). Use of Socialstyrelsen’s list has yielded fairly low 
prevalences (12-21%), which may reflect the low number of drugs included in the list or the good 
quality of prescribing in Sweden (Bergman et al. 2007, Olsson et al. 2010, Haasum et al. 2012).  
One Italian study and two Finnish studies used the same ARS score (Rudolph et al. 2008) and 
showed fairly similar prevalences (42-55%) in long-term care settings (Kumpula et al. 2011, 
Teramura-Grönblad et al. 2011, Landi et al. 2014). The highest prevalence was found in USA (74-
82%) in studies using either ACB score (Boustani et al. 2008) (Kolanowski et al. 2009, Palmer et al. 
2015) or ADS scale (Carnahan et al. 2006) (Chatterjee et al. 2010), both of which include a high 
number of DAPs.  
2.2.3.4 Factors associated with use of DAPs 
 
According to a large Swedish register-based study, the use of DAPs was associated with living in an 
institution (OR 2.58, 95% CI 2.48 to 2.68) (Haasum et al. 2012). According to a study among 
nursing home (NH) residents with dementia, higher age, impaired decision-making ability, and 
behavioural symptoms were negatively associated with the use of DAPs according to ADS level 2-
3, whereas higher number of drugs, schizophrenia, depression, anxiety, and Parkinson’s disease 
were positively associated with administration of these moderate and strong DAPs (Chatterjee et al. 
2010). According to a Finnish cross-sectional study in residential care facilities, lower age, higher 
number of drugs, use of cholinesterase inhibitors, psychiatric disorders, Parkinson’s disease, and 
higher level of disability were associated with the use of DAPs (Teramura-Grönblad et al. 2011). 
According to a population-based prospective cohort study, DAP users were more likely to be 
women, to have poor self-rated health, to have higher levels of depressive symptoms, and to have 
higher comorbidity than non-users (Gray et al. 2015).  
 
Among Finnish 400 community-dwelling older people (75-90 years) with cardiovascular diseases, 
74% used one or more DAPs (Uusvaara et al. 2011). Uusvaara defined DAPs by his own criteria, 
including 30 drugs based on the literature (Uusvaara et al. 2011). In a longitudinal study with both 
home-dwelling and institutionalized people, 47% used drugs with possible anticholinergic 
properties (Fox et al. 2011). Associating factors were older age, lower social class, former smoking, 
and more health conditions (Fox et al. 2011). In a Finnish national population cohort study, 51% of 
community-dwelling individuals with Alzheimer’s disease (AD) aged ≥65 years had been exposed 
to DBI medications (Gnjidic et al. 2014). DBI includes sedative drugs in addition to DAPs (Hilmer 
et al. 2007). Of people with AD, 16% had a high DBI; the respective figure was 8.7% among people 
without AD (Gnjidic et al. 2014). According to an Italian study, cognitive impairment and younger 
age were associated with DAP use in NHs (Landi et al. 2014). Of 235 home-dwelling Parkinson’s 
disease patients, 43% used DAPs and the use was associated with lower education and lower 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2.3.5 Adverse events related to DAPs 
 
Drugs with anticholinergic properties are known to be associated with a number of adverse drug 
reactions such as central nervous system effects, e.g. cognitive impairment, delirium, and falls, and 
peripheral side effects, e.g. dry mouth, dry eyes, mydriasis, anhidrosis, constipation, and urinary 
retention (Tune 2001, Rudolph et al. 2008, Puustinen et al. 2011, Gerretsen and Pollock 2011, 
Puustinen et al. 2012, Nishtala et al. 2016). The cholinergic neuron system is damaged in patients 
with dementia, and therefore, anticholinergic medication may lead to worsening of cognitive 
impairment (Chatterjee et al. 2010, Lechevallier-Michel et al. 2005) and may even be a risk factor 
for psychosis (Cancelli et al. 2008). 
Adverse effects related to the use of DAPs are well-known peripheral effects, such as dry mouth, 
tachycardia, urinary retention, constipation, peristaltic reduction, and inability to accommodate 
vision, and central effects, such as cognitive impairment, behavioural excitation, attention deficits, 
and delirium (Tune 2001, Boustani et al. 2008, Karimi et al. 2012, Salahudeen et al. 2014). Dry 
mouth may lead to increased risk of respiratory infections, dental problems, impaired nutritional 
status, and communication problems (Tune 2001). Constipation may cause pain, lead to increased 
use of laxatives, and urinary retention may cause discomfort and predispose to urinary tract 
infections and need for catheterization (Tune 2001). According to a review article, among 
individuals 80 years and older, increased exposure to DAPs was associated with negative health 
outcomes such as cognitive and physical impairment and falls. However, the relationship with 
hospitalization and mortality remained inconclusive (Cardwell et al. 2015). Use of DAPs seemed to 
be associated with lower physical function (Lowry et al. 2011, Landi et al. 2014). 
Thus, DAPs may have a number of unpleasant side effects and they may have a negative impact on 
the quality of life. In one study, anticholinergic burden did not have a relationship with the quality 
of life indicator “engagement in activities” (Kolanowski et al. 2009). However, in a Finnish study, 
the use of DAPs was associated with poor psychological well-being (Teramura-Grönblad et al. 
2011).  
Hospitalizations and falls 
 
In a population-based study consisting of 537 387 people, nine different anticholinergic risk scales 
and associations of adverse health outcomes were compared (Salahudeen et al. 2015). 
Anticholinergic burden scores irrespective of the anticholinergic scale were independently 
associated with a greater risk of hospital admissions, fall-related hospitalizations, hospital length of 
stay, and more visits to general practitioners (Salahudeen et al. 2015). 
According to a Finnish prospective study among community-dwelling older people with a mean 
follow-up of 3.3 years, there was an association between the use of DAPS and an increased number 
of hospital days (Uusvaara et al. 2011). In a Finnish cohort study with a follow-up of over one year, 
a dose-response relationship was found between cumulative anticholinergic and sedative drug use 
and hospitalizations in community-dwelling people with and without dementia (Gnjidic et al. 2014). 
According to a prospective multicentre observational study data, the use of DAPs was associated 
with negative outcomes such as falls, functional decline, and delirium (Landi et al. 2014). 
According to an Australian study with a 12-month follow-up, there was an association between DBI 
and falls among older people living in residential aged care facilities (RACFs) (Wilson et al. 2011). 
IRR was 1.69 (95% CI 1.22 to 2.34) for low DBI (<1) and 2.11 (95% CI 1.47 to 3.04) for high DBI 
(≥1) compared with those with DBI of 0 (Wilson et al. 2011). According to a cohort study among 
people 65 years and older, the use of DAPs was associated with central adverse effects like falls 
(Rudolph et al. 2008). A multicentre study found that exposure to DAPs and sedative drugs 
increased the risk for in-hospital falls (Dauphinot et al. 2014). According to a review article, the use 
of DAPs may be associated with reduced physical function, and avoiding DAPs may preserve 
function and prevent falls (Fox et al. 2014). 
In an Australian retrospective cohort study with a 2-year follow-up, DAPs were defined by 
anticholinergic risk scale (ARS) (Rudolph et al. 2008) and anticholinergic drug scale (ADS) 
(Carnahan et al. 2006) (Kalisch Ellett et al. 2014). Individuals taking at least two DAPs had IRR 
2.58 (95% CI 1.91 to 3.48) and those taking three or more DAPs IRR 3.87 (95% CI 1.83 to 8.21) 
for hospitalization for confusion or dementia (Kalisch Ellett et al. 2014). 
Mortality 
In a Finnish retrospective study among operated male hip fracture patients with a 3-year follow-up, 
the use of potent anticholinergic drugs was associated with increased mortality (Panula et al. 2009). 
However, two other Finnish studies found no association between anticholinergic drug use and 
mortality (Kumpula et al. 2011, Uusvaara et al. 2011). According to a Finnish cohort study with a 
2-year follow-up, there was no association between the use of DAPs and delirium or 2-year 
mortality (Luukkanen et al. 2011). However, Gnjidic and colleagues (2014) reported a dose-
response relationship between cumulative anticholinergic and sedative drug use and mortality.  
Based on a secondary analysis of an Australian educational RCT aiming to improve patient-based 
outcomes among patients in palliative care, there was no association between anticholinergic load 
and mortality (Agar et al. 2010). This RCT used a modified Clinician-Rated Anticholinergic Scale 
(Han et al. 2001, Han et al. 2008). In another Australian study in residential aged care facilities, no 
significant association was present between increasing DBI score and all-cause mortality (Wilson et 
al. 2012). According to a large prospective longitudinal study using the ACB scale (Boustani et al. 
2008) to define DAPs, the use of drugs with possible and definite anticholinergic properties was 
associated with increased mortality during a 2-year follow-up (Fox et al. 2011).  Among older 
hospitalized patients, higher ARS scores (Rudolph et al. 2008) with, but not without, hyponatremia 
predicted mortality (Lowry et al. 2011). Increased exposure to anticholinergic and sedative 
medications was not associated with mortality in a multicentre cohort study (Dauphinot et al. 2014). 
The EPIC-Norfolk prospective study found an association between the use of DAPs and mortality. 
Participants were aged from 40 to 79 years (Myint et al. 2015).  
According to a systematic review article examining nine studies, there was no clear evidence for an 
association between use of DAPs and increased mortality (Fox et al. 2014).  
Ruxton with researcher colleagues (2015) investigated associations between the use of DAPs and 
all-cause mortality, falls, and cognitive impairment in a systematic review and meta-analysis. 
Associations emerged between the use of DAPs and mortality according to drug class, individual 
medications, and drug scoring systems. In the meta-analysis, the ACB scale showed a significant 
association with all-cause mortality (OR 2.06, 95% CI 1.82 to 2.33). 
DAPs and cognition  
A relationship exists between cognition and acetylcholine function in the brain. In young people, 
scopolamine injection induced cognitive deficits more similar to that occurring in non-demented 
older people than to that found in Alzheimer’s disease (Flicker et al. 1990). Blockade of cholinergic 
transmission might lead to the development of both acute and chronic cognitive impairment 
(Boustani et al. 2008). Older people are particularly vulnerable to cognitive impairment resulting 
from DAP use. They have changes in blood-brain barrier ultrastructure and permeability, reduction 
in density of muscarinic receptors in the brain, high comorbidity, and polypharmacy, which often 
lead to accumulation of DAPs (Kay et al. 2005). The increase in blood-brain barrier permeability 
may allow DAPs to cross the blood-brain barrier, resulting in increased sensitivity to the central 
nervous adverse effects of DAPs (Karimi et al. 2012).  
 
Drugs with properties to inhibit acetylcholinesterase, the enzyme that hydrolyses acetylcholine, are 
used in the treatment of Alzheimer’s disease (AD), and they have the potential to slow the decline 
in cognition (Ellis 2005). According to a systematic review and meta-analysis, acetylcholinesterase 
inhibitors (AChEIs) have only a limited effect in treatment of AD, but there is a lack of other 
effective medications for AD (Hansen et al. 2007).  When DAPs are used concomitantly with 
AChEIs, DAPs may reduce the effect of AD medication (Lu and Tune 2003). Despite this, 
concomitant use of AChEIs and DAPs is common (Kolanowski et al. 2009, Modi et al. 2009, 
Teramura-Grönblad et al. 2011, Bell et al. 2012, Palmer et al. 2015). According to a register-based 
Swedish study, the use of DAPs was more common among cholinesterase inhibitor users than non-
users (Johnell and Fastbom 2008). In USA, nearly half of nursing home residents with dementia 
taking cholinesterase inhibitors were concomitantly using DAPs (Modi et al. 2009). DAPs were 
often used to treat adverse effects of acetylcholinesterase inhibitors such as urinary incontinence 
and gastrointestinal upset (Modi et al. 2009, Bell et al. 2012).  
Cognitive performance among 1780 home-dwelling subjects aged 70 years or over was studied in a 
French cohort study (Lechevallier-Michel et al. 2005). In multivariate logistic regression models, 
the use of DAPs showed a trend to produce worse results in the MMSE (p=0.05), but was 
significantly associated with lower visual memory (p=0.015) and lower verbal fluency (p=0.0015) 
(Lechevallier-Michel et al. 2005). DAPs may also be associated with mild cognitive impairment. 
According to a longitudinal cohort study, people aged over 60 years with a one-year consistent 
exposure to DAPs were significantly more often classified as mildly cognitively impaired than non-
users (Ancelin et al. 2006). However, there was no difference between users and non-users in the 
risk of developing dementia at follow-up after eight years (Ancelin et al. 2006). 
DAPs contribute to cognitive impairment, confusion, and delirium (Han et al. 2001, Rudolph et al. 
2008, Campbell et al. 2009, Cancelli et al. 2009). According to a prospective cohort study with a 2-
year follow-up, cumulative anticholinergic exposure may negatively affect verbal memory and 
executive function in older men (Han et al. 2008).  
According to a Finnish cross-sectional study, there was an inverse association between the number 
of DAPs and Mini-Mental State Examination (MMSE) scores, the lowest MMSE scores obtained 
by subjects with apolipoprotein E4-allele (APOE4), also after adjustments (Uusvaara et al. 2009). 
The results were similar when Clinical Dementia Rating Scale (CDR) scores were used to reflect 
cognitive function (Uusvaara et al. 2009).  When these same participants were divided into two 
groups, those using one or more DAPs and those not using DAPs, a higher proportion of users had 
low verbal fluency (<16) and low naming test (<12/15) in the Consortium to Establish a Registry 
for Alzheimer’s Disease (CERAD) test battery relative to non-users, also after adjusting for age, 
sex, and education (Uusvaara et al. 2013). According to a longitudinal cohort study, there was 
significant association between ApoE4 allele and sensitivity to DAP use. Those women with 
ApoE4 allele taking DAPs had a 2-fold higher risk of global cognitive decline than women without 
ApoE4 allele taking DAPs (Carrière et al. 2009). 
Cancelli et al. (2008) found in a cross-sectional study containing 230 AD patients an association 
between the use of DAPs and psychosis (OR  2.52, 95% CI 1.27 to 5.00). Fox et al. (2011) used the 
ACB scale to define DAPs in a prospective longitudinal study with a 2-year follow-up. After 
adjustment, the use of drugs with definite anticholinergic properties was associated with a greater 
decline in cognition compared to non-use; the same was not true for drugs with possible 
anticholinergic properties. In a longitudinal cohort study with an 8-year follow-up, an association 
was present between the use of DAPs and the rate of cognitive decline among patients with 
Parkinson’s disease (Ehrt et al. 2010). A Finnish longitudinal population-based study found an 
association between anticholinergic use and decline in cognitive functioning only in men (Puustinen 
et al. 2011). 
In a randomized controlled trial training to reduce DAP use in nursing homes, ADS score 
(Carnahan et al. 2006) declined in the intervention group compared with the control group, whereas 
there was no improvement in cognition (Kersten et al. 2013a).  However, according to a 
longitudinal cohort study among community-dwelling people aged 65 years or more, the risk of 
incident dementia was increased in those continuing DAP use (hazard ratio (HR) 1.65, 95% CI 1.00 
to 2.73), but not in those discontinuing DAP use (HR 1.28, 95% CI 0.59 to 2.76) (Carrière et al. 
2009). In a cross-sectional study, there was no gradual decline in cognitive function among nursing 
home residents when the anticholinergic scale increased above 3. However, mouth dryness 
worsened and serum anticholinergic activity increased (Kersten et al. 2013b). The impact of 
anticholinergic discontinuation on cognitive functions is poorly researched and poorly understood 
(Salahudeen et al. 2014). 
According to a population-based prospective cohort study, higher cumulative use of anticholinergic 
drugs was associated with an increased risk for all-cause dementia and AD (Gray et al. 2015). In a 
recent study, the associations between DAP use and cognition, brain metabolism, and brain atrophy 
were investigated in cognitively normal adults (Risacher et al. 2016). Anticholinergic burden scale 
was calculated using the ACB scale (Boustani et al. 2008). DAP use was defined as a minimum use 
of a drug for at least 1 month before baseline. Cognitively normal older adults predisposed to 
medium or high anticholinergic activity had poorer cognition, reduced cerebral glucose metabolism, 
increased brain atrophy, and increased clinical decline compared with non-users (Risacher et al. 
2016).  
A clinical review investigating the association between anticholinergic burden and cognitive side 
effects included 27 studies (Campbell et al. 2009). All but two studies found an association between 
the anticholinergic activity of medication and either cognitive impairment, dementia, or delirium 
(Campbell et al. 2009). According to another review, an association was noted between the use of 
DAPs and cognitive impairment and onset of psychotic symptoms particularly among older people 
with dementia and delirium (Cancelli et al. 2009). In a systematic review including nearly 61 000 
participants, 77% of studies reported cognitive decline with increasing anticholinergic load, but 
only limited evidence about delirium (Fox et al. 2014). Furthermore, a systematic review and meta-
analysis found an association between the use of DAPs and cognitive impairment (Ruxton et al. 
2015) (see Table 7). 
   
  
Table 7. Use of DAPs and cognitive decline. 
Study, country 
(setting) 
N/ Females % Age, years Study design, criteria Results 
Flicker et al. 1990, 
USA (CD) 
30/N.A. 18 to 30 Experimental design, 
scopolamine 
Scopolamine injection caused 
cognitive effects similar to 
normal ageing 
Lu and Tune 2003, 
USA 
(CD) 
69 AD patients: 53 no 
DAPs + 16 with DAPs/ 
No DAPs 49%; with        
DAPs 63% 
No DAPs: 









significantly lower MMSE 
scores after follow-up 
Lechevallier-
Michel et al. 2005, 
France (CD) 
1780: 244 with DAPs 
/58% 
Median 77 Cross-sectional study 
(PAQUID cohort), 
own list including 7 
drug classes 
Use of DAPs was significantly 
associated with lower visual 
memory, lower verbal fluency, 
lower MMSE 
Ancelin et al. 2006, 
France  (CD + 
institutionalized) 
372: 51 with DAPs/ 
 ≈76% 




Persistent DAP users had 
increased risk of being 
classified as MCI, not of 
developing dementia  
Han et al. 2008, 
USA (CD) 
544: 342 with 
DAPs/0% 
Mean age 74 Prospective cohort 
study, 12-month 
follow-up, CrAS 
Cumulative DAP exposure 
negatively affected verbal 
memory and executive function  
Uusvaara et al. 
2009, Finland (CD) 
400: 276 with 
DAPs/65% 
Mean age 80 Cross-sectional study, 
list according to 
previous literature 
Higher number of DAPs was 
associated with lower MMSE. 
APOE4 carriers vulnerable to 
DAPs 
Carrière et al. 2009, 
France (CD) 
6912: 520 with 
DAPs/60% 
65+ Cohort, 4-year 
follow-up, 
combination of 3 lists 
Use of DAPs was associated 
with increased risk of cognitive 
decline and dementia 
Ehrt et al. 2010, 
Norway (CD) 
235: 99 with DAPs 
/52% 
Mean age 75 Cohort study, 8-year 
follow-up, AAS 
Use of DAPs was associated 
with higher rate of cognitive 
decline in men with PD 
Fox et al. 2011, GB 
(CD and 
institutionalized) 
13004: 6010 with 
DAPs/60% 
Mean age 75 Cohort study, 2-year 
follow-up, ACB 
Dose-response relationship 
between greater ACB score and 
lower MMSE 
Puustinen et al. 
2011, Finland (CD 
and 
institutionalized) 
1196/59% Mean age 71 Longitudinal 
population based, 
mean follow-up 7.6 
years 
DAP use was associated with 
cognitive decline in men 
Uusvaara et al. 
2013, Finland (CD) 
400: 295 with 
DAPs/65% 
Mean age 80 Cross-sectional 
cohort study, list 
according to previous 
literature 
DAP use associated with low 
naming and verbal fluency 
scores 
Gray et al. 2015, 
USA (CD) 
3434: 2689 with DAPs 
at any time point 
during follow-up /60% 




cohort study, 10-year 
follow-up, Beers’ 
2012 
10-year higher cumulative 
exposure to DAPs was 
associated with increased risk of 
dementia 
Risacher et al. 
2016, USA (CD) 
402: 52 with 
DAPs/53% 
Mean age 73 Cohort, ACB scale, 
and other reports 
Cognitively normal DAP users 
lower scores in several 
cognitive tests + reduce glucose 
metabolish in FDG + increased 
brain atrophy in MRI 
AAS=Anticholinergic Activity Scale (modified Chew list (2010)); ACB=Anticholinergic Cognitive Burden Scale 
(Boustani et al. 2008); AD=Alzheimer’s Disease; CD=Community Dwelling; CrAS=Clinician-rated Anticholinergic 
Score (Han et al. 2001); FDG=fluorodeoxyglucose F18 positron emission tomography; MCI=Mild Cognitive 
Impairment; PAQUID = Personnees Agees QUID; PD=Parkinson’s Disease 
  
2.2.4 Psychotropic drugs 
Psychotropic drugs and other centrally acting drugs are in commonly use among older people 
(Gruber-Baldini et al. 2004, Hosia-Randell and Pitkälä 2005, Nurminen et al. 2009, Olsson et al. 
2010, Lustenberger et al. 2011, Stafford et al. 2011, Bourgeois et al. 2012, Pitkälä et al. 2015). 
Although they are often needed to alleviate symptoms of pain, mood, Parkinson’s disease, 
psychosis, anxiety, or dementia, they also have potential adverse effects that predispose older 
people to sedation and risks of cognitive decline, delirium, falls, and catastrophic disabilities 
(Leipzig et al. 1999, Schneider et al. 2005, Franco and Messinger-Rapport 2006, Hartikainen et al. 
2007, Bloch et al. 2011, Puustinen et al. 2012, Seitz et al. 2013).   
 
 2.2.4.1 Definitions of psychotropic drugs 
The Anatomical Therapeutic Chemical (ATC) classification system of the World Health 
Organization (WHO) classifies drugs into different categories according to their therapeutic, 
pharmacological, and chemical properties and the organ or system on which they act (WHO 2012). 
ATC central nervous system drugs (code N) include anesthetics (N01), analgesics (N02), 
antiepileptics (N03), antiparkinson drugs (N04), psycholeptics (N05), psychoanaleptics (N06), and 
other nervous system drugs (N07).  Common drugs used by older people affecting the central 
nervous system in these categories include opioids (N02A), antiepileptics (N03A), antiparkinson 
drugs (N04), antipsychotics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), 
antidepressants (N06A), and antidementia drugs (N06D) (WHO 2012).   
All of these drugs affect the central nervous system. Some of them have sedating effects as either 
the primary effect of the drug or an adverse effect (e.g. opioids, antiepileptics, some antiparkinson 
drugs, antipsychotics, anxiolytics, hypnotics, sedatives, and some antidepressants), whereas others 
have been designed to have other effects on the central nervous system. However, the WHO ATC 
code category N does not include all sedative drugs such as many anticholinergic drugs (e.g. muscle 
relaxants and antiemetics) (WHO 2012). Some researchers have defined drugs having a sedative 
load, including most WHO ATC central nervous system drugs, but also muscle relaxants, 
theophylline, and scopolamine (Taipale et al. 2009).  This is a practical way of measuring sedative 
load in older people, thus, implicating potentially harmful effects on dizziness, falls, and sedation 
(Taipale et al. 2009).  There are also other ways of defining drugs with sedative properties 
(Linjakumpu et al. 2003).  Linjakumpu’s own definition includes, besides the sedatives mentioned 
above, some antitussives, proton pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs 
(NSAIDs), beta-blockers, and other cardiovascular drugs.  
Most researchers have explored psychotropic medications, which have been defined solely to 
include antipsychotics (N05A), antidepressants (N06A), anxiolytics (N05B), and sedative-hypnotics 
(N05C) (Hosia-Randell and Pitkälä 2005, Gobert et al. 2005, Hanlon 2010a, Wastesson et al. 2014), 
and sedative antihistamines have also been taken into account (Ruths et al. 2013). These drugs are 
commonly used in institutional settings to manage neuropsychiatric symptoms in dementia (Pitkälä 
et al. 2004a, Nurminen et al. 2009). The Swedish Socialstyrelsen has defined a quality indicator for 
inappropriate use of psychotropic drugs (Socialstyrelsen 2010, Socialstyrelsen 2017). It states that 
older people should never use more than two psychotropic drugs simultaneously (Socialstyrelsen 
2010, Socialstyrelsen 2017).  The majority of criteria for inappropriate drugs for older people 
include most psychotropic drugs, especially antipsychotics, anxiolytics, and long-term use of 
hypnotics (Laroche et al. 2007, Rognstad et al. 2009, Socialstyrelsen 2010, AGS 2012, AGS 2015, 
Nyborg et al. 2015, O'Mahony et al. 2015). Heterogeneous definitions reduce comparability 
between studies.  
  
2.2.4.2 Prevalence of psychotropic drugs in institutional settings 
 
The known adverse effects of psychotropic drugs are emphasized in older people (Hanlon et al. 
1998, Nurminen et al. 2010, Puustinen et al. 2011, Maust et al. 2015, Aparasu et al. 2012). Despite 
this fact, the use of psychotropic medication is common among both home-dwelling and 
institutionalized older people. There have been concerns about the abundant use of psychotropic 
drugs among older people. The Omnibus Budget Reconciliation Act of 1987 (OBRA 87) was 
created to improve quality of care in US nursing homes (Omnibus Budget Reconciliation Act of 
1987). It included instructions to reduce the use of psychotropic drugs. Antipsychotic drug use in 
US nursing homes declined after implementation of this regulation, but anxiolytics and 
antidepressants use remained at the same level. Use of any psychotropic drug decreased from 41% 
to 36% (Garrard et al. 1995). However, since 1996 use of especially antidepressants but also 
antipsychotics, anxiolytics and sedatives has significantly increased in American nursing homes 
(Hanlon et al. 2010a). Excessive psychotropic drug use among people with dementia has also 
received attention in France (Haute Autorité de santé AMI-Alzheimer program 2012). 
Contemporary use of psychotropics is common. In Sweden, 39% Of nursing home residents 
received three or more psychotropic drugs (Bergman et al. 2007). 
 
According to a Swedish register-based study, about 37% of older people (75+ years) dispensed any 
drug used at least one psychotropic drug (Wastesson et al. 2014).  According to a Finnish register-
based study, 53% of community-dwelling people with AD used at least one psychotropic one year 
after diagnoses, the respective figure among people without AD being 33% (Taipale et al. 2014). In 
Finland, about 37% of community-dwelling population samples (75+ years) were on psychotropics 
in Lieto and Kuopio in the 1990s (Linjakumpu et al. 2002, Hartikainen et al. 2003).  In Europe, 
43% of home care older people were on psychotropics (Fialová et al. 2005). About 6% of home 
care patients in nine European countries were on antipsychotics (Alanen 2007). There was wide 
variation in the use of one or more antipsychotics between different countries, ranging from 3% in 
Denmark to 12% in Finland (Alanen 2007). Older people living in institutional settings are usually 
administered a higher number of psychotropic drugs than the community-dwelling elderly (Haasum 
et al. 2012). Whereas in 2008 3% of community-dwelling older people used >2 psychotropic drugs 
defined as inappropriate by Socialstyrelsen, the respective figure for institutionalized older residents 
was 19% (Haasum et al. 2012). 
Table 8 presents the prevalence of psychotropic drug use in institutional settings. The prevalence of 
users of psychotropic drugs has varied between 36% and 80% in institutional settings, being fairly 
consistently >50% in prevalence studies published after the year 2000. In Norway, the prevalence 
of psychotropic drugs increased from 52% to 71% between the years 1985 and 2009 (Nygaard et al. 
2004, Ruths et al. 2013). In other European countries, the prevalence of psychotropic drugs has 
varied between 52% and 85% (Olsson et al. 2010, Richter et al. 2012, Rolland et al. 2012). In 
Finland, the prevalence of any psychotropic drug has ranged from 71% to 80% (Hosia-Randell and 
Pitkälä 2005, Alanen et al. 2006, Nurminen et al. 2009). The use of psychotropic drugs in Finland 
has shown a trend for a decrease in nursing homes, while remaining at the same level in assisted 
living facilities (Pitkälä et al. 2015).  
The use of antipsychotics is common, varying from 15% to up to 54% in nursing homes and other 
long-term care facilities in Europe and being highest in Spain (de Mauleon et al. 2014). In Norway, 
the use of antipsychotics remained at the same level in 1997-2009, but conventional neuroleptics 
use decreased and atypical use increased (Ruths et al. 2013). In Finland, the use of antipsychotics in 
nursing homes and other long-term care facilities has varied between 21% and 48% (Hosia-Randell 
and Pitkälä 2005, Alanen et al. 2006, Raivio et al. 2007, Nurminen et al. 2009, de Mauleon et al. 
2014, Pitkälä et al. 2015). The prevalence of the use of antipsychotics in long-term institutional care 
in Finland decreased from 42% in 2001 to 39% in 2003, however, this decrease was not statistically 
significant (Alanen et al. 2006). Adequate indications may not be fulfilled in all cases (Alanen et al. 
2006). The use of antipsychotics is more common among patients with dementia (Raivio et al. 
2007, Bell et al. 2010), and this trend is seen also in other countries (Macdonald et al. 2002, Olsson 
et al. 2010, Barro-Belaygues et al. 2011). Neuropsychiatric symptoms of dementia are treated with 
antipsychotics even though there is limited evidence of their effects (Sink et al. 2005). The use of 
atypical antipsychotics is nowadays more common in nursing homes than the use of conventional 
antipsychotics (Liperoti et al. 2003); a cross-sectional analysis of nursing homes in USA (Kamble et 
al. 2008), Finland (Bell et al. 2010), and Norway (Ruths et al. 2013) revealed the same trend. The 
use of atypical antipsychotics has also increased together with a decrease in the use of conventional 
antipsychotics among older patients with schizophrenia in Finland (Talaslahti et al. 2013). 
According to a Finnish cross-sectional study, residents with dementia used more frequently 
antipsychotics but less frequently antidepressants and sedative-hypnotics than residents without 
dementia (Bell et al. 2010). In a recent Finnish study, 36% of people in residential care were on 
antipsychotics and 26% on antidepressants (Kuronen 2017). 
Antidepressants are also widely used among older people. Of residents in institutional settings, 12-
48% are administered antidepressants (Bourgeois et al. 2012, Micca et al. 2013). In addition to 
treating depression, antidepressants are used for insomnia, anxiety, and neuropathic pain (Bourgeois 
et al. 2012). According to a randomized placebo-controlled trial, there was evidence that the 
antidepressants sertraline and mirtazapine might be no more effective than placebo in 13 weeks, but 
they may produce more adverse reactions when treating depression in Alzheimer’s disease 
(Banerjee et al. 2013). There are also trials that show positive effects when older people with major 
depressive disorder (MDD) are treated with an antidepressant. According to a meta-analysis, 
vortioxetine treatment among people aged 55-88 years with MDD was effective and well tolerated 
(Nomikos et al. 2017). Major depressive symptoms may increase mortality in patients with mild 
dementia and depression should be treated carefully (Petersen et al. 2017). In institutional settings, 
the use of antidepressants has varied between 6% and 59% (Table 8). The use of antidepressants is 
on the rise (Nygaard et al. 2004, Hanlon et al. 2010a, Ruths et al. 2013). In Finland, the use of 
antidepressants in institutional settings has varied between 34% and 46% (Hosia-Randell and 
Pitkälä 2005, Alanen et al. 2006, Bell et al. 2010, Pitkälä et al. 2015).  
 
The long-term use of anxiolytics, sedatives, and hypnotics is common, although it is known that 
they are addictive and difficult to withdraw (Ruths et al. 2013). Among community-dwelling older 
people, the use of benzodiazepines was associated with cognitive decline (Hanlon et al. 1998, 
Puustinen et al. 2011, Puustinen et al. 2012). According to a Finnish study among home-dwelling 
older people, 35% with dementia and 29% without dementia used hypnotics (Hartikainen et al. 
2003). The use of anxiolytics and hypnotics decreased in nursing homes in Helsinki, Finland from 
41% and 11% in 2003 to 17% and 6% in 2011, respectively (Pitkälä et al. 2015). The use of 
anxiolytics in assisted living facilities in Helsinki has diminished from 24% in 2007 to 16% in 
2011. However, the use of hypnotics remained at the same level, 10-12% (Pitkälä et al. 2015). In 
Norway, the use of anxiolytics and hypnotics in nursing homes increased from 1997 to 2009 (Ruths 
et al. 2013) (see Table 8). 
The use of opioids has also been common (Berman et al. 2007, Jensen-Dahm et al. 2015, Pitkälä et 
al. 2015, Sandvik et al. 2016), and at least in Finland their use has been increasing, although they 
are used less in Finland than in other countries.  Pain treatment is challenging among older people, 
and especially people with dementia are at very high risk for under-treatment of pain (Plooij et al. 
2012). Non-steroidal anti-inflammatory drugs (NSAIDs) have adverse effects among older people 
(Abraham et al. 2008) and a number of drug-drug interactions (Bleumink et al. 2003, Swedish, 
Finnish, Interaction, X-referencing (SFINX) database). Their use has decreased (Sandvik et al. 
2016), which may partly explain the increased use of opioids. In Norway, the use of opioids has 
increased in nursing homes from 11% to 24% between 2000 and 2011 (Sandvik et al. 2016). 
Similar figures are seen in nursing homes in Finland (Pitkälä et al. 2015). In an American study, 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  2.2.4.3 Factors associated with use of psychotropic drugs  
Factors associated with the use of psychotropic drugs seem to be younger age (Draper et al. 2001, 
Ruths et al. 2001, Bergman et al. 2007, Kamble et al. 2008, Olsson et al. 2010, Petek et al. 2011, 
Ruths et al. 2013) and female gender (Draper et al. 2001, Petek et al. 2011, Ruths et al. 2013), 
whereas some studies suggest younger age and male gender to be associated with antipsychotic 
medication (Alanen et al. 2006). Potentially inappropriate antipsychotic use is more common in 
older age (Laffon de Mazières et al. 2015). One study found that in up to two-thirds of cases 
neuroleptic drug prescriptions were potentially inappropriate and one reason for this was the large 
number of physicians involved in patient care in nursing homes (Laffon de Mazières et al. 2015). 
Patients having inappropriate prescribing of neuroleptic drugs were more often ≥85 years old and 
suffering from dementia (Laffon de Mazières et al. 2015). Female gender seemed to be a predictor 
also of hypnotic or sedative drug use (Johnell and Fastbom 2011, Ruths et al. 2013) as well as use 
of antidepressants and SSRIs (Hosia-Randell and Pitkälä 2005, Ruths et al. 2013). However, men 
used more antipsychotics (Hosia-Randell and Pitkälä 2005, Ruths et al. 2013) and anxiolytics other 
than benzodiazepines (buspirone, clomethiazole) than women (Hosia-Randell and Pitkälä 2005). 
Higher number of regularly used drugs, dementia, depression, living in bigger nursing homes, and 
male physicians were associated with use of psychotropics (Petek et al. 2011). According to a 
Canadian cross-sectional study, the use of antipsychotics in both ALFs and LTCFs was associated 
with lower mean age, dementia, psychiatric disorders and behavioural symptoms, frailty, and use of 
antidepressants, and in LTCF also with hypnotic and/or sedative use, physical restraints, and history 
of falls (Stock et al. 2017). 
When comparing residents in nursing homes with or without dementia, those with dementia 
received any psychotropic, any antipsychotic, and any antidepressant more often than those without 
dementia (Lustenberger et al. 2011). Psychotropic drug use was often associated with behavioural 
symptoms (Sørensen et al. 2001, Nygaard et al. 2004, Kamble et al. 2008, Petek et al. 2011, Stock 
et al. 2017), but not with cognitive impairment (Nygaard et al. 2004). According to the SHELTER 
study, overall prevalence of psychotropic use in European long-term facilities was 33%, and the 
strongest association with use was found with severe behavioural symptoms (Foebel et al. 2014). 
Hyperactive behaviour seemed to be one predictor for the use of antipsychotic medication (de 
Mauleon et al. 2014).  
Lower MMSE was associated with the use of antipsychotics (Macdonald et al. 2002). Dementia and 
behavioural symptoms are predictors of nursing home placement (Phillips and Diwan 2003), and 
residents having dementia with behavioural symptoms are at high risk of receiving antipsychotics 
(Alanen et al. 2006, Rolland et al. 2012). Nevertheless, in dementia-specific units the use of 
antipsychotics was more appropriate (de Mauleon et al. 2014). In Finland, one reason for high 
psychotropic use in institutional settings may also be the low staffing level, which in the five years 
preceding the study had been criticized in Finnish nursing homes (Hosia-Randell and Pitkälä 2005). 
Psychotropic drugs were widely used among nursing home residents despite the higher risk for 
adverse reactions in this population (Hosia-Randell et al. 2008). 
Practitioners must also be careful when prescribing antidepressants for depression in dementia 
because they might not be more effective than placebo, but will have more adverse effects 
(Banerjee et al. 2013). However, in one review antidepressants did improve depression among 
people with dementia (Franco and Messinger-Rapport 2006). Antidepressants are also used to treat 
pain (Bourgeois et al. 2012, Micca et al. 2013) and insomnia and anxiety (Bourgeois et al. 2012). 
Factors associated with antidepressant use were polypharmacy, peptic ulcer, insomnia, pain, and 
constipation (Bourgeois et al. 2012). 
2.2.4.4 Adverse events related to psychotropic drugs 
Psychotropic drug groups have typical adverse effects (Rang et al. 2016).  Antipsychotic drugs, 
especially conventional antipsychotics but also atypical antipsychotics, may cause extrapyramidal 
symptoms. Tardive dyskinesia is a serious and often irreversible unwanted adverse event caused by 
conventional antipsychotics (Rang et al. 2016) as well as atypical antipsychotics (Woods et al. 
2010). Dry mouth, blurred vision, constipation, urinary retention, and sedation may occur as 
anticholinergic side effects. Antipsychotic drugs may also cause orthostatic hypotension and weight 
gain. Phenothiazines may cause jaundice. Typical antipsychotics may also cause QT-time 
prolongation (Aparasu et al. 2012). Clozapine use requires blood count monitoring to identify 
potential leucopenia and agranulocytosis, which may be fatal. Also endocrine effects may appear, 
such as increased plasma prolactin concentration, leading to lactation. Drowsiness and sedation are 
other common side effects of antipsychotics (Rang et al. 2016). Tricyclic antidepressants are 
chemically related to phenotiazines. Postural hypotension, dry mouth, blurred vision, and 
constipation may appear as side effects. There is also a risk of ventricular arrhythmias.  Side effects 
of SSRIs include nausea, diarrhoea, agitation, insomnia, and sexual dysfunction.  Mirtazapine may 
cause dry mouth and weight gain, mianserin agranulocytosis and aplastic anaemia. Many 
antidepressants also have drug-drug interactions (Rang et al. 2016).  Anxiolytics and hypnotics may 
cause drowsiness, sedation, confusion, impaired coordination, tolerance, and dependence (Rang et 
al. 2016).  
According to a case-control study, the use of both conventional and atypical antipsychotic drugs 
among nursing home residents with dementia may increase the risk for hip fractures. Sustaining a 
hip fracture increases mortality among older people with dementia, and antipsychotic use-related 
hip fractures might be a significant contributor to this (Jalbert et al. 2010). According to a 
longitudinal, prospective study, concomitant use of drugs acting on the central nervous system is 
associated with fractures among people aged ≥65 years (Nurminen et al. 2010, Nurminen et al. 
2013). Many second-generation antipsychotics are known to increase the risk of metabolic 
syndrome. There are only a few studies focusing on older adults, but likely the findings from 
younger adults apply to older people as well (Brooks et al. 2009). 
According to a meta-analysis of randomized, placebo-controlled trials, atypical antipsychotics may 
cause such adverse effects as somnolence, urinary tract infections, incontinence, extrapyramidal 
symptoms and abnormal gait, increased risk for cerebrovascular events, and even increased risk for 
deaths when treating people with dementia (Schneider et al. 2006). 
Table 9 presents the adverse outcomes of psychotropics and central nervous system drugs among 
residents in institutional care. 
Psychotropic drugs and falls 
An association exists between the use of psychotropic drugs and falls among older people.  
A systematic review and meta-analysis consisting of both home-dwelling and institutionalized 
people aged over 60 years showed that use of psychotropic drugs in combination or at higher doses 
increased the incidence of falls (Leipzig et al. 1999). In an Australian cohort study, olanzapine and 
antidepressants were significantly associated with falls, and atypical antipsychotics were not 
associated with fewer falls than conventional antipsychotics among nursing home and hostel 
residents (Hien et al. 2005). The association between falls and use of central nervous system drugs, 
especially psychotropic drugs, was also shown in a systematic review containing both home-
dwelling and institutionalized people ≥60 years (Hartikainen et al. 2007). According to this review, 
especially benzodiazepines seemed to be one of the main risks for falls and fractures among older 
people. Also antidepressants, especially tricyclic antidepressants (TCAs) and selective serotonin 
reuptake inhibitors (SSRIs), may have even higher risk for falls. This review article shows also that 
antipsychotic drugs seem to increase risk for falls. One explanation is their extrapyramidal adverse 
effects and anticholinergic properties (Hartikainen et al. 2007). In a meta-analysis, the risk for falls 
among institutionalized older people was increased with psychotropic drug use (Bloch et al. 2011) 
A cross-sectional study showed that the use of psychotropic medication in nursing homes was 
associated with falls (Olazarán et al.  2013). According to an observational study among 2854 home 
care people, use of any psychotropic drug, atypical antipsychotic drug, or benzodiazepine with a 
long or short elimination time increased risk for falls (Landi et al. 2005). A study among Australian 
community-dwelling veterans aged ≥65 years showed that use of three or four psychoactive 
medicines doubled the risk for falls resulting in hospitalization and use of five or more tripled the 
risk (Pratt et al. 2014). According to a systematic review and meta-analysis, the use of olanzapine, 
imipramine, mirtazapine, nortriptyline, amitriptyline, paroxetine, or trazodone was associated with 
increased risk of falling (Ruxton et al. 2015). The study included older people (≥65 years), both 
community-dwelling and institutionalized. A retrospective, longitudinal cohort study among 
nursing home residents with dementia suggested that the use of an antidepressant as a monotherapy 
was associated with higher risk of fractures and falls than the use of an antipsychotic as a 
monotherapy (Wei et al. 2017). The reason for this remained unclear. 
 
Psychotropic drugs and cognition 
 
A meta-analysis containing 15 RCTs, including 3353 patients with dementia using atypical 
antipsychotics and 1757 patients randomized to placebo, showed worsening in cognitive tests 
among drug users (Schneider et al. 2006). According to a longitudinal study, psychotropic 
medication (groups were all antidepressants, SSRIs, antipsychotics, and benzodiazepines) might be 
associated with more rapid cognitive decline in Alzheimer’s disease (Rosenberg et al. 2012). There 
was also evidence of opioid use and cognitive decline in subjects aged 65 years or over (Dublin et 
al. 2015). A prospective cohort study with a 3-year follow-up found that use of benzodiazepine was 
associated with cognitive decline among community-dwelling older people (Hanlon et al. 1998). 
According to a Finnish longitudinal study, the use of opioids with benzodiazepines or any 
psychotropic medication or any CNS medication was associated with cognitive decline among 
cognitively intact older people (Puustinen et al. 2011). Another Finnish longitudinal study shows 
that benzodiazepines or any psychotropic drug use may be an independent risk factor for cognitive 
decline in cognitively disabled subjects ≥75 years (Puustinen et al. 2012). The effect of 
bentzodiazepines on cognition may be long-lasting or even permanent; withdrawal of 
benzodiazepines as a hypnotic did not improve cognitive performance among older people even 
after a 6-month follow-up (Puustinen et al. 2014). 
 
 Association of psychotropic drugs with use of health services and mortality 
 
The efficacy of atypical antipsychotics for neuropsychiatric symptoms among people with dementia 
is limited (Schneider et al. 2006), risperidone and olanzapine having some evidence of efficacy 
(Sink et al. 2005, Seitz et al. 2013).  It was shown in a meta-analysis that use of atypical 
antipsychotics compared with placebo might lead to increased mortality in patients with dementia. 
Most patients lived in nursing homes (Schneider et al. 2005). There have also been contrary 
findings. In a Finnish study, the use of conventional or atypical antipsychotic medication among 
older patients with dementia did not increase mortality or hospital admissions (Raivio et al. 2007). 
In any case, the Food and Drugs Administration (FDA) Public Health Advisory has highlighted the 
risk of deaths with both atypical (FDA 2013) and conventional antipsychotics among people with 
dementia (FDA 2010).  
Conventional antipsychotics may have an even higher risk of deaths than atypical antipsychotics 
(Wang et al. 2005, Aparasu et al. 2012, Sikirica et al. 2013). It has been suggested that especially 
conventional but also atypical antipsychotics are associated with higher mortality when used to treat 
neuropsychiatric symptoms among outpatients with dementia (Kales et al. 2007). These patients 
were compared with patients using other psychiatric medication (SSRIs, other newer 
antidepressants, TCAs, anticonvulsants, anxiolytics/hypnotics, combinations, or no psychiatric 
medication) (Kales et al. 2007). Furthermore, the combination of conventional and atypical 
antipsychotics leads to the poorest survival (Kales et al. 2007). A retrospective cohort study among 
nursing home residents also found that use of conventional antipsychotics was associated with a 
higher risk of mortality than use of atypical antipsychotics (Liperoti et al. 2009).  
Cardiovascular adverse effects like QT-time prolongation, anticholinergic effects, extrapyramidal 
symptoms, and infections might be explanations for increased mortality risk in the use of typical 
antipsychotics (Aparasu et al. 2012). Due to the risk of sudden cardiac death, cardiovascular status 
and electrocardiography (ECG) monitoring are needed when treating older people with 
antipsychotic drugs (Narang et al. 2010).  The risk of sudden cardiac death was increased even in a 
younger population using antipsychotics (Ray et al. 2001). Cardiovascular and cerebrovascular risk 
factors may be the link to the increased risk of death with conventional antipsychotics (Liperoti et 
al. 2009). A retrospective case-control study suggests that the effect of antipsychotics on mortality 
in elderly patients with dementia may be even higher than previous studies indicate, and it appears 
to be dose dependent (Maust et al. 2015).  
 
Older people with schizophrenia have a higher mortality than the general age- and gender-matched 
population (Talaslahti 2015). The most common causes of death (e.g. cardiovascular, neoplasms) 
were the same, but unnatural causes (e.g. suicides, accidents) were 11-fold. The risk of psychiatric 
hospitalization was associated with antipsychotic polypharmacy and the use of antidepressants 
(Talaslahti 2015). 
A cohort (SHELTER) study investigated antipsychotic drug interactions and mortality among older 
nursing home residents with cognitive impairment in seven European Union countries and Israel 
(Liperoti et al. 2017). Antipsychotic drug interactions were observed in 46% of participants 
receiving antipsychotics, 11% of whom were exposed to two or more interactions (Liperoti et al. 
2017). Antipsychotic drugs interactions were associated with higher mortality also after adjusting 
for potential confounders (Liperoti et al. 2017). 
A random sample of demented older people, 44% of them institutionalized, showed that especially 
use of antipsychotics and also concomitant use of any kind of psychotropic drugs was a risk factor 
for death compared with non-use of psychotropic drugs (Hartikainen et al. 2005). 
On the other hand, intensive care of depression in older adults, including both optimal 
antidepressant use and psychotherapy, decreased mortality relative to usual care (Gallo et al. 2013). 
In one analysis of residents of long-term care facilities, the concurrent use of three or more 
psychotropic drugs was not associated with an increased risk of mortality (Bell et al. 2009). 
Sedative load was not a significant risk for deaths among residents in long-term care facilities 
(Taipale et al. 2009). 
According to a recent Norwegian longitudinal (75-month follow-up) study among nursing home 
residents, neither use of antipsychotics nor other psychotropics was associated with increased risk 
of mortality (Selbaek et al. 2016). 
Psychotropic drugs and quality of life 
A secondary data analysis of an RCT in nursing home residents explored the use of psychotropics 
and its association with physical and psychosocial outcomes (Galik and Resnick 2013).  Those 
residents not on psychotropics (all psychotropics) had significantly better functional outcomes 
(p=0.01), and a trend (p=0.05) was observed of a better overall quality of life compared with 
psychotropic users (Galik and Resnick 2013). According to a longitudinal study, the use of 
antipsychotic medication might not decrease the quality of life among nursing home residents, 
however, neuropsychiatric symptoms do negatively affect the quality of life (van de Ven-Vakhteeva 
et al. 2013). Antidepressant use had a positive impact on quality of life like positive self-image and 
negative affect (van de Ven-Vakhteeva et al. 2013). The use of antipsychotics among residents with 
schizophrenia in long-term institutional care was associated with a severe degree of functional 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2.5 Proton pump inhibitors (PPIs) 
Proton Pump Inhibitors (PPIs) are one of the most frequently prescribed drug classes in the world 
(Forgacs and Loganayagam 2008). PPIs have proven to be very effective drugs in the treatment of 
gastro-oesophageal reflux with associated complications and dyspeptic conditions (Forgacs and 
Loganayagam 2008). Furthermore, PPIs are commonly used to protect against gastrointestinal 
bleedings among users of NSAIDs, low-dose aspirin, anticoagulants, corticosteroids, or serotonin 
reuptake inhibitors (Lanza et al. 2009, AGS 2015, Niu et al. 2016).  However, they are widely 
overused, especially in nursing homes. Of patients taking these drugs, 25-70% do not have an 
appropriate indication for use, and many drug-related problems are associated with the use of PPIs 
(Forgacs and Loganayagam 2008).  
Several criteria for potentially inappropriate medications (PIMs) have included PPIs in their lists. 
PPIs are mentioned in Swedish recommendations for older people’s medication (Socialstyrelsen 
2010). The use of PPIs should be reviewed periodically and they should not be used without an 
appropriate indication. The STOPP and START criteria limited full dosage of PPI use to 8 weeks 
(Gallagher et al. 2008), and Beers’ list 2015 does not recommend PPI use >8 weeks in high-risk 
patients (AGS 2015).  
Long-term use of PPIs may lead to decreased absorption of vitamin B12, vitamin C, iron, calcium, 
and magnesium (Arkkila 2015, Teramura-Grönblad 2017). There is evidence that use of acid-
suppressive drugs, such as H2 receptor antagonists (H2RAs) and PPIs, is associated with increased 
risk of pneumonia, probably by reduction of gastric acid secretion, allowing spread of oral 
infections (Laheij et al. 2004). There is also an association between the use of PPIs and enteric 
infections, including Clostridium difficile infections (Leonard et al. 2007). The FDA has made a 
safety announcement about this risk (FDA 2012). According to a meta-analysis containing 17 
RCTs, the use of PPIs was associated with an elevated risk of cardiovascular events in patients with 
gastro-oesophageal reflux disease (GERD). High risk occurred especially in the omeprazole 
subgroup and in long-term treatment (Sun et al. 2016). Another meta-analysis found that 
combination use of clopidogrel with PPIs might increase the risk of major adverse cardiovascular 
events among patients with coronary artery disease (Niu et al. 2016). This effect was seen only with 
patients with a certain clopidogrel metabolizing P450 enzyme allele (Niu et al. 2016).  
According to a retrospective case-control study, patients with hip fractures were more likely than 
controls to have received PPIs or H2RAs over the 2-year period preceding the fracture, and the risk 
for hip fracture decreased after discontinuation of the drug. This association was seen only among 
persons who had additional risk factors for hip fractures such as alcohol abuse, arthritis, diabetes, 
kidney disease, or glucocorticoid use (Corley et al. 2010). A meta-analysis of studies with cohort 
and case-control design found an association between the use of PPIs and hip fractures, spine 
fractures, and fractures overall (Zhou et al. 2016). The mechanism underlying the effect of PPI use 
on risk of fracture is unknown. One hypothesis is that PPIs decrease calcium absorption, which 
leads to decrease in bone mineral density. PPI use may also induce hypomagnesemia, which might 
increase fracture risk (Zhou et al. 2016).   
A cross-sectional study (n=1987) suggested that the use of PPIs is independently associated with 
diarrhoea (Teramura-Grönblad et al. 2010). In a cross-sectional Finnish study consisting of 2818 
residents in assisted living facilities (ALFs), long-term care hospitals (LTCHs), and acute geriatric 
wards (AGWs), after adjustment, the use of PPIs was associated with increased mortality in LTCHs 
and AGWs, but not in ALFs (Teramura-Grönblad et al. 2012).  
2.2.6 Non-steroidal anti-inflammatory drugs (NSAIDs) 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used for pain especially in inflammatory 
disorders, however, they are considered to be one of the medications most commonly causing 
adverse reactions among older people (Boparai and Korc-Grodzicki 2011). In Sweden, they are 
deemed inappropriate for older people because they may cause gastrointestinal ulcers and bleeding, 
fluid retention, heart failure, and renal dysfunction (Socialstyrelsen 2010). STOPP and START 
criteria define NSAIDs as inappropriate medication due to their unwanted effects on renal function, 
gastrointestinal bleeding, hypertension, and heart failure (Gallagher et al. 2008). In the last two 
updated Beers’ criteria, they were included in the inappropriate list (AGS 2012, AGS 2015).  
According to a review article, the use of NSAIDs in treatment of older adults with osteoarthritis 
may lead to adverse effects such as renal insufficiency and gastrointestinal toxicity (O’Neil et al. 
2012). There is also some evidence of cardiovascular adverse events, thus, the use of NSAIDs 
should be limited to short-term use only (O’Neil et al. 2012). 
NSAIDs inhibit the enzymes cyclo-oxygenase (COX) 1 and 2, leading to a decrease in 
prostaglandin synthesis (Bleumink et al. 2003). Under normal conditions, prostaglandins do not 
significantly affect renal circulation. However, when effective circulating volume is decreased, such 
as in heart or renal failure or dehydration, renal prostaglandins increase renal blood flow and 
enhance excretion of sodium and water (Bleumink et al. 2003).  If prostaglandin synthesis is 
inhibited with NSAIDs, another type of renal enzyme, angiotensin II, may produce excessive 
vasoconstriction and a decline in renal blood flow and glomerular filtration rate, potentially 
resulting in acute renal failure (Bleumink et al. 2003). Water and sodium retention may lead to 
cardiac failure. NSAIDs influence cardiovascular homeostasis with an effect on renal function, and 
COX-2 selective inhibitors may apparently also induce heart failure in susceptible patients (Pitkälä 
et al. 2002b, Bleumink et al. 2003).  
The use of NSAIDs negatively influences the antihypertensive effects of thiazides, loop diuretics, 
α-adrenergic blockers, β-adrenergic blockers, and ACE inhibitors. If a patient is hypovolemic, 
NSAIDs may lower the effect of diuretics and lead to fluid retention (Bleumink et al. 2003). 
In addition, there is evidence that exposure to NSAIDs with the longest half-life may be associated 
with an increased risk of chronic renal disease (Ingrasciotta et al.  2015). Use of NSAIDs has been 
found to be responsible for peptic ulcer among older people (Griffin et al. 1988). According to a 
study including patients aged 60+ years hospitalized for bleeding gastric or duodenal ulceration, 
NSAID use together with some independent risk factors, such as previous peptic ulcer, heart failure, 
use of oral anticoagulants or corticosteroids, diabetes, and smoking, account for 80% of the 
predisposing factors for ulcer bleeding (Weil et al. 2000).  
There is also some evidence for increased mortality. In a retrospective cohort study among veterans 
aged 65+ years, an association emerged between mortality following gastrointestinal or 
cardiovascular events and proportion of time receiving NSAIDs or COX-2 selective NSAIDs 
(Abraham et al. 2008). According to a recent review and meta-analysis, the use of NSAIDs was 
associated with an increased risk of acute myocardial infarction (Bally et al. 2017). 
 
2.3 Educational intervention studies to reduce harmful drug use in institutional settings 
 
A number of randomized controlled trials, both educational interventions and medication reviews 
by pharmacists, have been performed to reduce the use of PIMs (Forsetlund et al. 2011). These 
interventions may reduce PIM use among nursing home residents. However, many of these studies 
have been of low quality and include a risk of bias (Forsetlund et al. 2011). Table 10 summarizes 
the studies aimed at reducing PIM use. 
RCTs are cluster randomized, meaning that units are randomized instead of single residents. 
In USA, Avorn and colleagues performed a cluster RCT, aimed at reducing psychoactive 
medication use in nursing homes. Physicians, nurses, and nursing assistants of intervention homes 
received an educational programme focused on geriatric psychopharmacology (Avorn et al. 1992).  
In the intervention homes, the use of psychoactive medication decreased significantly. 
Antipsychotic drugs and diphenhydramine had been discontinued significantly more often in 
intervention than control homes (Avorn et al. 1992).  There was also a trend for an improvement in 
some cognitive tests. However, there was an increase in residents’ reports of depression in the 
intervention homes. Despite the reduction in antipsychotic use in intervention nursing homes, there 
was no significant increase in behavioural disorders among residents (Avorn et al. 1992). 
An educational RCT was conducted to reduce antipsychotic use and to identify factors predicting 
antipsychotic withdrawal or dose reduction (Meador et al. 1997). Nursing homes were the units that 
were randomized and analysed. Education started with a 45- to 60-minute session held by the study 
geropsychiatrist for physicians in which antipsychotics and other psychotropics were discussed, 
followed by educational activities for nursing home staff. Nursing staff received education by a 
trained nurse-educator and written instructions were also provided (Meador et al. 1997). This 
intervention resulted in a 23% reduction in days on antipsychotics in the intervention homes relative 
to control homes (p=0.014). Of patients continuing use, 25% had a dosage reduction of 50% or 
more. There was no increase in behavioural symptoms or use of benzodiazepines or antidepressants.   
An RCT was performed in Swedish nursing homes to explore the effects on both the quantity and 
quality of psychotropic drug prescribing (Schmidt et al. 1998a). Nursing homes were randomized. 
In intervention homes, a trained pharmacist spent one day per month over a 12-month period to 
enhance communication in teams about drug use. The programme focused on improving teamwork 
of physicians, pharmacists, selected nurses, and nursing assistants. Drug use of individual residents 
was discussed. The intervention resulted in a significant decrease in prescribing of antipsychotics, 
benzodiazepine hypnotics, and TCAs, but antidepressant use increased (Schmidt et al. 1998a). 
Results were collected one month before the study and at the end of the 12-month intervention. 
In an Australian RCT, nursing staff received problem-based education for 11 hours in each 
intervention NH with support of telephone calls, wall charts, bulletins, and clinical pharmacy visits, 
averaging 26 contact hours per intervention home. Individual medical reviews were performed and 
were available to the resident’s physician (Roberts et al. 2001). The intervention resulted in 
significantly decreased use of benzodiazepines, NSAIDs, laxatives, and histamine H2-receptor 
antagonists. Drug use in the intervention group diminished by 15% compared with controls, thus 
decreasing drug costs (Roberts et al. 2001). However, no significant changes were observed in 
mortality, hospitalizations, adverse events, or the disability index (Roberts et al. 2001).  
Another Australian RCT aimed to improve the implementation of evidence-based clinical practice 
with outreach visits in order to reduce falls and prevent strokes (Crotty et al. 2004). The 
intervention consisted of two 30-minute visits by a pharmacist to physicians. Evidence-based 
guidelines on fall prevention, psychotropic drug prescribing, and stroke prevention, such as blood 
pressure monitoring and use of aspirin in residents with increased stroke risk and the use of 
warfarin in residents with atrial fibrillation, were implemented (Crotty et al. 2004). There was no 
difference in the use of psychotropic drugs between groups, except that the use of “as needed” 
antipsychotics was significantly higher in the intervention group than in the control group (relative 
risk (RR) 4.95; 95% CI 1.69 to 14.50) (Crotty et al. 2004). There was no difference in falls between 
the groups. However, number of falls increased in both groups, which may be due to their better 
documentation. No difference emerged between the groups in recording of high blood pressure 
(>140/90 mmHg) or use of aspirin or warfarin (Crotty et al. 2004). 
In Great Britain, nursing home staff was trained to reduce the use of neuroleptics among residents 
with dementia (Fossey et al. 2006). At the beginning of the study, a consultant old age psychiatrist 
and a senior member of the nursing staff reviewed residents’ medication in all participating nursing 
homes. Prescribing physicians received recommendations to stop inappropriate neuroleptics and 
also telephone calls if this was not implemented within two weeks.  After randomization, the staff 
of intervention homes received training for two days a week for 10 months. Training focused on 
person-centred care and good treatment practices as an alternative to treating behavioural symptoms 
with neuroleptics (Fossey et al. 2006). At 12 months, the proportion of residents on neuroleptics 
was significantly lower in intervention homes than in control homes. No difference was observed 
between groups in the use of other psychotropics or in falls, agitation, aggression, quality of life, or 
well-being (Fossey et al. 2006).  
In Tasmania, a controlled trial was performed with the aim to reduce the use of antipsychotics and 
benzodiazepines among nursing home residents (Westbury et al. 2010). Nursing home physicians 
received one session concerning psychotropic use, and nursing home staff received two sessions. 
The intervention consisted also of newsletters every other month and an educational pamphlet for 
relatives and residents. Two pharmacist’s medication audits and feedback cycles were included. 
The intervention resulted in benzodiazepine use decreasing from 32% to 27% (p<0.005), and 
antipsychotic use decreasing from 20% to 19% (p<0.05) in intervention homes, whereas in control 
homes no change in the use of these medications occurred (Westbury et al. 2010). 
An RCT was performed in Spain, where nursing home physicians received education on older 
people’s medication for 10 hours (García-Gollarte et al. 2014). The physician educational 
programme was followed by on-demand support (prescription advice) by phone. As a result of 
intervention, the mean number of inappropriate drugs according to STOPP criteria was higher in the 
control group than in the intervention group. In addition, the proportions of residents with 
polypharmacy, antipsychotics, and duplicate medication were higher in the control group than in the 
intervention group (García-Gollarte et al. 2014). The number of fallers increased significantly in the 
control group, but did not change in the intervention group. The number of residents with delirium 
increased in the control group and decreased in the intervention group. Use of physician and nurse 
visits did not change in the control group (-0.22, p=0.3), but decreased significantly in the 
intervention group (-0.76, p=0.01). Emergency room visits and days in hospital increased in the 
control group, but remained unchanged in the intervention group (García-Gollarte et al. 2014). 
Results are from the 3-month period after the intervention. 
Summary of studies (see Table 10). 
A recent RCT from Israel showed that pharmacist review followed up by recommendations may 
decrease the number of drugs used by frail older people (Frankenthal et al. 2014). It also suggested 
a decline in falls, but no change in hospitalizations, QoL, or ADL according to the Functional 
Independence Measure (FIM) among participants. Several other RCTs have been performed among 
nursing home residents in which the intervention is based on pharmacist review of residents’ 
medication (Furniss et al. 2000, Zermansky et al. 2006, Patterson et al. 2010). They are not included 
in Table 10 since education is not a part of the intervention.  
 
A recent Cochrane review on interventions to optimize prescribing in institutional care included 12 
RCTs (N=10953) (Alldred et al. 2016). Besides educational interventions targeted at professionals, 
the interventions included organizational interventions (e.g. medication review services), case 
conferencing, and information and communication technology. Evidence suggested that medication 
appropriateness improved, but no effect was seen on adverse drug events (Alldred et al. 2016). The 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4 Summary of PHMs                                                                                                                                       
 
There are multiple definitions for PHMs (Spinewine et al. 2007). Beers’ criteria were the first 
explicit criteria aimed at decreasing the use of inappropriate drugs among nursing home residents 
(Beers et al. 1991). The criteria defined drugs as inappropriate if their adverse effects exceeded their 
benefits, if they lacked efficacy, or if there was a safer alternative available. These criteria and their 
updated versions (Beers 1997, Fick et al. 2003, AGS 2012, AGS 2015) have been criticized for 
being US based, and many PIM criteria have been developed in other countries. However, Beers’ 
criteria are internationally well known. The use of PIDs according to Beers’ criteria is common and 
has ranged from 17% to 83% in institutional settings. In a systematic review, the use of Beers’ PIDs 
was associated with adverse drug reactions but not with quality of life (Jano and Aparasu 2007). 
The effect on hospitalizations and mortality is unclear (Klarin et al. 2005, Perri et al. 2005, Jano and 
Aparasu 2007, Price et al. 2014).  
Drugs with anticholinergic properties (DAPs) block cholinergic muscarinic receptors. Permeability 
of the blood-brain barrier increases in old age. In addition, the ageing brain is vulnerable to toxic 
effects of DAPs (Ehrt et al. 2010). There are many scales to define DAPs and to measure 
anticholinergic burden (Han et al. 2001, Ancelin et al. 2006, Carnahan et al. 2006, Hilmer et al. 
2007, Boustani et al. 2008, Chew et al. 2008, Rudolph et al. 2008, Ehrt et al. 2010, Sittironnarit et 
al. 2011). The prevalence of DAPs varies markedly depending on the criteria used (Salahudeen et 
al. 2015). Their use is associated with adverse events such as hospital admissions and fall-related 
hospitalizations (Salahudeen et al. 2015). Contradictory results have emerged about the relationship 
between DAP use and mortality (Wilson et al. 2012, Ruxton et al. 2015). Many studies have shown 
that DAP use is associated with cognitive decline (Rudolph et al. 2008, Campbell et al. 2009, 
Cancelli et al. 2009, Uusvaara et al. 2013, Gray et al. 2015, Ruxton et al. 2015).  
Centrally affecting drugs, including psychotropics, are commonly used among older people 
(Gruber-Baldini et al. 2004, Hosia-Randell and Pitkälä 2005, Nurminen et al. 2009, Bourgeois et al. 
2012, Pitkälä et al. 2015). They are used, for example, to treat neuropsychiatric symptoms in 
dementia, which are common in institutional settings (Sørensen et al. 2001, Foebel et al. 2014). The 
prevalence of psychotropics ranges from 36% to 80% in institutional settings. Antipsychotic drug 
use is associated with risk of fractures (Nurminen et al. 2010, Nurminen et al. 2013) and hip 
fracture (Jalbert et al. 2010). Use of psychotropics, including antipsychotics, antidepressants, and 
benzodiazepines, may lead to falls (Hartikainen et al. 2007). Antipsychotic drug use may lead to 
cerebrovascular adverse events among people with dementia (Schneider et al. 2005). The use of 
atypical or conventional antipsychotics may also increase mortality among people with dementia 
(Schneider et al. 2006, Aparasu et al. 2012, Sikirica et al. 2013). Use of antipsychotics among 
patients with dementia may also lead to cognitive decline (Schneider et al. 2006, Puustinen et al. 
2012). Attention has been paid to excessive use of psychotropics. The Omnibus Budget 
Reconciliation Act of 1987 in the USA (OBRA 87) improved the quality of care in US nursing 
homes (Omnibus Budget Reconciliation Act of 1987, Garrard et al. 1995). In addition, there are 
criteria in other countries regulating the use of psychotropics. For example, in Sweden the 
concomitant use of >2 psychotropics is considered inappropriate (Socialstyrelsen 2010).  
Proton pump inhibitors (PPIs) are effective in dyspeptic conditions. However, they are overused 
and often lead to drug-related problems (Forgacs and Loganayagam 2008). Long-term use of PPIs 
may lead to malabsorption of vitamin B12 and calcium (Arkkila 2015, Teramura-Grönblad 2017).  
Use of PPIs is also associated with increased risk of pneumonia (Laheij et al. 2004), enteral 
infections such as Clostridium difficile (Leonard et al. 2007), and fractures (Zhou et al. 2016). 
Long-term use of PPIs is mentioned in several criteria of inappropriate medications for older people 
(Gallagher et al. 2008, Socialstyrelsen 2010, AGS 2015). Their use, both the indication and the 
length of use, should be reviewed periodically. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used for treatment of pain. Among older 
people, they are one of the medications most commonly causing unwanted effects (Boparai and 
Korc-Grodzicki 2011). They may cause gastrointestinal ulcers and bleeding (Griffin et al. 1988, 
Gallagher et al. 2008, Socialstyrelsen 2010, O’Neil et al. 2012), fluid retention and heart failure 
(Pitkälä et al. 2002b, Bleumink et al. 2003, Gallagher et al. 2008, Socialstyrelsen 2010), and renal 
failure (Pitkälä et al. 2002b, Bleumink et al. 2003, Gallagher et al. 2008, Socialstyrelsen 2010, 
Ingrasciotta et al. 2015). Potentially harmful medications for older people include NSAIDs 
according to several different criteria (Gallagher et al. 2008, Socialstyrelsen 2010, AGS 2012, AGS 
2015). 
In summary, there are many ways to define drugs that should not be used among older people. 
There is no consensus about the best criteria. The latest Beers’ 2015 criteria include drugs that are 
also included in the criteria used here: psychotropics, DAPS, PPIs, and NSAIDs. Use of potentially 
inappropriate medication is associated with adverse effects as well as adverse events such as falls, 
fractures, infections, hospitalizations, cerebrovascular events, and even mortality.  
Educational intervention studies have been performed in institutional settings to reduce the use of 
PIMs, especially psychotropic drugs. They are based on different learning theories, e.g. problem-
based (Roberts et al. 2001), academic detailing (Avorn et al. 1992, Wetbury et al. 2010), active 
educational programme (Meador et al. 1997), or individualized psychological intervention (Fossey 
et al. 2006). Educational programmes have also been structurated. Most of studies have focused on 
psychotropic use, also laxatives and NSAIDs (Roberts et al. 2001), and evidence-based medication 
(Crotty et al. 2004). These interventions have managed to reduce PIMs, however, other outcomes 
have been conflicting (Meador et al. 1997, Crotty et al. 2004, Fossey et al. 2006, Westbury et al. 
2010). Only very recent trials have managed to decrease falls (Frankenthal et al. 2014), use of 
health services, or delirium (García-Gollarte et al. 2014).  
 
3 Aims of the study 
 
The aim of these studies was to explore the use of potentially harmful medications (PHMs) among 
older residents in assisted living facilities in Helsinki, Finland and in nursing homes in Kouvola, 
Finland and to investigate in a randomized controlled trial (RCT) the effects of staff training on the 
use of PHMs and its outcomes in these settings. 
 
Specific aims were as follows: 
 
1. to determine the burden and overlapping of PHMs among older people in assisted living 
facilities in Helsinki and in nursing homes in Kouvola (Study 1) 
2. to evaluate the association of burden of PHMs on residents’ health-related quality of life 
(HRQoL), psychological well-being (PWB), and 3-year mortality (Study 1) 
3. to describe the feasibility of an educational intervention in institutional settings (Study 2) 
4. to evaluate the effect of an educational intervention on the use of PHMs among older people in 
assisted living facilities during a 12-month follow-up with an RCT design (Study 3) 
5. to investigate the effects of an educational intervention on HRQoL, hospitalizations, and 
mortality of participants during a 12-month follow-up with an RCT design (Study 3) 
6. to evaluate the effect of an educational intervention on residents’ falls and cognition during a 




4.1 Participants and setting 
 
Participants were recruited among residents aged ≥65 years in assisted living facilities in Helsinki 
(Studies 1-4) and in nursing homes in Kouvola (Study 1). Residents and their closest proxies were 
approached personally, one by one. They received information about the study and gave written 
informed consent to participate. If there was evidence of a participant’s significant cognitive decline 
(MMSE<20), her or his closest proxy (relative or spouse) gave written consent to participate before 
any study procedures were initiated. Significant cognitive decline was defined at MMSE<20 in the 
study protocol (Pitkälä et al. 2012). 
 
There were five inclusion criteria to participate in the study: 
1. Age ≥65 years and living permanently in assisted living facilities in Helsinki or in a nursing 
home in Kouvola 
2. Native Finnish speaking 
3. Using ≥ one drug 
4. Having estimated survival ≥ 6 months 
5. Voluntary participation, written informed consent to participate in the study was given by the 
participant or her or his closest proxy in the case of the participant’s MMSE<20 
 
In 2011, there were 36 units of assisted living facilities in Helsinki housing altogether 1378 
residents. Of these, 7 units with 20 wards and 320 residents were selected, and 227 residents 
consented to participate in the study. From the Kouvola nursing homes containing 106 residents, 99 
residents chose to participate in the study. Those who did not participate either refused or were 
unavailable. Study 1 included participants from both Helsinki assisted living facilities and Kouvola 
nursing homes, whereas Studies 2, 3, and 4 comprise only participants from Helsinki assisted living 
facilities. All participants were examined with same measurements at the same time. 




Table 11. Characteristics and medication of participants at baseline.  






Age, mean (SD) 83 (8) 84 (7) 84 (7) 
Females, % 65 77 68 
Education <8 years, % 60 62 80 
MMSE, mean (SD) 8.8 (8.2) 10.0 (8.2) 9.6 (7.8) 
Charlson comorbidity index, 
mean (SD) 
3.2 (2.0) 2.5 (1.8) 2.2 (1.4) 
Mean number of regular drugs  
(SD) 
7.5 (2.8) 7.8 (3.1) 7.3 (3.1) 
Mean number of pro re nata 
drugs (SD) 
3.6 (2.3) 2.9 (2.0) 2.5 (1.3) 
Mean number of harmful 
drugs (SD) 
2.9 (1.8) 2.5 (1.7) 
 
2.9 (1.8) 
Proportion using Beers’ drugs 
2003, % 
25 19 58 
Proportion using 
anticholinergic drugs, % 
78 66 57 
Proportion using >2 
psychotropic drugs, % 
34 35 31 
SD = standard deviation; MMSE = Mini Mental State Examination (Folstein et al. 1975); Charlson 
comorbidity index (Charlson et al. 1987; Beers’ drugs (Fick et al. 2003). 
 
Participants’ mean age ranged from 83 (intervention group) to 84 years (Kouvola). The proportion 
of females varied from 65% (intervention group) to 77% (control group). Of Kouvola nursing home 
residents, 80% had an education < 8 years; the corresponding proportion of Helsinki assisted living 
facilities residents was 60-62%. MMSE was quite low in all groups, ranging from 8.8 to 10.0. 
Participants had a high number of serious comorbidities according to the Charlson comorbidity 
index (Charlson et al. 1987), which ranged from 2.2 to 3.2, the highest being in the intervention 
group. The Charlson comorbidity index takes into account both number and severity of 
comorbidities and their association with survival. Participants regularly used more than 7 drugs on 
average. The mean number of pro re nata drugs varied from 2.5 to 3.6. The mean number of PHMs 
was 2.5 in the control group and 2.9 in the intervention and Kouvola groups. The proportion using 
Beers’ drugs 2003 was 19% in the control group, 25% in the intervention group, and 58% in the 
Kouvola group. The proportion using anticholinergic drugs varied from 57% (Kouvola group) to 
78% (intervention group). The proportion using >2 psychotropic drugs concomitantly ranged from 
31% to 35%.  
Altogether 227 subjects from Helsinki participated in the RCT. Of these, 41 were lost during the 6-
month follow-up (26 from the intervention group and 15 from the control group). Of the 41 subjects 
lost, 38 were deceased and one intervention participant and two control participants were lost to 
follow-up due to admission to hospital.  During the 12-month follow-up altogether 63 participants 
died (39 in the intervention group and 24 in the control group). For the Kouvola group, only 
baseline data are used in Study 1. 
 
4.2 Study design and randomization  
Study 1 had a cross-sectional design with a 3-year follow-up for mortality.  
 
Studies 2, 3, and 4 were based on a randomized controlled intervention trial (RCT) performed at 
Helsinki assisted living facilities. The RCT protocol was registered in the 
registration number ACTRN12611001078943. To avoid 
contamination of the intervention, units were randomized instead of individual participants. Thus, a 
cluster randomization was used. All 36 units in Helsinki were assessed and participating wards were 
selected by using the Minimum Data Set (MDS)/Resident Assessment Instrument (RAI) version 2.0 
for home care (Morris et al. 2000). This was done to ensure that participating wards in the 
intervention and control arms had as similar as possible case-mix (psychogeriatric impairment, 
physical disability, or cognitive impairment). 
Once the case-mix according to the MDS of each participating ward was clarified, the wards were 
paired into 10 dyads with similar characteristics. There were altogether 320 residents in these 
selected wards in Helsinki. Of these 320 residents, 93 refused or did not fulfil the inclusion criteria. 
Therefore, 227 residents were included in the study.  Baseline assessment was performed after 
written informed consent to participate was received. 
Computer-generated random numbers were used to randomize units into intervention arm or control 
arm. Altogether 118 subjects participated in the intervention group and 109 subjects in the control 
group.  
The intervention consisted of two half-day training sessions for staff on potentially harmful drugs in 
older people. The residents were assessed at 6 months and 12 months.  





























Figure 1. Flow chart of the studies 
4.3 Measurements  
Trained study nurses assessed residents three times: at baseline, at 6 months, and at 12 months. 
Study nurses were independent of the study intervention and unaware of the randomization 
procedures. Assessments were performed with the same procedures and at the same time in 
Helsinki and Kouvola. 
The baseline visit lasted about one hour. The participant’s demographic data were retrieved from 
medical records and from the closest proxies; these data included age, gender, and education 
defined as: 1 = primary school or less, 2 = vocational school, 3 = middle school, 4 = upper 
secondary school, 5 = technical college, 6 = university.  Education was dichotomized in further 
analyses as less than 8 years (=primary school or less) and as 8 years or more. 
Residents’ diagnoses were retrieved from medical records, and comorbidity for each resident was 
calculated using the Charlson comorbidity index (Charlson et al. 1987), which is a validated and 
widely used measure of comorbidity among older people in institutional care (Buntinx et al. 2002). 
The Charlson comorbidity index is a weighted measure that takes into account both the number and 
seriousness of conditions. It has been shown to be a predictor of short-term mortality (Charlson et 
al. 1987). Residents rated their own health as healthy, quite healthy, quite unhealthy, or unhealthy. 
In the analyses of Study 1, self-rated health was categorized as healthy (healthy, quite healthy) or 
unhealthy (quite unhealthy, unhealthy).  
All medications of participants, both regularly and pro re nata used, were retrieved from 
participants’ medical records as a point of prevalence on the day of assessment. The Anatomical 
Therapeutic Chemical (ATC) classification system recommended by the World Health 
Organization (WHO 2012) was used to classify medications. The following medications were 
defined as potentially harmful medications (PHMs): (1) Beers’ potentially inappropriate drugs 
2003, (2) Drugs with anticholinergic properties (DAPs), (3) Use of >2 psychotropics concomitantly, 
(4) Proton Pump Inhibitors (PPIs), and (5) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 
NSAIDs included both selective and non-selective NSAIDs, because also coxib use was a predictor 
of mortality among people aged >65 years with gastrointestinal or cardiovascular events (Abraham 
et al. 2008). Low-dose acetylsalicylic acid (< 250 mg) was not included in its use as antithrombotic 
therapy (You et al. 2012), and topically used NSAIDs were also excluded.  Moreover, Beers’ 2012 
list includes only oral NSAIDs (AGS 2012). The proportion of users and number of PHMs per 
participant were determined.  
PHMs and their definitions are presented in Table 12. 
 Anatomical Therapeutic Chemical classification; DAPs=Drugs with Anticholinergic Properties; NSAID=Non-
Steroidal Anti-Inflammatotory Drug; PID=Potentially Inappropriate Drug; PPI=Proton Pump Inhibitor
 
Nutritional status was measured using the Mini Nutritional Assessment (MNA) (Guigoz et al. 
2002). The MNA is a reliable and validated instrument to examine the nutritional status of older 
people. The MNA score varies from 0 to 30, an MNA score <17 indicates malnourishment, 17 to 
23.5 indicates the risk of malnourishment, and >23.5 indicates good nutritional status (Appendix 5). 
Cognition was assessed by using the Mini Mental State Examination (MMSE) (Folstein et al. 
1975), verbal fluency (Morris et al. 1989, Morris et al. 1993), and the clock drawing test (Morris et 
al. 1989, Morris et al. 1993). MMSE is the most widely used test measuring cognition of older 
people. MMSE is presented in Appendix 6. Verbal fluency is a part of CERAD (Morris et al. 1989). 
In verbal fluency, the participant names as many animals as possible within one minute; the cut-off 
point for normal is ≥16 (Hänninen et al. 2010). The Clock Drawing Test is a simple measure of 
visuospatial ability (Sunderland et al. 1989). The face of a clock with 12 numbers and clock hands 
is drawn with the time reading 11:10. The task is graded from 0 to 6; a result <5 is considered 
abnormal (Hänninen et al. 2010). The residents’ stage of dementia was assessed using the Clinical 
Dementia Rating (CDR) scale (Hughes et al. 1982). The CDR score also includes estimations of 
cognitive, social, and physical functioning. There are six domains to assess cognition and function: 
memory, orientation, judgement and problem solving, community affairs, home and hobbies, and 
personal care (Hughes et al. 1982). Each domain is given a rating of 0, 0.5, 1, 2, or 3. When the 
final score is determined, the memory domain may increase or decrease the overall rating by 1. 
CDR score 0 means no dementia, 0.5 possible or very mild dementia, 1 mild dementia, 2 moderate 
dementia, and 3 severe dementia (Hughes et al. 1982). CDR, clock drawing test, and verbal fluency 
are presented in Appendix 7.  
Quality of life was measured by using the 15D health-related quality of life scale (15D HRQoL) 
(Sintonen 2001). The 15D HRQoL is a generic, validated, and self-administered measure of 
HRQoL with scores ranging from 0 (poorest) to 1 (excellent) (Sintonen 2001). If the person is 
physically or mentally unable to reply, proxy administration can also be used (Sintonen 2001). The 
15D includes 15 domains related to mobility, vision, hearing, breathing, sleeping, eating, speech, 
elimination, usual activities, mental function, discomfort and symptoms, depression, distress, 
vitality, and sexual activity. 15D is widely used and available in several languages (Sintonen 2001). 
15D includes an item on mobility, which was used in Study 4 as a covariate for falls. The 
participant was considered as dependent in mobility if she/he needed help to move around indoors 
or was totally inmobile. 
Psychological well-being was assessed using the psychological well-being (PWB) scale (Routasalo 
et al. 2009). The PWB scale includes six items: life satisfaction (yes/no), feeling useful (yes/no), 
having plans for the future (yes/no), having zest for life (yes/no), feeling depressed (seldom or 
never/sometimes/often or always), and loneliness (seldom or never/sometimes/often or always) 
(Routasalo et al. 2009). The PWB score was calculated by summing the scores for each item and 
dividing by the number of items completed by the participant. Score 0 represents the poorest and 
score 1 the best PWB. The content of questions of PWB have good reliability and criterion validity, 
as its items represent areas considered important in psychological well-being in World Health 
Organization Quality of Life Instruments (WHOQOL-BREF) (Routasalo et al. 2009). It has also 
prognostic validity in survival (Pitkälä et al. 2004b). The PWB scale is presented in Appendix 8. 
The 6- and 12-month assessments included MMSE, verbal fluency, clock drawing test, 15D 
HRQoL, PWB scale, and drug use.  
Information on falls was retrieved from the nurse’s daily entries during the 12-month follow-up. At 
12 months, data on the use of health and social services were retrieved from patients’ medical 
records and and mortality data from the Population Register Centre of Finland. 
In Study 1, data on mortality during the 3-year follow-up were obtained from from Population 
Register Centre of Finland. 
Table 13 describes the timeline of all assessments.   
Table 13. Timeline of study assessments 












+     
Demographics   +    
CDR  +    
MNA  +    
Diagnoses   +    
Medication  + + +  
MMSE  + + +  
Verbal fluency  + + +  
Clock drawing test  + + +  
15D HRQoL  + + +  
PWB  + + +  
Falls   + +  
Hospitalization and 
use of health 
services 
   +  
Mortality    + + 
CDR=Clinical Dementia Rating; MMSE=Mini Mental State Examination; MNA=Mini Nutritional Assessment; 




The intervention was an educational intervention using problem-based learning methods and a 
learner-centred approach. After RAI assessments, the selected dyads were randomly divided into 
two groups, the intervention and the control arms. The nursing staff of the intervention arms 
received education on two afternoons by three geriatricians. Also consulting physicians were 
welcomed to educational sessions. The intervention arm included 10 wards. There were altogether 
17 registered nurses and three consulting physicians. One of the physicians was a geriatrician, and 
he participated in one of the training sessions. One of the two primary care physicians also 
participated in one session.  
Contents of the first 4-hour session included polypharmacy, changes in drug metabolism in older 
age, especially renal failure and use of Renbase (Renbase 2011), common drug-drug interactions 
and use of the SFINX database (SFINX 2011), and potentially harmful drugs (psychotropic drugs, 
Beers’ criteria drugs, drugs with anticholinergic properties, NSAIDs, and PPIs) and their adverse 
effects. Also discussed were potentially beneficial drugs, such as vitamin D (Bischoff-Ferrari et al. 
2009) and anticoagulation in case of atrial fibrillation (You et al. 2012), for institutionalized older 
people.  
Renbase is a database of information on the pharmacokinetics and safety of various drugs in renal 
failure. It gives dosage recommendations for 1500 drugs. The SFINX (Swedish, Finnish, 
Interaction, X-referencing) database is a drug-drug interaction database containing information on 
the consequences of and recommendations for about 18 000 drug-drug interactions. 
 
The second 4-hour session was a case-based and problem-oriented learning workshop. Each ward 
brought 2-3 of their own patient cases with various drug problems, and participants were 
encouraged to discuss in groups and to present cases to their peers. Participants were advised to 
explore the medication lists of the residents in their wards and to discuss these drug problems 
subsequently with their consulting physicians to improve their patients’ care. Each participant also 
received a 2-page list of harmful drugs to identify them in practice. Nursing staff in all wards of the 
nursing homes in Kouvola received this training. Nursing staff in the control wards in Helsinki 
received similar training after a 12-month follow-up. 
 
4.5 Outcome measures  
 
The primary outcome measures were the proportion of persons using PHMs (Beers’ drugs, DAPs, 
>2 psychotropics, NSAIDs, and PPIs) in Studies 2-4 and change in the number of PHMs in Studies 
3 and 4.  
Secondary outcome measures were change in the health-related quality of life according to the 15D 
HRQoL (Sintonen 2001) in Study 3 and changes in cognition measured by clock drawing test 
(Sunderland et al. 1989) and verbal fluency (Morris et al. 1989) during the 12-month follow-up in 
Study 4. Number of falls and fallers were retrieved from patients’ records in Study 4. Recording 
falls is part of nursing staff routine care procedures, and this information may be considered 
reliable. The use of health care services – mainly hospitalizations – during the 12-month follow-up 
was retrieved from medical records in Study 3. Mortality up to 12 months was compared between 
the intervention and control arms in Study 3. In Study 1, mortality data were retrieved from the 
Population Register Centre at the end of the 3-year follow-up. 
4.6 Statistical analyses 
 
Sample size calculation in the RCT was based on the change in the prevalence of potentially 
harmful medication use. The required sample size was calculated assuming that 36% of the control 
group use inappropriate drugs (Raivio et al. 2006), aiming at a minimum group difference of 20% 
after the intervention, with type I error 5% and power 80%. These assumptions resulted in 106 
participants per group.  
In the baseline findings of the RCT (Studies 2,3, and 4), the categorical variables (e.g. gender, 
education, diagnoses) were described as proportions (%) and analysed by X2 or Fischer’s exact test 
when appropriate. The continuous variables (e.g. age, PWB) were presented using means with 
standard deviations (SD) or ranges. For variables with normal distribution, statistical comparisons 
between the groups were performed using Student’s t test. For non-normally distributed continuous 
variables, statistical comparison between the groups was performed using the Mann-Whitney U 
test. The normality of the variables was tested with the Shapiro-Wilk W-test.  
All residents assessed at baseline and at least once during the two follow-ups were included when 
analysing changes in the use of medications and HRQoL in Study 3 and when analysing changes in 
the cognitive measures in Study 4 (modified intention-to-treat analyses). All randomized residents 
were included when analysing use of health services and mortality in Study 3 and when analysing 
the number and rate of falls in Study 4 (intention-to-treat analyses).  
In Studies 3 and 4, repeated measures were analysed using generalized estimating equation (GEE) 
models, with appropriate distribution and link functions, and an unstructured correlation structure, 
with treatment groups, time, and their interaction as fixed factors. GEE models were developed as 
an extension of general linear models (e.g. ordinary least squares (OLS) regression analysis) for 
analysis of longitudinal and other correlated data. The GEE models took into account the 
correlation between repeated measurements for the same participant. These models do not require 
complete data for all participants at all time points. Incidence rate ratios (IRRs) for hospital days 
and ambulatory services in Study 3 and for falls in Study 4 were estimated and compared between 
the groups using the Poisson regression models with robust standard error. Cox proportional hazard 
model was used to test the effect of intervention on mortality. Analyses were adjusted for age, sex, 
and comorbidities and in the falls analysis also for mobility. Confidence intervals (95%) were 
calculated for the most important outcomes.  
In Study 1, clinical and demographic characteristics of residents in four PHM burden groups (G) 
(G0=no PHMs, G1=PHMs according to one criterion, G2=PHMs according to two criteria, 
G3=PHMs according to three criteria) (Beers’ 2003, DAPs, or >2 psychotropics concomitamtly) 
were compared. The statistical hypothesis of linearity was evaluated using analysis of variance 
(ANOVA), Cochran-Armitage test, and logistic models. In case of violation of the assumptions 
(non-normality), a bootstrap-type test was used. The relationship between group allocation and each 
of the main outcomes was analysed with multivariate forward stepwise continuation-ratio logistic 
regression for ordered response data.  
 
P-values <0.05 were considered statistically significant. 
Analyses were performed using STATA software (version 14.0) (StataCorp LP, College Station, 
TX, USA). 
 
4.7 Ethical considerations 
 
The Ethics Committee of Helsinki University Central Hospital approved the study protocol. 
Participants and their closest proxies received information about the study and its content and 
purpose, and each participant or her/his closest proxy gave written informed consent to participate 








Baseline findings are presented in the Methods section. 
 
5.1 Burden of PHMs (Study 1) 
Study 1 examined the overlap and burden of potentially harmful medications (Figure 2). PHM was 
defined as use of any of the following: Beers’ 2003 drugs, DAPs, or >2 psychotropics.  
Of all 326 participants, 221 used DAPs; 93 used only DAPs as PHM, 57 used concomitantly >2 
psychotropic drugs, but not Beers’ drugs, and 30 used concomitantly Beers’ 2003 PIDs but not >2 
psychotropic drugs. Of all participants, 105 used concomitantly >2 psychotropic drugs; 2 had only 
excess psychotropic use as PHM, and 5 used also Beers’ 2003 PIDs. Of all participants, 105 used 
Beers’ 2003 PIDs; 29 had only Beers’ 2003 PIDs as PHM. Of all participants, 30 used DAPs and 
Beers’ drugs simultaneously. Altogether 41 of all 362 participants used PHM according to all three 
criteria, and 69 did not use medication according to any of these three criteria.  
 
In Study 1, participants in the Helsinki assisted living facility and Kouvola nursing homes were 
divided into four groups according to their use of PHMs. Participants in Group 0 (G0)(n=69) did 
not use any PHMs according to the three criteria of Beers’ 2003 potentially inappropriate drugs, 
DAPs, or concomitant use of >2 psychotropic drugs. Participants in Group 1 (G1)(n=124) used 
PHMs according to one criterion, participants in Group 2 (G2)(n=92) used PHMs according to two 
criteria, and participants in Group 3 (G3)(n=41) used PHMs according to all three criteria. When 
calculating the total number of PHMs, each PHM was counted only once even if it was included in 
several definitions.  
Medication use and characteristics in the four groups are summarized in Table 14. There were 
significant differences in characteristics and medication use between the groups. The mean number 
of regular drugs ranged from 6.5 to 9.7; the number of drugs increased stepwise as more PHM 
criteria were fulfilled. The same significant difference was seen in the mean number of PHDs, 
increasing from 0.8 to 4.8, as well as in the mean number of Beers’ drugs, DAPs, and psychotropic 
drugs. Participants who used PHMs from all three categories were younger. However, there were no 
significant differences in gender, Charlson’s comorbidity index, or MMSE between the groups.  
 
Table 14. Characteristics and use of medications among groups according to fulfilling 0-3 criteria 
for potentially harmful medications (PHMs). 









Age, mean±SD 85.9±7.5 83.8±6.9 82.4±7.3 81.4±6.7 <0.001 
Gender: female, % 66.7 74.2 72.8 56.1 0.41 
Charlson comorbidity index2, 
mean±SD  
2.4 ± 1.7 2.7±1.8 2.5±1.5 3.0±1.8 0.31 
MMSE3, mean±SD  8.7±6.5 9.1± 8.4 9.7±8.3 11.1±9.0 0.13 
Number of regular drugs, 
mean±SD 
6.5±2.9 6.8±2.8 8.4±2.8 9.7±2.6 <0.001 
Number of potentially harmful 
drugs4, mean±SD 
0.8±0.7 2.0±0.9 3.6±1.2 4.8±1.2 <0.001 
Beers’ drugs, mean±SD 0±0.0 0.3±0.5 0.5±0.7 1.5±0.7 <0.001 
Drugs with anticholinergic 
properties5, mean±SD 
0±0.0 0.9±0.7 1.5±0.9 2.0±0.8 <0.001 
Psychotropic drugs, mean±SD 0.8±0.7 1.4±0.8 2.9±1.1 3.9±1.0 <0.001 
Self-rated health good, % 86.2 70.8 65.3 66.7 0.015 
PWB6, mean±SD 0.74±0.18 
(n = 60) 
0.68±0.23 
(n = 104) 
0.67±0.23 
(n = 81) 
0.61±0.25 
(n = 37) 
0.0044 
15D7, mean±SD 0.64±0.11 0.60±0.12 0.60±0.13 0.59±0.12 0.022 
G0=participants not fulfilling any of the PHM criteria (Beers’ PIDs, DAPs, or use of >2 psychotropics concomitantly); 
G1=participants fulfilling 1 criterion; G2=participants fulfilling 2 criteria; G3=participants fulfilling 3 criteria; 
1Differences between the groups were evaluated using analysis of variance (ANOVA), Cochran-Armitage test, or 
logistic models. In case of violation of assumptions (non-normality), a bootstrap-type test was used. No adjustments 
were made in these analyses; 2Charlson et al. 1987; 3 Folstein et al. 1975; 4Included Beers’ 2003 drugs, anticholinergic 
drugs, and psychotropic drugs; 5 Fick et al. 2003, Rudolph et al. 2008, Socialstyrelsen 2010; 6Routasalo et al. 2009; n = 
number of responders in this item; 7Sintonen 2001 
 
 
5.1.1 Predictors of burden of PHMs and associations with participants’ quality of life and 
mortality 
 
In forward stepwise ordered (continuation-ratio) logistic regression for burden of PHMs (by 4 
classes from G0 to G3), younger age  (OR) 0.94, 95% CI 0.90 to 0.99; p=0.014], lower HRQoL 
according to 15D (0.57 per SD, 95% CI 0.39 to 0.85; p=0.006), and higher MMSE (1.06, CI 1.01 to 
1.11; p=0.028) were associated with higher burden of PHMs.  
 
Burden of PHMs was associated with lower scores in HRQoL according to 15D, in PWB, and in 
self-rated health. 15D was 0.64 in G0, 0.60 in G1, 0.60 in G2, and 0.59 in G3 (p=0.0031, adjusted 
for age, gender, and comorbidity). The respective figures in PWB were 0.74, 0.68, 0.67, and 0.61 
(p=0.0041, adjusted for age, gender, and comorbidity). In G0, 86% of participants felt healthy, the 
respective figures being in G1 71%, G2 65%, and G3 67% (p=0.020, adjusted for age, gender, and 
comorbidity). In PWB and self-rated health, a number of participants with low cognition were 
unable to answer. Only responders’ answers were analysed. If a person is unable to reply, proxy 
administration can also be used with 15D HRQoL (Sintonen 2001).  
Data on mortality over the 3-year follow-up were obtained from the Population Register Centre. 
The proportion of participants deceased was 64% in the group in which residents did not use PHMs 
according to any PHM criteria, 62% in the group where residents used PHMs according to one 
criterion, 48% in the group where residents used PHMs according to two criteria, and 51% in the 
group where residents used PHMs according to three criteria. No differences in mortality emerged 
between the groups according to burden of PHMs when adjusted for age and gender (p=0.10). 
 
5.2 Educational intervention to reduce PHM use among residents in assisted living facilities 
 
5.2.1 Baseline findings and feasibility (Study 2) 
 
Characteristics and medications of participants at baseline are described in Table 11. At baseline, no 
significant differences were present between the intervention and control arms in mean age, 
education, or cognition. Participants in the intervention group had more comorbidities than 
participants in the control group (p<0.004). The proportion of females tended to be lower in the 
intervention group than in the control group (p=0.050). No significant difference emerged in the 
mean number of regular drugs between the groups (p=0.79). However, in the intervention group the 
mean number of pro re nata drugs was significantly higher than in the control group, 3.6±2.3 versus 
2.9±2.0 (p=0.007). There was also a significant difference in the proportion of subjects using 
harmful medications, 83% versus 72%, respectively (p=0.038). However, there was no significant 
difference in the mean number of harmful drugs, 2.9±1.8 versus 2.5±2 (p=0.28). Nor were there 
significant differences in the proportion of subjects using Beers’ 2003 PIDs, 25% versus 19% 
(p=0.25), the proportion using DAPs, 78% versus 66% (p=0.089), or the proportion using >2 




Three units were randomized into the intervention arm with three wards in two units and four wards 
in one unit. Table 15 describes the number of registered nurses in the wards and how they 
participated in the educational sessions. In 7 of the 10 wards, nurses participated in both training 
sessions. There were also two wards in which the nurses did not participate in the first session, but 
participated in the second session. Unfortunately, in one ward the nurses did not participate in either 
of the sessions. Instead, they received tailored individual training. In addition, there were three 
treating physicians in the intervention wards: one geriatrician and two primary care physicians. The 
geriatrician and one of the primary care physicians participated in one afternoon session.  
 
Table 15. Participation in intervention training sessions. 
Unit 
(U) 
Wards, n Registered nurses, n Sessions, nurses, n Sessions, physicians, n 
 U 1        3                   5                6       1(GP) 
 U 2        3                  5                5       0 (GP) 
 U 3        4                  7                6       1 (geriatrician) 
GP= general practioner 
 
5.2.2 Effect of intervention on use of PHMs (Study 3) 
 
Over the 12-month follow-up period, the prevalence of PHMs decreased significantly in the 
intervention group (-11.7%, 95% CI -20.5 to -2.9; p=0.009). No significant change occurred in the 
control group (+3.4%, 95% CI -3.7 to 10.6; p=0.34). There was a significant difference in change in 
the prevalence of the use of PHMs between the groups at 12 months (p=0.022, adjusted for age, 
sex, and comorbidities). The mean number of harmful drugs decreased in the intervention group (-
0.43, 95% CI -0.71 to -0.15; p= 0.0024), whereas in the control group it remained stable (+0.11, 
95% CI -0.09 to +0.31; p= 0.27). The difference in change in the mean number of PHMs between 






Figure 3. Change from baseline in the mean number of potentially harmful medications at 6 months 
and 12 months. P-values between the groups are adjusted for age, sex, and comorbidities. 
 
When the PHMs were examined separately, the use of psychotropic drugs decreased significantly in 
the intervention group compared with the control group (p=0.022, adjusted for age, sex, and 
comorbidities). The decrease in the number of Beers’ drugs (p=0.23) and DAPs (p=0.17) in the 







































Figure 4. Change from the baseline in the mean number of Beers’ potentially inappropriate drugs, 
drugs with anticholinergic properties, and psychotropic drugs. 
 
5.2.3 Effect of intervention on participants’ quality of life (Study 3) 
Participants’ quality of life was measured at baseline, 6 months, and 12 months using the 15D 
Health-Related Quality of Life (15D HRQoL) scale.  
When the effect of the intervention on the quality of life was assessed, HRQoL declined 
significantly more slowly in the intervention group (-0.038; 95% CI -0.054 to -0.022) than in the 
control group (-0.072, 95% CI -0.089 to -0.055; p=0.005, adjusted for age, sex, and comorbidities). 
Breathing, sleeping, and speech were the dimensions of 15D that benefited most in the intervention 
group (Figure 5). 
 
Figure 5. Changes from baseline in 15D HRQoL dimensions. 
Change from baseline to 12 months











































5.2.4 Effect of intervention on participants’ hospitalization and use of health services  
(Study 3) 
 
A significant difference was present in the use of hospital days between the intervention and control 
groups. Residents in the intervention group used less hospital days, 1.4/person/year (95% CI 1.2 to 
1.6), whereas the respective figure in the control group was higher, 2.3/person/year (95% CI 2.1 to 
2.7) (IRR 0.60, 95% CI 0.49 to 0.75; p <0.001, adjusted for age, sex, and comorbidities). There was 
no significant difference in the use of ambulatory services between the groups: in the intervention 
group 0.7/person/year (95% CI 0.5 to 0.8) and in the control group 0.6/person/year (95% CI 0.5 to 
0.8) (IRR 0.98 (95% CI 0.69 to 1.39); p=0.92, adjusted for age, sex, and comorbidities).  
 
5.2.5 Effects of intervention on participants’ mortality (Study 3) 
 
Mortality was investigated over the one-year follow-up. At 12 months, 33% of the participants in 
the intervention group were deceased, and the respective figure in the control group was 22% 
(unadjusted p=0.064). When adjusted for age, sex, and comorbidities in the Cox proportional 
hazard model, no significant difference in mortality was present between the intervention and 
control groups (HR 1.04, 95% CI 0.79 to 1.36; p=0.79). 
 
5.2.6 Effect of intervention on participants’ falls (Study 4) 
 
Data on falls were retrieved from each participant’s medical records. There were significantly less 
falls in the intervention group (n=171 falls; 2.25 falls/person/year, 95% CI 1.93 to 2.62) than in the 
control group (n=259 falls; 3.25 falls/person/year, 95% CI 2.87 to 3.67). The age-, sex-, and 
comorbidity-adjusted IRR for falls in the intervention wards was 0.72, 95% CI 0.59 to 0.88; p 
<0.001. When adjusted for age, sex, and mobility, the respective IRR was 0.80, 95% CI 0.66 to 
0.97; p=0.025. There were 42 fallers in the intervention group, 27 falling more than once during the 
12-month follow-up, and 60 fallers in the control group (p=0.0032). Altogether, 41 individuals fell 
more than once. Four residents in the control group fell between 20 and 22 times each and in the 
intervention group three residents fell 28 times each. When the residents were stratified according 
to their baseline MMSE, the residents with MMSE scores ≥10 points benefited from the 
intervention with respect to falls. There were no differences between the intervention and control 
groups in residents with MMSE <10 (see Figure 6). The number of participants in different MMSE 
groups is presented in Table 16. 
 







Figure 6. IRR (Incident Risk Ratio) for falls stratified to according to participants’ baseline MMSE. 
MMSE= Mini Mental State Examination (Folstein et al. 1975) 
 
5.2.7 Effect of intervention on participants’ cognition (Study 4) 
Cognition was assessed using verbal fluency (Morris et al. 1989) and clock drawing test (Morris et 
















verbal fluency or clock drawing test between the intervention and control groups at 6 months or 12 




                              
 
Figure 7.                                                                    Figure 8.  
Changes in cognition in the intervention            Changes in cognition in the intervention 
and control groups according to verbal               and control groups according to clock 
fluency scores (Morris et al. 1989).                      drawing test (Morris et al. 1989). 
P=0.37 at 6 months and 0.88 at 12 months,         P=0.088 at 6 months and 0.53 at 12 months, 
















































































6.1 Main findings 
 
There was a high burden in the use of PHMs in institutional settings. In this cross-sectional study, 
13% of participants used PHMs from all three categories of PHMs (Beers’ drugs, DAPs, >2 
psychotropics), and 79% used PHMs from at least from one category of PHMs. Use of PHMs was 
associated in a stepwise manner with poorer HRQoL, PWB, and self-rated health. The use of PHMs 
was not associated with mortality over a 3-year follow-up.  
The educational intervention in the cluster randomized controlled trial was successful in several 
respects. There were some differences in characteristics of the intervention and control arms at 
baseline, and the outcomes had to be adjusted accordingly in the final analyses. Of the participants, 
83% in the intervention group and 72% in the control group were administered PHMs at baseline. 
The training using activating learning methods was fairly well accepted by staff.  
The intervention had an effect on the use of PHMs. The mean number as well as the proportion 
using PHMs decreased significantly in the intervention group relative to the control group during 
the one-year follow-up.  Of the potentially harmful drugs, the use of psychotropic drugs decreased 
significantly in the intervention group compared with the control group. HRQoL decreased 
significantly slower and the use of hospital days was significantly lower in the intervention group 
than in the control group.  
The incidence of falls decreased significantly in the intervention group compared to the control 
group. The participants with MMSE>10 in the intervention group had less falls than the respective 
controls, whereas in participants with MMSE<10 no difference was observed between the groups.  
The intervention had no effect on cognition according to the verbal fluency or clock drawing test. 
No difference emerged in mortality between the intervention and control groups over the one-year 
follow-up. 
6.2 Strengths and limitations of the study 
This study was carefully planned and included an exploration of the use of PHMs in various 
institutional settings at baseline. The PHMs were defined with internationally validated criteria. The 
list of PHMs was a combination of several lists in order to be comprehensive. It consisted of the 
Beers’ 2003 list (Fick et al. 2003), including those drugs available in Finland at the time of the 
study, a combination of several anticholinergic lists (Fick et al. 2003, Rudolph et al. 2008, 
Socialstyrelsen 2010), and the concomitant use of >2 psychotropics (Socialstyrelsen 2010), PPIs 
(Teramura-Grönblad et al. 2010), and NSAIDs (Socialstyrelsen 2010). At the time of planning these 
studies, the criteria for PHMs had to be retrieved from various sources since, for example, the 
available Beers’ criteria in 2011 (Fick et al. 2003) included only few psychotropics. Moreover, all 
DAPs, NSAIDs, or PPIs available in Finland were not included in the Beers’ criteria. At the time of 
planning the study in 2010, there was an increasing number of reports of adverse events with these 
medications. Therefore, a novel list of PHMs was created for this study based on the literature and 
in agreement with the research team. In fact, the Beers’ criteria (AGS 2012, AGS 2015) have 
evolved since 2011, and the current criteria (AGS 2015) are fairly similar to the PHM list compiled 
here. Medications of the participants were retrieved from medical records to ensure reliability. 
  The effectiveness of the educational intervention was tested in a rigorous randomized controlled 
trial. There were very few exclusion criteria for older participants. Sample size was calculated to 
ensure sufficient statistical power to detect clinically meaningful differences between the 
intervention and control groups. A cluster randomization design was used to avoid contamination of 
intervention procedures. The units were selected using Minimum Data Set (MDS)/Resident 
Assessment Instrument (RAI) to ensure as similar as possible patient profiles in the intervention and 
control arms.  
The study nurses performing the assessments were experienced and well trained. They were kept 
unaware of the group to which units were randomized. The assessment tests used in this study are 
widely used and well validated. Therefore, the data collection may be considered reliable. The 
primary outcome measures were selected to be sensitive to change. The number of PHMs at 
baseline was high; therefore, there was no floor effect in reducing them. 15D HRQoL has been 
shown to be sensitive to change in previous Finnish studies (Pitkälä et al. 2008). It can be used even 
if a participant is unable to answer; in these cases, the participant’s closest proxy can anwer 
(Sintonen 2001).  
The intervention was planned to be light and easy to implement in other facilities in the future. We 
used activating and problem-based learning methods (Dolmans et al. 2005), which might encourage 
nurses to pay attention to medication problems when caring for their patients. Finally, the studies 
assessed important and relevant outcomes for older people such as quality of life, falls, cognition, 
and hospitalizations. 
 
The studies also have several limitations. Due to cluster randomization, there were some differences 
at baseline in the characteristics of participants between the intervention and control groups. This 
was taken into account in the analyses. The results have been adjusted for age, sex, and 
comorbidity, and, in case of falls, also for mobility. There was a high staff turnover, and some 
nurses may have moved from intervention wards to control wards. This may have diluted some of 
the trial effects.  
The population in RCT was old and had high comorbidity so there was a fairly high attrition rate, 
28%, over the one-year follow-up. When analysing the changes in the use of PHMs and HRQoL, 
modified intention-to-treat analyses were used, i.e. all residents assessed at least at 6 months or 12 
months were included. However, intention-to-treat analyses were used when analysing falls, health 
service utilization, and mortality, and thus, all randomized residents were included.  
Many participants had severe cognitive decline. When PWB and self-related health were tested, 
these participants were unable to answer. Only responders’ answers could be analysed.  
In Study 1, medications, HRQoL, and PWB were assessed cross-sectionally. Even if we found 
associations between burden of PHMs and decline in HRQoL and PWB, causality in this cross-
sectional study cannot be established. Participants were frail older people, and mortality and drop-
out rates were high. The study was performed in two types of facilities in two communities, and the 
results might not be generalizable to other cultures. 
6.3 Medication use (Studies 1–4) 
The mean number of regularly used drugs among all participants of this study was 7.5. Therefore, a 
large proportion of participants had polypharmacy (Onder et al. 2012b). In Finnish studies 
exploring drug use in institutional settings, the number of regularly used drugs has been at a similar 
level (Hosia-Randell et al. 2008, Nurminen et al. 2009, Pitkälä et al. 2015). Our result also 
corresponds well with the findings among institutionalized older people in Europe (Onder et al. 
2012b, Bourgeois et al. 2012, Johnell and Fastbom 2012) and in Australia (Stafford et al. 2011).  
There are numerous criteria to recognize inappropriate drugs for older people and to improve the 
quality of medication (Samsa et al. 1994, Fick et al. 2003, Basger et al. 2008, Gallagher and 
Mahony 2008, Rognstad et al. 2009). Many of these are suitable only in their own countries and 
some are fairly complicated and difficult to apply in clinical practice (Spinewine et al. 2007). The 
list used in this study was compiled from different sources (Fick et al. 2003, Rudolph et al. 2008, 
Socialstyrelsen 2010) to be as comprehensive as possible. The list was explicit. Thus, only drugs to 
be avoided were included in the PHMs.  
The proportion of residents using PHMs was quite high, 83% in the intervention group.  The 
proportion using Beers’ inappropriate drugs varied between 19% in the control group and 58% in 
the Kouvola group. The proportion of those using DAPS varied from 57% in Kouvola to 78% in the 
intervention group, and the proportion of those using >2 psychotropics from 31% in Kouvola to 
34% in the intervention group. In previous Finnish studies, about one-third of nursing home 
residents and acute hospital patients received Beers’ potentially inappropriate drugs (Raivio et al. 
2006, Hosia-Randell et al. 2008). According to studies in Europe, up to half of NH residents were 
on Beers’ PIDs (Ruggiero et al. 2010). In USA, this proportion varied from 26% to 50% 
(Briesacher et al. 2005, Lau et al. 2004). The highest figures were from Brazil, 83% (Vieira de 
Lima et al. 2013).  
The use of DAPs was quite high. In earlier Finnish studies, the proportions of elderly residents 
using DAPs have varied between 42% and 55% (Kumpula et al. 2011, Teramura-Grönblad et al. 
2011). These two studies had used ARS score (Rudolph et al. 2008) to define DAPs. However, the 
present study used also DAPs from two other criteria, Beers’ 2003 and Swedish quality indicator 
list 2010. This may in part explain the higher prevalence in the present study than in previous 
studies. In Sweden, the prevalence of DAPs in institutional settings was lower (12% to 21%) 
(Bergman et al. 2007, Olsson et al. 2010, Haasum et al. 2012). These studies used the Swedish 
quality indicator list, which contains less DAPs than the combination list applied here. In other 
countries, the prevalence has varied from 21% to 82% (Kersten et al. 2013b, Kolanowski et al. 
2009). The results have depended on – besides the criteria to define DAPs – also on the 
characteristics of the cohorts studied. 
Two-thirds of the participants used >2 psychotropics concomitantly. According to other Finnish 
studies, use of psychotropic drugs has been common among institutionalized older people. About 
71-80% have been administered at least one psychotropic in these studies (Hosia-Randell and 
Pitkälä 2005, Alanen et al. 2006, Nurminen et al. 2009). In Sweden, the use of psychotropics among 
institutionalized older people has varied from 38% to 85% (Schmidt et al. 1998a, Holmqvist et al. 
2003, Lövheim et al. 2008, Olsson et al. 2010), the lowest use being from the year 1982 (Lövheim 
et al. 2008). According to studies from other countries, use of psychotropics among institutionalized 
older people has been common; at least half of the residents have been on psychotropics (Table 8).  
 
PPIs are one of the most frequently used medications (Forgacs and Loganayagam 2008). In our 
study, the proportion of PPI users was 37-42%. According to other recent Finnish studies, the 
proportion of PPI users has been from 22% to 24% (Teramura-Grönblad et al. 2010, Teramura-
Grönblad et al. 2012). The data in the two studies by Teramura-Grönblad et al. were from 2003 and 
2007, while the data in our study was from 2011; thus, based on these results the use of PPIs in 
Finland has increased. Of residents in US nursing homes, 27% received PPIs (Rane et al. 2017). 
NSAID users comprised 3.3% in the intervention group and 5.5% in the control group. These 
proportions are similar to those in Norwegian NHs (Sandvik et al. 2016). 
6.4 Burden of PHMs (Study 1)    
The burden of PHMs was high among residents in assisted living facilities and nursing homes. 
More than three in four residents used PHMs according to at least one of the three criteria: Beers’ 
PIDs 2003, DAPs, or concomitant use of >2 psychotropic drugs. To our knowledge, few studies 
have simultaneously investigated PHMs according to various criteria. The use of PHMs according 
to multiple definitions was associated with lower health-related quality of life (HRQoL), lower 
psychological well-being (PWB), and lower self-rated health. Very few studies have investigated 
the associations between use of various PHMs and QoL. One earlier study found a better quality of 
life among nursing home residents not receiving psychotropics than among those administered 
psychotropics (Galik and Resnick 2013). However, the adequate use of antidepressants seemed to 
positively affect quality of life (van de Ven-Vakhteeva et al. 2013). Use of DAPs has been 
associated with lower PWB (Teramura-Grönblad et al. 2011). In addition, high drug burden index 
(DBI) was associated with lower QoL (Bosboom et al. 2012), whereas use of Beers’ drugs had no 
relationship with QoL (Franic and Jiang 2006, Bosboom et al. 2012). In any case, our findings 
suggest that the burden of PHMs is associated with lower HRQoL, although
 
No association was present between burden of PHMs at baseline and 3-year mortality. This is in 
line with most previous studies investigating the use of Beers’ PIDs and mortality (Gupta et al. 
1996, Onder et al. 2005, Klarin et al. 2005, Raivio et al. 2006, Pasina et al. 2014), although some 
studies have found an association (Lau et al. 2005, Perri et al. 2005). Results considering the use of 
DAPs and mortality have also been contradictory. According to a Finnish retrospective study 
among hip fracture patients, the use of DAPs was associated with mortality (Panula et al. 2009). 
Other Finnish studies have observed no association between DAP use and increased mortality 
(Kumpula et al. 2011, Uusvaara et al. 2011). Gnjidic and colleagues in a population cohort study 
found a dose-response relationship between cumulative anticholinergic and sedative use and 
mortality (Gnjidic et al. 2014). Some other international studies have reported an association 
between DAPs and mortality (Fox et al. 2011, Lowry et al. 2011, Myint et al. 2015, Ruxton et al. 
2015), while others have not found this association (Agar et al. 2010, Wilson et al. 2012, Dauphinot 
et al. 2014). Use of psychotropic drugs, especially antipsychotics, among people with dementia has 
been associated more clearly with mortality (Hartikainen et al. 2005, Schneider et al. 2005, Wang et 
al. 2005, Gill et al. 2007, Liperoti et al. 2009, Aparasu et al. 2012, Liperoti et al. 2017), although 
contradictory findings have also emerged for psychotropics (Raivio et al. 2007, Bell et al. 2009). 
The reason that the burden of PHMs was not reflected in a poor prognosis, i.e. mortality, in our 
study is probably due to the characteristics of the participants. They were very frail with a high 
number of serious comorbidities. Their prognosis was poor in any case, and improving their 
prognosis was challenging. Whether the medication of participants changed after the study period 
remains unknown.  
 
6.5 Educational intervention to reduce the use of PHMs (Studies 2-4) 
 
The intervention was educational and based on constructive learning theory and activating learning 
methods (Dolmans et al. 2005). This theory-based training may change the attitudes of nurses 
towards their patients. Training was based on nurses’ own cases, which they had to elaborate. Most 
nurses participated willingly in training sessions and they were very interested and enthusiastic 
about education. There were many questions when discussing problems in their patients’ 
medications and trying to find solutions. Trainers received favourable feedback from the nurses. 
Nurses were encouraged to discuss theirpatients' medication problems and to bring issues to their 
treating physicians, who were ultimately responsible for the medication. This kind of education may 
bring meaningfulness to nurses’ work.  Nurses are fairly independent in their work and carry much 
responsibility for their residents’ medication. Treating physicians visit only once a week or even 
more rarely in assisted living facilities. In case of complications with a resident, nurses must contact 
their physicians or the doctor on call, and the decision about possible drug changes largely depends 
on how the nurse describes the situation. It is crucial that nursing staff have a wide knowledge 
about the actions and possible adverse effects of medications.  
There was also some contradictory feedback; some nurses thought that this training was not suitable 
for nurses and that it only imposed upon their everyday work. There was some resistance to 
training. The reason for this remained unclear. One explanation may be that it is demanding to work 
in assisted living facilities, where residents are frail and physically disadvantaged. Most of them 
suffer from dementia and they may have behavioural symptoms, 
. Nurses may thus have been stressed, leading to the negative attitudes. 
In this RCT, the intervention was designed to be quite light, lasting only two afternoons, and it was 
successful in decreasing the use of PHMs in the intervention group. This kind of intervention could 
easily be implemented in other units.  
The use of PHMs, especially psychotropics, decreased in the intervention group compared with the 
control group. This finding is in line with previous educational intervention trials (Avorn et al. 
1992, Meador et al. 1997, Schmidt et al. 1998a, Roberts et al. 2001, Fossey et al. 2006, Westbury et 
al. 2010, García-Gollarte et al. 2014). In addition to the modern learning methods used in this 
intervention, one explanation for the successful intervention effects might be the high use of PHMs 
at baseline.  
HRQoL decreased significantly in both groups, but more slowly in the intervention group than in 
the control group. In this patient group, a large proportion suffered from dementia and other serious 
chronic diseases, inevitably leading to a decline in HRQoL. Thus, it is beneficial for the patient 
group even if the current HRQoL can be maintained or its decline slowed down. To our knowledge, 
this is the first educational PHM intervention to succeed with respect to HRQoL.    
There was a lower number of hospital days in the intervention group than in the control group. This 
may be due to the decrease in complications related to adverse events of PHMs. The lower number 
of falls in the intervention group supports this speculation. However, the causal relationships 
between PHMs and hospitalizations cannot be confirmed in this study. To our knowledge, there is 
only one recent study in which use of health care services was reduced along with the reduction of 
PHMs (García-Gollarte et al. 2014). 
There was a significant decrease in the number of falls per person per year in the intervention group 
compared with the controls. This is in line with two recent pharmacist-led studies to reduce PHMs 
(Patterson et al. 2010, Frankenthal et al. 2014).  However, most earlier studies have not been able to 
show a reduction in falls along with the decrease in PHMs (Crotty et al. 2004, Fossey et al. 2006, 
García-Gollarte et al. 2014). The decrease in the number of falls in our study may be considered the 
result of the educational intervention. The use of psychotropics decreased significantly in the 
intervention group, and some psychotropics represent a strong risk factor for falls (Hartikainen et al. 
2007, Huang et al. 2012). It is necessary to restrict the excessive or inappropriate use of these drugs 
(Hill and Wee 2012, Huang et al. 2012).  
Falls are common among older people, both home-dwelling and institutionalized (AGS and BGS 
2011, Ambrose and Hausdorff 2013). Injuries and fractures may be the result of falls, and these may 
lead to hospitalization or utilization of other health services as well as to functional decline (AGS 
and BGS 2011). There are numerous risks for falling, both intrinsic (person-specific) and extrinsic 
(environmental) (Ambrose and Hausdorff 2013), and certain medications increase the risk for 
falling (Leipzig et al. 1999, Hartikainen et al. 2007, Huang et al. 2012). In addition to psychotropic 
drugs, several other drugs, such as some antihypertensives (increasing) and vitamin D (decreasing), 
may affect the risk for falling (Leipzig et al. 1999, Hien et al. 2005, Hartikainen et al. 2007, AGS 
and BGS 2011, Huang et al. 2012). At baseline, the intervention and control groups were similar in 
their use of these drugs.  Those individuals with MMSE >10 seemed to benefit from the 
intervention with respect to falls, whereas those with <10 points did not. This may be due to the fact 
that those with severe dementia did not walk much any more, thus being at lower risk of falling than 
those with MMSE >10.  
There was no effect on cognition in the intervention group relative to the control group. The effect 
of intervention was measured with clock drawing test and verbal fluency. Verbal fluency seemed to 
decrease in both groups, albeit not significantly. DAPs and some antipsychotics are known to 
negatively influence cognition (Schneider et al. 2006, Boustani et al. 2008, Rudolph et al. 2008, 
Campbell et al. 2009, Cancelli et al. 2009, Uusvaara et al. 2009). The use of DAPs did not decrease 
significantly in the intervention group relative to the control group. Therefore, it is logical that no 
difference was seen in cognition between the groups. The use of psychotropics decreased in the 
intervention group compared with the control group. However, the negative effect of psychotropics 
on cognition may be long-lasting. In a Finnish cohort study with a 6-month follow-up among 
residents aged ≥55 years, withdrawal of benzodiazepines as a hypnotic did not improve results in 
cognitive tests. Long-term daily users had slower reaction times at baseline and after the 6-month 
withdrawal than benzodiazepine-free controls (Puustinen et al. 2014).  
In this study, participants were old (mean age 83-84 years), and 93% suffered from various degrees 
of dementia, with a mean MMSE ranging from 8.8 to 10. Thus, it was likely that the cognitive 
abilities of the participants will in any case slowly decrease.  
Mortality was studied over the one-year follow-up of the RCT. There was no significant difference 
between the intervention and the control group in the multivariate model adjusted for age, sex, and 
comorbidities. In this RCT, the use of psychotropic drugs decreased significantly in the intervention 
group. Positive outcomes did not decrease the risk of participants’ mortality, however, neither did 
the risk increase. Thus, the intervention was safe. Participants were old and had numerous serious 
comorbidities. MMSE scores were low, with mean values at 10. Thus, the participants had a high 
number of competing causes for death. According to a recent Cochrane review about interventions 
to improve prescribing for older people in care homes, there was no evidence of an effect of the 
intervention on mortality (Alldred et al. 2016). Our study is in line with this finding. 
There were many favourable findings in this study: less harmful medications, especially 
psychotropics, fewer hospital days, fewer falls, and better QoL. However, we do not know how 
lasting these results will be. Staff turnover is frequent, requiring continuity in drug training. A large 
number of older people living in institutional settings suffer from dementia. Dementia is often 
associated with behavioural symptoms. These residents are treated with antipsychotic drugs even 
though their efficacy is limited (Sink et al. 2005). However, sometimes the residents need to be 
treated with antipsychotics, e.g. patients with psychotic symptoms. Anyway, the need for these 
medications should be evaluated regularly. In addition, nonpharmacological interventions are 
available to treat behavioural symptoms. Our study suggests that it is possible to decrease the use of 




1. The use of PHMs according to three different criteria (Beers’ PIDs, DAPs, and concomitant 
use of  >2 psychotropics) is highly prevalent among institutionalized older people (Study 1). 
2. At baseline, the burden of potentially harmful medications (PHMs) was associated with a 
lower quality of life according to three different indicators: 15D HRQoL, PWB, and self-rated 
health. The   burden of PHMs was not associated with mortality of participants (Study 1). 
3. This kind of light intervention with two afternoon sessions is easy to implement in residential 
care units (Study 2). 
4. RCT with educational intervention decreased the use of PHMs, especially psychotropic drugs 
(Study 3). 
5. As a result of the educational intervention, HRQoL declined more slowly and the use of 
hospital days was lower in the intervention group than in the control group. No difference was 
present in mortality (Study 3). 
6. As a result of the educational intervention, there were less falls in the intervention group than 
in the control group. No difference was present in changes of cognition (Study 4). 
 
The use of PHMs is common among institutionalized older people. Their use can be reduced with 





8 Implications for clinical practice and for future research  
 
It is important to regularly assess the frail older patients’ medications, which in an institutional 
setting include a high number of PHMs. The PHMs decrease QoL and increase risk of falling and 
hospitalizations. By decreasing the number of PHMs, especially psychotropics, clinicians can 
improve HRQoL and reduce falls and hospital days in this frail population. 
Nurses are key persons to manage medications of residents in institutional settings. Activating 
training targeted to nurses is beneficial for the residents. This kind of educational intervention is 
light and easily implemented in institutional settings. It could also be part of nurses’ continuing 
education. Staff turnover is high so it is important to regularly organize the training. Education on 
medication for older persons should be available also for consulting physicians and medical 
students. 
Older people’s medications frequently change. It is therefore important to assess and continually 
update the list of PHMs for the elderly. Computerized database systems should be constantly 
developed to recognize potential adverse drug reactions on the basis of drug lists in medical 
records. 
The changes in PHMs over time should be explored in different institutional cohorts. Relevant 
outcomes for older people, such as QoL, falls, and use of health services, should be assessed 
simultaneously in these studies.   
The present educational RCT should be repeated in different settings and cultures to determine 
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Comparison of Beers’ 2003 and 2012 lists of inappropriate medications independent of diagnoses or 
conditions. Differences are highlighted. Changes in Beers’ list 2015 (AGS 2015) are presented as 
footnotes in the table.  
Beers 2003 (Fick et al. 2003) Beers 2012 (AGS 2012) Concerns /Comments 
Anticholinergic drugs  
First-generation antihistamines: Highly anticholinergic; tolerance when 
used as hypnotic; risk of confusion, dry 
mouth, constipation. Diphenhydramine 
can be used in certain situations like 
acute severe allergic reaction 
 Brompheniramine  











Tripelennamine Dropped 2012 
 Antiparkinson agents: More effective alternatives available, 
not recommended for extrapyramidal 
(EP) symptoms caused by 
antipsychotics 
 Benztropine (oral) 
 Trihexyphenidyl 
Gastrointestinal antispasmodic drugs: Highly anticholinergic, effectiveness 
uncertain Belladonna alkaloids  Belladonna-alkaloids 
Clidinium-chlordiazepoxide  Clidinium-chlordiazepoxide 
Dicyclomine Dicyclomine 
Hyoscyamine  Hyoscyamine 
Propantheline  Propantheline 
 Scopolamine 
Muscle relaxants and antispasmodics: Anticholinergic adverse effects, 






Oxybutynin (not extended-release) 
 
Inappropriate with chronic constipation Anticholinergic 
Central nervous system drugs 
Tertiary tricyclic antidepressants, alone or in combination: Strongly anticholinergic, sedating, may 
cause orthostatic hypotension. 
Compared with Beers’ 2003, doxepin 











Dropped 2012 Long half-life, risk of CNS stimulation 
and agitation 
Antipsychotics Increased risk of stroke and death 
among persons with dementia 
Conventional antipsychotics: 
 Chlorpromazine  
 Fluphenazine  
 Haloperidol  
 Loxapine  
 Molindone  
 Perphenazine  
 Pimozide  
 Promazine  
 Thiothixene  
 Trifluoperazine  
 Triflupromazine  
Mesoridazine Mesoridazine Anticholinergic, risk of QT-interval 
prolongation, EP adverse effects 1 Thioridazine Thioridazine 
Atypical antipsychotics: 
 Aripiprazole  
 Asenapine  
 Clozapine  
 Iloperidone  
 Lurasidone  
 Olanzapine  
 Paliperidone  
 Quetiapine  
 Risperidone  
 Ziprasidone  
Barbiturates: High risk of physical dependence, 
tolerance when used for insomnia, risk 
of overdose at lowdosages 








Benzodiazepines   
Doses of short- and intermediate-acting benzodiazepines: Compared with Beers’ 2003, there is 
no longer a maximum dose for 
benzodiazepines. They should be 
generally avoided among older people 
because they increase the risk of 
cognitive impairment, delirium, falls, 
and fractures. They may be appropriate 
in certain situations like ethanol or 
benzodiazepine withdrawal, rapid eye 
movement sleep disorders, and end-of-
life care 
Alprazolam >2 mg/d Alprazolam 
 Estazolam 
Lorazepam >3 mg/d Lorazepam 
Oxazepam >60 mg/d Oxazepam 
Temazepam >15 mg/d Temazepam 
Triazolam >0.25 mg/d Triazolam 









Halazepam  Dropped 2012 No longer available in USA 
 Chloral hydrate Tolerance, risk of overdose 2 
Meprobamate Meprobamate Very sedating and addictive  
 Non-benzodiazepine hypnotics: Adverse effects similar to those of 





Other central nervous drugs   
Ergot mesyloids Ergot mesylates Ineffective 
Cyclandelate Dropped 2012 Ineffective 
Isoxsuprine Isoxsuprine Ineffective 
Amphetamines and anorexic agents Dropped 2012 Risk of dependence, hypertension, 
angina pectoris, myocardial infarction; 
inappropriate in 2012 with insomnia 
Pain   
Meperidine Meperidine Ineffective, may cause 
neurotoxicitylike confusion 
Long-term use of NSAIDs: Non-COX-selective NSAIDs, oral in 
Beers’ 2012; risk of GI bleeding and 
peptic ulcer especially in those aged 
>75 years or taking corticosteroids, 
anticoagulants, or antiplatelet agents 
















Indomethacin Indomethacin Of all NSAIDs, indomethacin has the 
most adverse effects 
Ketorolac Ketorolac Asymptomatic GI bleedings 
Pentazocine Pentazocine CNS adverse effects like confusion, 
safer alternatives available 
Propoxyphene and combinations Dropped 2012 No longer available in USA 
Cardiovascular, antiarrhythmic drugs (Class Ia, Ic, III), and antithrombotics  
Doxazosin Doxazosin Alpha agonists. May cause 




Clonidine Clonidine Alpha agonists, central. Orthostatic 




Methyldopa Alpha agonists. Risk of bradycardia 
and depression 
Reserpine at doses > 0.25 mg Reserpine (>0.1 mg/d) Alpha agonist. Depression, sedation, 
orthostatism 
Amiodarone Amiodarone Risk of QT-interval prolongation and 
torsade de pointes tachycardia, 
pulmonary disorders, thyroid disorders 
 Dofetilide Rate control yields better balance than 
rhythm control, antiarrhythmic drugs 
should be avoided as first-line 









Disopyramide Disopyramide Strongly anticholinergic, risk of heart 
failure in elderly patients 
Digoxin >0.125 mg/d Digoxin > 0.125 mg/d Risk of toxic effects for decreased 
renal clearance among older people 
Short acting nifedipine Nifedipine, immediate release May cause hypotension and 
constipation 
 Spironolactone > 25 mg/d Hyperpotassaemia, especially if taking 
NSAID, ACE-inhibitor, AT-receptor 
blocker, or potassium supplement 
Guanethidine Dropped 2012 Risk of orthostatic hypotension 
Guanadrel 
Ethacrynic acid Dropped 2012 Risk of hypertension and fluid 
imbalance 
Short-acting dipyridamole Short-acting dipyridamole Risk of orthostatic hypotension 
Ticlopidine Ticlopidine No better than aspirin, more toxic 
Gastrointestinal drugs and others  5, 6 
Bisacodyl Dropped 2012 Risk of bowel dysfunction Long-term 
use of stimulant laxatives, except when 
using opiates 
Cascara sagrada 
Mineral oil Mineral oil Risk of aspiration 
Trimethobenzamide Trimethobenzamide Extrapyramidal adverse effects 7 
 Metoclopramide Risk of extrapyramidal side effects, 
even tardive dyskinesia 
Cimetidine Dropped 2012 CNS adverse effects, confusion; 2012 
inappropriate with delirium 
Nitrofurantoin Nitrofurantoin Risk of pulmonary toxicity, ineffective 
when GFR <60 ml/min 8 
Ferrous sulphate >325 mg/d  Risk of constipation, absorption is no 
better with higher doses 
Drugs for endocrine disorders  
Oestrogens only (oral) Oestrogens with or without progestins Risk of breast and endometrium 
cancer, vaginal oestrogens for 
treatment of vaginal dryness seem to be 
safe when oestradiol < 25 μg twice a 
week 
Methyltestosterone Methyltestosterone Risk of prostatic hypertrophy, cardiac 
problems, contraindicated in men with 
prostatic cancer 
 Testosterone 
Desiccated thyroid Desiccated thyroid May cause cardiac effects 
 Growth hormone Risk of oedema, arthralgia, 
gynaecomastia, allowed only if 
pituitary gland removed 
 Insulin, sliding scale Risk of hypoglycaemia9 
 Megestrol Risk of thrombotic events and possibly 
death 
Chlorpropamide Chlorpropamide Risk of prolonged hypoglycaemia and 
SIADH 
 Glyburide Risk of prolonged hypoglycaemia 
1 Mesoridazine removed, no longer marketed in USA, 2 Chlorarl hydrate removed, no longer marketed in USA 3 Non-
benzodiazepine hypnotics are always to be avoided, 4 Antiarrhythmic drugs except disopyramide, and dronedarone 
removed and amiodarone and digoxin as first-line treatment for atrial fibrillation, 5 PPIs added, should be evaluated 
after 8 weeks of use, risk of Clostridium difficile infection and bone fractures, 6 Desmopressin added to genitourinary 
drugs, risk of hyponatremia, 7 Trimethobenzamide removed,8 Nitrofurantoin can be used short time carefully in 
individual with GFR ≥30 ml/min, 9 Insulin, sliding scale  - rationale modified, ACE=angiotensin converting enzyme, 
AT=angiotensin, CNS=central nervous system, COX=cyclo-oxygenase, EP=extrapyramidal, GFR=glomerular filtration 




Appendix 2.  
 
Beers’ inappropriate drugs 2003 available in Finland 2011-2012. 
 
Drug ATC-CODE Concern 
Indomethacin M01AB01 Produces the most CNS adverse effects of all available non-
steroidal anti-inflammatory drugs 
Oxybutynin G04BD04 Causes anticholinergic adverse effects and effectiveness is 
questionable 
Amitriptyline N06AA09 Amitriptyline and doxepin are strong anticholinergic and sedating, 
not good choices for older people, chlordiazepoxide is a long-
acting benzodiazepine 
 




Meprobamate N05BC01 Highly addictive and sedating 
Lorazepam >3 mg/day N05BA06 Older people are very sensitive to benzodiazepines, smaller doses 
may be as effective and safer Oxazepam >60 mg/day N05BA04 
Alprazolam >2 mg/day N05BA12 
Temazepam >15 mg/day N05CD07 
Triazolam >0.25 mg/day N05CD05 
Chlordiazepoxide N05BA02 Have a long half-life in older people, producing prolonged 
sedation and the risk for falls and fractures Chlordiazepoxide-clidinium A03CA02 
Diazepam N05BA01 
Digoxin >0.12 5mg/day C01AA05 Older people’ decreased renal clearance may lead to increased risk 
of toxic effects 
Dipyridamole (short-acting) B01AC07 Risk for orthostatic hypotension 
Belladonna-alkaloids  A03BB Highly anticholinergic and effectiveness is uncertain 
Diphenhydramine D04AA32 Highly anticholinergic 
Hydoxyzine N05BB01 
Ergot mesyloids C04AE01 Not effective in the doses studied 
Ferrous sulphate >325 mg/day B03A Higher doses do not increase the absorption, but increase the 
incidence of constipation 




N06BA CNS stimulant adverse effect 
Naproxen M01AE02 Risk for GI bleedings, renal failure, high blood pressure, and heart 
failure Piroxicam * M01AC01 
Fluoxetine N06AB03 Long half-life, risk for CNS stimulation, sleep disturbances, and 
agitation 
Bisacodyl, cascara sagrada, and 
Neoloid ** 
A06AB02 Risk for bowel dysfunction 
Amiodarone C01BD01 Risk for QT-interval prolongation and torsades de pointes 
arrhythmias 
Orphenadrine M03BC01 Anticholinergic adverse effects and sedation 
Nitrofurantoin J01XE01 Risk for renal impairment, safer alternative available 
Nifedipine (short-acting) C08CA05 Risk for hypotension and constipation 
Clonidine C02AC01 Risk for orthostatic hypotension and CNS adverse effects 
Cimetidine A02BA01 CNS adverse effects like confusion 
Oestrogens only (oral) G03C Risk for breast and endometrial carcinoma, lack of 
cardioprotective effect in older women 
* In Finland, only topically available, not considered inappropriate in study 
**If used twice a week = regular use. Not considered inappropriate in study if opioid in use 
  
Appendix 3.  
 
Drugs with anticholinergic property.  




Fick et al. 
2003 
Included1 
Alimemazine R06AD01  +   
Amantadine N04BB01 +    
Amitriptyline N06AA09 + + + X 
Atropine A03BA01 + +   
Baclofen M03BX01 +   X 
Belladonna alkaloids A03BA04   +  
Benztropine  N04AC01 +    
Biperidene N04AA02  +  X 
Butylscopolamine A03BB01  +   
Carbidopa-levodopa N04BA01 +   X 
Carisoprodol M03BA02 +  +  
Cetrizine R06AE07 +   X 
Chlorpheniramine  R06AB02 + + +  
Chlorpromazine  N05AA01 +   X 
Chlorprotixene N05AF03  +  X 
Chlorzoxazone M03BB03   +  
Cimetidine A02BA51 +    
Clidinium bromide A03CA02     
Clinidine-
chlordiazepoxide 
N05BA02   + X 
Clomipramine N06AA04  +  X 
Clozapine N05AH02 + +  X 
Codeine R05DA04     
Cyclobenzaprine M03BX08 + + +  
Cyproheptadine R06AX02 + + +  
Dariphenasine G04BD  +  X 
Desipramine N06AA01 +    
Dexchlorpheniramine R06AB52  + +  
Dicyclomine   A03AA07 +  +  
Dimenhydrinate R06AA52  +   
Diphenhydramine  R06AA02 +  + X 
Dipyridamole B01AC07   + X 
Disopyramide C01BA03  + +  
Doxepin N06AA12   + X 
Entacapone N04BX02 +   X 
Fesoterodine G04BD  +  X 
Fluphenazine  N05AB02 +   X 
Glycopyrrone R03BB06  +  X 
Haloperidol N05AD01 +   X 
Hydroxyzine N05BB01 + + + X 
Hyoscyamine A03BA03 + + +  
Imipramine N06AA02 +    
Levomepromazine N05AA02  +  X 
Loperamide A07DA03 +   X 
Loratadine R06AX13 +   X 
Maprotiline N06AA21  +   
Meclizine R06AE05 +    
Methocarbamol M03BA03 +  +  
Methylscopolamine A03BB03  +   
Metoclopramide A03FA01 +   X 
Mirtazapine N06AX11 +   X 
Morphine N02AG  +   
Nortriptyline N06AA10 + +  X 
Olanzapine N05AH03 +   X 
Orphenadrine M03BC01   + X 
Oxybutynin G04BD04 + + + X 
Paroxetine N06AB05 +   X 
Perphenazine N05AB03 +  + X 
Pramipexole N04BC05 +   X 
Prochlorperazine N05AB04 +   X 
Promethazine D04AA10 + + +  
Propantheline A03AB05   +  
Pseudoephedrine R01BA02 +   X 
Quetiapine N05AH04 +   X 
Ranitidine A02BA02 +   X 
Risperidone N05AX08 +   X 
Scopolamine A04AD01  +  X 
Selegiline N04BD01 +   X 
Soliphenasine G04BD  +  X 
Thiethylperazine R06AD03  +   
Thioridazine N05AC02 +    
Thiothixene N05AF04 +    
Tizanidine M03BX02 +   X 
Tolterodine G04BD + +  X 
Trazodone N06AX05 +   X 
Trifluoperazine N05AB06 +    
Trihexyphenidyl N04AA01  +   
Tripelennamine R06AC04   +  
Ziprasidone N05AE04 +   X 


















Psychotropic and other drugs considered potentially harmful medications (PHMs) in addition to Beers 2003 and DAPs. 
ATC-group Drug ATC-code 






















































































































































































































































   Väärin Oikein
1.  Mikä vuosi nyt on?   0  1
2.  Mikä vuodenaika nyt on?   0  1
 (talvi = joulu, tammi, helmi
 kevät = maalis, huhti, touko
 kesä = kesä, heinä, elo
 syksy = syys, loka, marras; aina ± 1 vko)
3.  Monesko päivä tänään on? (± 1 pv)  0  1
4.  Mikä viikonpäivä tänään on?   0  1
5.  Mikä kuukausi nyt on?   0  1
6.  Missä maassa olemme?   0  1
7.  Missä maakunnassa olemme? 0  1
 (Myös vanhan läänijaon mukaiset
 vastaukset hyväksytään)
8.  Mikä on tämän paikkakunnan nimi?  0  1
9.  Mikä on tämä paikka jossa olemme?  0  1
 (Sairaalan/terveyskeskuksen nimi, kotiosoite)
10.  Monennessako kerroksessa olemme?  0  1
11.  Seuraavassa pyydän Teitä painamaan mieleen
 kolme sanaa. Kun olen sanonut ne, toistakaa
 perässäni. (Kaksi vaihtoehtoista sarjaa)
 PAITA – RUSKEA – VILKAS
 RUUSU – PALLO – AVAIN
 PAITA  RUUSU  0  1
 RUSKEA  tai  PALLO  0  1
 VILKAS  AVAIN  0  1
 (Merkitään ensimmäisellä kerralla muistetut sanat.
 Jos ensimmäisessä toistossa tulee virheitä, sanoja
 kerrataan, kunnes kaikki kolme sanaa on opittu.)
 Toistoja____(enintään 5 kertaa).
12.  Nyt pyydän Teitä vähentämään 100:sta 7 ja saamastan- 
 ne jäännöksestä 7 ja edelleen vähentämään 7, kunnes 
 pyydän lopettamaan.
  93......  0  1
  86......  0  1
  79......  0  1
  72......  0  1
  65......  0  1
 (Kysymys voidaan toistaa kerran, jos sitä ei heti ymmär-
 retä. Jos henkilö tekee välillä virheen, mutta jatkaa siitä
 oikein vähentäen 7 virheellisestä luvusta, tulee vääriä




Seuraavassa esitän Teille erilaisia pieniä muistiin ja älyllisiin toimintoihin liittyviä kysymyksiä ja tehtäviä:
KÄÄNNÄ
   Väärin Oikein
13.  Mitkä olivat ne kolme sanaa, jotka
 pyysin Teitä painamaan mieleenne?
 (Sanojen järjestyksellä ei ole merkitystä.)
 PAITA  RUUSU  0  1
 RUSKEA  tai  PALLO  0  1
 VILKAS  AVAIN  0  1
14.  Nyt kysyn Teiltä kahden esineen nimeä.
 a) Mikä tämä on? – näytetään rannekelloa  0  1
 b) Mikä tämä on? – näytetään lyijykynää  0  1
15.  Nyt luen Teille lauseen. Pyydän Teitä
 toistamaan sen perässäni:
 EI MITÄÄN MUTTIA EIKÄ JOSSITTELUA  0  1
 (Annetaan piste vain, jos lause on täysin oikein. 
 Lausetta ei saa toistaa.)
16.  Seuraavaksi annan Teille paperin ja 
 pyydän Teitä tekemään sille jotain.
 (Paperi asetetaan pöydälle tutkittavan eteen.)
 Ottakaa paperi vasempaan käteenne. Taittakaa
 se keskeltä kahtia ja asettakaa polvienne päälle.
 (Ohjeita ja lausetta ei saa toistaa eikä henkilöä
 saa auttaa.)
 Ottaa paperin vasempaan käteen  0  1
 Taittaa sen   0  1
 Asettaa paperin polville   0  1
17.  Näytän Teille tekstin ”SULKEKAA SILMÄNNE”.
 Pyydän Teitä lukemaan sen ääneen ja
 noudattamaan sen ohjetta.   0  1
 (Annetaan piste vain, jos sekä lukee tekstin
 että sulkee silmänsä.)
18.  Kirjoittakaa kokonainen lyhyt lause 
 mielenne mukaan. (ks. seuraava sivu) 0  1
 (Yksi piste, jos lause on ymmärrettävä ja 
 siinä on ainakin subjekti ja predikaatti. 
 Kirjoitusvirheet eivät vaikuta.)
19.  Voisitteko piirtää tämän kuvion alapuolelle
 samanlaisen kuvion. (ks. seuraava sivu) 0  1
 (Annetaan piste, jos kaikki sivut ja kulmat ovat tallella
 ja leikkauspinta on nelikulmainen.)


















































































































Taulukko 1. Kirjaa ruudukkoon haastattelun perusteella potilaan toimintakyky kullakin CDR-luokituksen osa-alueella. 


























vain hyvin opittu 
aines säilynyt; uusi 
aines unohtuu pian. 












Orientaatio Täysin orientoitunut. 
Täysin orientoitunut 
lukuun ottamatta pieniä 
vaikeuksia aikasuhteissa. 
Esim. ei muista 
päivämäärää. 
Jonkin verran vaikeuksia 
aikasuhteissa; tutkimus-
tilanteessa orientoitunut 
paikkaan; muuten voi 
olla maantieteellistä 
desorientaatiota. Esim. 
vieraassa paikassa ei 






aikaan ja usein 
paikkaan. Esim. 








































syyksiä ja eroja; sosi-
aalinen arvostelukyky 
yleensä heikentynyt. 























saattaa silti olla mukana 
























ja harrastukset hyvin 
säilyneet.  



































































































Tutkittavan nimi ______________________________    Nro ___________  
Pvämäärä _______________ 
 
Kellotestin tulos  ________________________ pistettä 





































Appendix 8. Psychological well-being (PWB) (Routasalo et al. 2009). 
PÄIVÄMÄÄRÄ __________________ 
POTILAAN NIMI _______________________________ NRO _____ 
Seuraavaksi vielä muutama kysymys elämänasenteistanne  
1. Oletteko tyytyväinen elämäänne?   kyllä   en   
2. Tunnetteko itsenne tarpeelliseksi?   kyllä   en   
3. Onko Teillä tulevaisuudensuunnitelmia?   kyllä   ei   
4. Onko Teillä elämänhalua?    kyllä   ei   
5. Oletteko masentunut?  1. harvoin tai ei koskaan  
 2. toisinaan  
 3. usein tai aina  
4. Kärsittekö yksinäisyydestä?  1. harvoin tai ei koskaan  
 2. toisinaan  
 3. usein tai aina  
 
        1 Pidän itseäni terveenä 
        2 Pidän itseäni melko terveenä 
 3 Pidän itseäni sairaana 




12 Original publications  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

